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ABSTRACT 
 
Osteoarthritis (OA) is a degenerative and progressive disease, characterized by cartilage 
breakdown which covers the bone ends and by synovial membrane inflammation, causing 
disability, joint swelling and pain. The relief of severe pain is the main goal of the acute 
treatment, but little is known about the mechanisms involved in the development of pain in OA. 
It has been demonstrated the role of ATP (adenosine 5'-triphosphate) in processes of hyperalgesia 
through activation of purinergic receptors P2X3, P2X2/3 and P2X7. Therefore, the aims of this 
study were: (1) to investigate the role of P2X3, P2X2/3 and P2X7 receptors in articular 
hyperalgesia in the knee joint arthritis model in males and estrus females rats and, if so, whether 
there are sex differences in the effect induced by the selective P2X3, P2X2/3 and P2X7 receptors 
antagonists. (2) to test the hypothesis that the carrageenan-induced articular inflammation 
increases the expression of P2X3 receptor in chondrocytes of articular cartilage of the knee joint. 
(3) to verify whether the mechanism by which the P2X3, P2X2/3 and P2X7 receptors activation 
contributes to articular hyperalgesia depends on previous pro-inflammatory cytokines release and 
neutrophil migration. (4) to investigate whether the P2X3, P2X2/3 and P2X7 receptors activation 
induces articular hyperalgesia in the rat’s knee joint which depends on release of inflammatory 
mediators. (5) to verify whether the activation of P2X3, P2X2/3 and P2X7 receptors contributes 
to the articular hyperalgesia induced by the inflammatory mediators bradykinin, pro-
inflammatory cytokines, PGE2 and dopamine. For the aims 1, 4 and 5, the articular hyperalgesia 
was quantified by the rat knee joint Incapacitation Test. The immunofluorescence method was 
used for the aim 2. For aims 3 and 4, the ELISA and MPO immunoenzymatic assays were used. 
The results demonstrate that P2X3, P2X2/3 and P2X7 receptors activation by endogenous ATP is 
essential for the development of carrageenan-induced articular hyperalgesia in the knee joint of 
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male and estrus female rats, which are more sensitive than males to anti-hyperalgesic and anti-
inflammatory effects induced by the P2X7 receptor antagonist. During carrageenan-induced joint 
inflammation occurs an increased of P2X3 receptors expression in chondrocytes of the articular 
cartilage. The essential role played by P2X3, P2X2/3 and P2X7 receptors in the development of 
articular hyperalgesia is mediated by an indirect sensitization of the primary afferent nociceptors 
dependent on the previous pro-inflammatory cytokines release and neutrophil migration. 
Moreover, the P2X3, P2X2/3 and P2X7 receptors activation induces articular hyperalgesia which 
depends on bradykinin, sympathomimetic amines, prostaglandins and pro-inflammatory 
cytokines release. Finally, the articular hyperalgesia induced by inflammatory mediators 
bradykinin, PGE2 and dopamine depends on the P2X3 and P2X2/3 receptors activation, while the 
P2X7 receptor activation contributes to the bradykinin- and dopamine- induced articular 
hyperalgesia. In conclusion, our results suggest that P2X3, P2X2/3 and P2X7 receptors are 
interesting pharmacological targets for the treatment of inflammatory joint diseases such as 
osteoarthritis. In particular, selective P2X7 receptor antagonists can be used to reduce 
inflammation and pain in the knee joint, especially in women. 
 
Keywords: Articular hyperalgesia, P2X3 and P2X7 purinergic receptors, Chondrocytes, Pro-
inflammatory cytokines, Neutrophil migration. 
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RESUMO 
A osteoartrite (OA) é uma doença degenerativa e progressiva, caracterizada pela 
degradação da cartilagem que reveste as extremidades ósseas e inflamação da membrana sinovial, 
causando incapacidade física, inchaço articular e dor. Embora o alívio da dor severa seja o 
principal objetivo no tratamento agudo, pouco se sabe sobre os mecanismos envolvidos no 
desenvolvimento da dor na OA. Estudos demonstram a participação do ATP (adenosina 5’-
trifosfato) em processos de hiperalgesia através da ativação dos receptores purinérgicos P2X3, 
P2X2/3 e P2X7. Portanto, os objetivos deste estudo foram: (1) investigar a participação dos 
receptores P2X3, P2X2/3 e P2X7 na hiperalgesia articular em modelo de artrite na articulação do 
joelho de ratos machos e fêmeas em estro e se há diferenças sexuais no efeito induzido pelos 
antagonistas de receptores P2X3, P2X2/3 e P2X7. (2) testar a hipótese de que a inflamação 
articular induzida pela carragenina aumenta a expressão do receptor P2X3 nos condrócitos da 
cartilagem articular da articulação do joelho de ratos. (3) verificar se o mecanismo pelo qual a 
ativação dos receptores P2X3, P2X2/3 e P2X7 contribui para a hiperalgesia articular depende da 
liberação prévia de citocinas pró-inflamatórias e da migração de neutrófilos. (4) investigar se a 
ativação dos receptores P2X3, P2X2/3 e P2X7 induz hiperalgesia na articulação do joelho de 
ratos dependente da liberação de mediadores inflamatórios. (5) testar a hipótese de que a ativação 
dos receptores P2X3, P2X2/3 e P2X7 contribui para a hiperalgesia articular induzida pelos 
mediadores inflamatórios: bradicinina, citocinas pró-inflamatórias, PGE2 e dopamina. Para os 
objetivos 1, 4 e 5, a hiperalgesia articular foi quantificada através do teste de Incapacitação 
Articular. Para o objetivo 2, foi utilizado o ensaio de imunofluorescência. Para os objetivos 3 e 4 
foram utilizados os ensaios imuno-enzimáticos ELISA e MPO. Os resultados demonstram que a 
ativação dos receptores P2X3, P2X2/3 e P2X7 pelo ATP endógeno é essencial para o 
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desenvolvimento da hiperalgesia articular induzida pela carragenina na articulação do joelho de 
ratos machos e fêmeas em estro, que são mais sensíveis do que os machos aos efeitos anti-
hiperalgésicos e anti-inflamatórios induzidos pelo antagonista de receptor P2X7. Durante a 
inflamação articular induzida pela carragenina ocorre um aumento na expressão dos receptores 
P2X3 nos condrócitos da cartilagem articular. O papel dos receptores P2X3, P2X2/3 e P2X7 na 
hiperalgesia articular é mediado pela sensibilização indireta dos nociceptores aferentes primários, 
dependente da liberação prévia de citocinas pró-inflamatórias e da migração de neutrófilos. Além 
disso, a ativação dos receptores P2X3, P2X2/3 e P2X7 induz hiperalgesia articular dependente da 
liberação de bradicinina, aminas simpatomiméticas, prostaglandinas e citocinas pró-inflamatórias. 
Finalmente, a hiperalgesia articular induzida pelos mediadores inflamatórios bradicinina, PGE2 e 
dopamina depende da ativação de receptores P2X3 e P2X2/3, enquanto que a ativação de 
receptor P2X7 contribui para a hiperalgesia articular induzida pela bradicinina e dopamina. 
Concluindo, os resultados apresentados sugerem que os receptores P2X3, P2X2/3 e P2X7 são 
alvos farmacológicos interessantes para o tratamento das doenças inflamatórias articulares como 
a osteoartrite. Particularmente em relação ao receptor P2X7, antagonistas seletivos podem ser 
usados para reduzir a dor e inflamação no joelho, especialmente em mulheres. 
 
Palavras-chave: Hiperalgesia articular, Receptores purinérgicos P2X3 e P2X7, Condrócitos, 
Citocinas pró-inflamatórias, Migração de neutrófilo.   
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I. INTRODUÇÃO 
 
I.I. Dor e a Osteoartrite 
A dor é um fenômeno complexo que pode ser definido como uma percepção desagradável 
de uma sensação nociceptiva e que envolve uma série de aspectos tanto cognitivos quanto 
sensoriais. Essa definição envolve dois componentes: a percepção e a nocicepção. Percepção 
dolorosa é uma função integrativa modulada por condições motivacionais, emocionais e 
psicológicas, bem como pela história pregressa individual (MERSKEY & BOGDUK, 1994). 
Nocicepção (do latim nocere, “ferir”), ou sensação nociceptiva, resulta da ativação de uma 
população específica de neurônios aferentes primários, denominados de nociceptores, que são 
amplamente distribuídos por todo o organismo, presentes na pele, membranas, mucosas, vísceras, 
músculos, tendões, articulações e vasos sanguíneos (JULIUS & BASBAUM, 2001; ALMEIDA 
et al., 2004; WILLIS, 2007; GOLD & GEBHART, 2010). Os nociceptores detectam 
seletivamente estímulos capazes de comprometer a integridade física do organismo e transmitem 
a informação nociceptiva para o sistema nervoso central (MILLAN, 1999; JULIUS & 
BASBAUM, 2001; WILLIS, 2007).  
Em determinadas condições, quando os estímulos nocivos são intensos e resultam em 
lesão tecidual, a dor é acompanhada por fenômenos paralelos, como a hiperalgesia. Este 
fenômeno é resultado da sensibilização das fibras neuronais sensoriais responsáveis pela ativação 
do sistema nociceptivo. Essa sensibilização dos nociceptores, caracterizada 
eletrofisiologicamente pela diminuição do limiar de excitabilidade necessário para ativar o 
nociceptor (RIEDEL & NEECK, 2001), ocorre por ação de mediadores inflamatórios que são 
produzidos durante e no final do processo inflamatório (HUANG et al., 2006; VERRI et al., 
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2006). Estes mediadores inflamatórios atuam em seus respectivos receptores, induzindo como 
resultado final, alterações metabólicas que facilitarão a produção de potenciais de ação pelos 
nociceptores (FERREIRA et al., 1978; NAKAMURA & FERREIRA, 1987).  
A osteoartrite (OA) é uma doença degenerativa e progressiva, na qual a cartilagem que 
reveste as extremidades ósseas se deteriora, causando diferentes graus de incapacidade, inchaço 
articular, dor e inflamação (ROCHA et al., 1999; HUNTER, 2009). Pode afetar toda a estrutura 
articular, incluindo a membrana sinovial, a cartilagem articular, o osso subcondral, o menisco e 
os músculos periarticulares (FELSON, 2006) e os fatores de risco incluem a obesidade, o 
envelhecimento, lesão articular e fatores mecânicos e metabólicos (FELSON, 2003). Esta 
artropatia, que corresponde à forma mais comum de artrite, pode ocorrer em qualquer articulação 
do corpo, mas sua ocorrência é mais comum nos joelhos, nos quadris e nas mãos (HUNTER & 
ECKSTEIN, 2009) e tem sido relatado que as mulheres têm maior prevalência de OA na 
articulação do joelho do que os homens (NEVITT & FELSON, 1996; FELSON & NEVITT, 
1998; SRIKANTH et al., 2005, FELSON, 2006).  
Tem sido sugerido que a inflamação articular em casos de OA é o resultado, pelo menos 
em parte, de uma interação cíclica entre a cartilagem danificada e a membrana sinovial 
inflamada. Estudos demonstraram uma relação estreita entre a expressão de citocinas pró-
inflamatórias e os sintomas da OA (FERNANDES et al., 2002; STANNUS et al., 2010). Os 
produtos da degradação da cartilagem são fagocitados pelas células sinoviais, resultando em uma 
sinóvia inflamada, que por sua vez produz mediadores e citocinas pró-inflamatórias. Isto resulta 
em um aumento da liberação de enzimas proteolíticas, que por sua vez colaboram com a 
degradação da cartilagem (SELLAM & BERENBAUM, 2010). 
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A dor e a rigidez nas articulações com consequente limitação dos movimentos, redução da 
participação em atividades laborais e baixa qualidade de vida são os principais problemas 
enfrentados por pacientes com artropatias inflamatórias (YELIN et al., 2007) e embora o alívio 
da dor severa seja frequentemente o principal objetivo no tratamento agudo dessas condições, os 
tratamentos analgésicos atuais têm ou eficácia incompleta, ou efeitos adversos potencialmente 
graves, limitando as opções de tratamento para os pacientes com OA (ROCHA et al., 1999; 
BERENBAUM, 2011).  Os processos periféricos envolvidos na dor em condições como a OA 
são pouco conhecidos, desta forma uma melhor compreensão desses mecanismos pode permitir 
avanços no desenvolvimento de terapias locais para o tratamento dos sintomas da OA (HUNTER, 
2009). 
 
I.II. Modelos experimentais para o estudo da artrite 
Os aspectos da fisiopatologia da artrite do joelho tais como dor e inflamação associadas 
com a destruição periarticular, podem ser estudados através de modelos pré-clínicos pela injeção 
de agentes inflamatórios na articulação do joelho de roedores (TONUSSI & FERREIRA, 1992; 
ROCHA et al., 1999). O teste de incapacitação articular (IA) para ratos foi desenvolvido para 
avaliar indiretamente a dor articular do joelho através da perturbação da marcha do animal, 
definida como a incapacidade de um animal (rato) para deambular normalmente, depois de 
submetido à injeção intra-articular de um agente inflamatório (TONUSSI & FERREIRA, 1992). 
A carragenina é um mucopolissacarídeo sulfatado extraído de algas marinhas vermelhas, 
denominadas Chondrus, comumente usado como um agente inflamatório por provocar uma 
reação inflamatória local aguda (GARDNER, 1960), resultando em edema e hiperalgesia, que são 
os sintomas mais frequentes das artropatias em seres humanos. Vários tipos de carragenina 
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podem ser encontrados de acordo com seu teor de sulfato e sua configuração estrutural: kappa 
(κ), iota (ι) e lambda (λ), sendo o último o mais eficiente como irritante por ser mais rico em 
resíduos sulfatados (DI ROSA et al., 1971). 
A injeção intra-articular de carragenina em ratos é um modelo experimental amplamente 
utilizado para estudar a hiperalgesia e inflamação nas articulações (SLUKA et al., 1997; 
SOLANO & HERRERO, 1999; LAWAND et al., 2000; MIN et al., 2001; OLIVEIRA et al., 
2005; RODRIGUES et al., 2006; TEIXEIRA et al., 2010a; VALENTI et al., 2010; GOMIS et al., 
2013). A carragenina induz hiperalgesia mediada pela liberação de dois mediadores inflamatórios 
finais, as prostaglandinas e as aminas simpatomiméticas, que sensibilizam diretamente os 
nociceptores aferentes primários (GOLD et al., 1996; KHASAR et al., 1999; RUSH & 
WAXMAN, 2004). A produção desses mediadores finais depende da liberação prévia de uma 
cascata de citocinas, que envolve inicialmente a formação da bradicinina, que por sua vez, induz 
à liberação da citocina pró-inflamatória fator de necrose tumoral α (TNFα) (FERREIRA et al., 
1993a). Esta citocina desencadeia a liberação de duas vias distintas de citocinas, uma mediada 
pela interleucina 1β (IL-1β) e interleucina 6 (IL-6) que estimulam a síntese da ciclooxigenase-2 
(COX-2) convertendo o ácido araquidônico em prostaglandinas (PGE) e outra mediada pela 
interleucina 8 (IL-8, em humanos) ou CINC-1 (em ratos) que estimula a produção de aminas 
simpatomiméticas (CUNHA et al., 1991; CUNHA et al., 1992; LORENZETTI et al., 2002). 
 
I.III. O ATP como mediador inflamatório 
Além dos mediadores inflamatórios citados, estudos demonstraram o papel importante do 
ATP (adenosina 5’-trifosfato) como mediador da hiperalgesia inflamatória (WU et al., 2004; 
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MCGARAUGHTY & JARVIS, 2005; OLIVEIRA et al., 2005; WANG et al., 2007; TEIXEIRA 
et al., 2010a e b; PRADO et al., 2013).  
O ATP está presente em todas as células do corpo (MCCLESKEY & GOLD, 1999), uma 
vez que é a fonte de energia essencial das células. Experimentos demonstraram que algumas 
fibras nervosas sensoriais liberam ATP (HOLTON, 1959) e essa descoberta levou à proposição 
do termo “neurônios purinérgicos” (BURNSTOCK, 1972). Esses achados foram muito 
importantes, pois evidenciaram o papel extracelular do ATP, que até então era somente 
conhecido por sua função intracelular. Atualmente existem inúmeras evidências da ação do ATP 
extracelular como molécula sinalizadora em diversos processos fisiológicos e patológicos 
(BURNSTOCK & SAWYNOK, 2010; BURNSTOCK, 2013).  
No meio extracelular o ATP exerce suas funções por meio da ativação de receptores 
conhecidos como purinérgicos, que são distinguidos em dois tipos, nomeados de P1 e P2, os 
quais medeiam as funções fisiológicas da adenosina e do ATP, respectivamente (ABBRACCHIO 
& BURNSTOCK, 1998). Em meados da década de 1990, vários estudos demonstraram a 
diversificada distribuição desses receptores nos tecidos de mamíferos e em 1994, estudos que 
evidenciaram as diferenças estruturais e propriedades eletrofisiológicas dos receptores P2 
levaram a proposição de um novo sistema de divisão dos receptores P2 em duas grandes famílias: 
Receptores P2Y: metabotrópicos, acoplados à proteína G e Receptores P2X: ionotrópicos ligante-
dependentes (FREDHOLM et al., 1994; HYNIE, 1995). 
 
I.IV. Os receptores purinérgicos P2X3 e P2X7  
Dados obtidos em nosso laboratório demonstram a participação do ATP endógeno no 
desenvolvimento da hiperalgesia inflamatória induzida pela carragenina na articulação 
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temporomandibular (OLIVEIRA et al., 2005; TEIXEIRA et al., 2010a) e no tecido subcutâneo da 
pata de ratos através da ativação de receptores purinérgicos (OLIVEIRA et al., 2009; TEIXEIRA 
et al., 2010b). Durante o processo inflamatório, o ATP é liberado das células lesadas, tais como 
macrófagos, plaquetas, neutrófilos, bem como células mortas  (DUBYAK & EL-MOATASSIM, 
1993, BEIGI et al., 1999, SIKORA et al., 1999, CAMPWALA & FOUNTAIN, 2013) para o 
meio extracelular e contribui com o desenvolvimento da hiperalgesia inflamatória via ativação 
dos receptores purinérgicos P2X.  
Especificamente, os receptores purinérgicos P2X são canais ionotrópicos ativados pelo 
ATP, cuja ativação induz despolarização da membrana celular através do aumento da 
permeabilidade ao Na+, K+ e Ca2+ (DUBYAK & EL-MOATASSIM, 1993; VALERA et al., 
1994). Dentre os sete subtipos de receptores purinérgicos P2X (P2X1 - P2X7) (BUELL et al., 
1996), os subtipos P2X3 e P2X7 têm sido muito estudados por estarem envolvidos em processos 
de hiperalgesia e inflamação em vários tecidos, como por exemplo, na pele (DELL'ANTONIO et 
al., 2002a e b; MCGARAUGHTY et al., 2003; WU et al., 2004; CHESSELL et al., 2005; 
FULGENZI et al., 2005; MCGARAUGHTY et al., 2007; OLIVEIRA et al., 2009; TEIXEIRA et 
al., 2010b; PRADO et al., 2013), no tecido muscular (HORI et al., 2010), em vísceras 
(FULGENZI et al., 2008; BURNSTOCK, 2012), na polpa dental (RENTON et al., 2003), além 
de tecidos articulares como a articulação temporomandibular (ATM) e articulação do joelho de 
ratos (SHINODA et al., 2005; SEINO et al., 2006; BROOM et al., 2008; TEIXEIRA et al., 
2010a).   
Os receptores P2X3 e P2X2/3 estão localizados nos terminais sensoriais aferentes 
periféricos e centrais de fibras C amielínicas e de fibras Aδ mielínicas, predominantemente na 
subpopulação não peptidérgica dos nociceptores, onde medeiam a neurotransmissão sensorial 
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(BURNSTOCK & KNIGHT, 2004; GEVER et al., 2006). A expressão desses receptores em 
células não neuronais é pouco explorada, mas foi demonstrado que queratinócitos da epiderme 
possuem RNA mensageiro para o receptor P2X3 (INOUE et al., 2005) e que células endoteliais 
do timo (GLASS et al., 2000), células uroteliais (SUN & CHAI, 2004) e condrócitos (VARANI 
et al., 2008) expressam o receptor purinérgico P2X3. 
Em condições normais, os condrócitos são responsáveis por manter um equilíbrio 
dinâmico entre a síntese e degradação da matriz extracelular, fornecendo funcionalidade 
mecânica à articulação (VARANI et al., 2008). Em doenças degenerativas como a OA, o 
metabolismo dos condrócitos é instável devido à produção excessiva de citocinas pró-
inflamatórias e de enzimas que degradam a matriz extracelular pela membrana sinovial 
inflamada. Consequentemente, os condrócitos respondem a essas condições inflamatórias, 
participando das atividades catabólicas que levam à degradação da matriz cartilaginosa, incluindo 
o aumento da liberação de óxido nítrico (NO) e de mediadores inflamatórios como a PGE2 (de 
MATTEI et al., 2002; VARANI et al., 2008; LEE et al., 2013). Ainda, estudos in vitro têm 
demonstrado que a presença de IL-1β (GUERNE et al., 1990; LOTZ et al., 1992; AIDA et al., 
2006) ou do fluído sinovial de pacientes com OA (HOFF et al., 2013) estimulam a produção de 
citocinas pró-inflamatórias pelos condrócitos. 
Sabe-se que o ATP extracelular é frequentemente encontrado no líquido sinovial de 
pacientes com artropatias (RYAN et al., 1991; KUMAHASHI et al., 2011) e tem sido sugerido 
que os nucleotídeos extracelulares, sinalizando através de receptores purinérgicos, podem 
desempenhar um papel importante na regulação do metabolismo da cartilagem (HOEBERTZ et 
al., 2003). Além disso, foi demonstrado que o ATP e o difosfato de adenosina (ADP) estimulam 
a produção de PGE em cultura de condrócitos (CASWELL et al., 1991), que pode ser aumentada 
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na presença das citocinas pró-inflamatórias IL-1β , IL-1α e TNF-α (CASWELL et al., 1992; 
LEONG et al., 1993; KOOLPE et al., 1999).  
Trabalhos desenvolvidos em nosso laboratório demonstraram que o ATP extracelular, 
através da ativação dos receptores P2X3 e P2X2/3, é essencial para o desenvolvimento da 
hiperalgesia mecânica induzida pela carragenina no tecido subcutâneo da pata de ratos 
(OLIVEIRA et al., 2009) e para a hiperalgesia induzida pela carragenina na ATM de ratos 
(TEIXEIRA et al., 2010a). Um estudo mostrou que receptores P2X3 são expressos nas fibras 
nociceptivas aferentes que inervam o tecido articular dos joelhos de ratos (DOWD et al., 1998). 
Além disso, foi sugerido que a ativação do receptor P2X3 está envolvida na hipersensibilidade 
mecânica induzida por adjuvante completo de Freund (CFA) da articulação do joelho de ratos 
(SEINO et al., 2006). 
Em relação aos receptores P2X7, no tecido periférico eles são seletivamente expressos em 
células de origem hematopoiéticas, incluindo mastócitos, linfócitos, eritrócitos, fibroblastos, 
monócitos, macrófagos periféricos e sinoviócitos do tipo B (SURPRENANT et al., 1996; 
COLLO et al., 1997; MANCINO et al., 2001; CAPORALI et al., 2008). No SNC, receptores 
P2X7 funcionais estão localizados na micróglia, astrócitos e em células de Schwann (COLLO et 
al., 1997; SIM et al., 2004). Nos gânglios das raízes dorsais, os receptores P2X7 parecem ser 
seletivamente localizados em células da glia (ZHANG et al., 2005).  
Sabe-se que o receptor P2X7 apresenta um papel importante no desenvolvimento dos 
processos inflamatórios por modular a produção de mediadores inflamatórios (LISTER et al., 
2007). Durante a inflamação induzida por CFA ou lipopolissacarídeos (LPS), o receptor P2X7 
contribui com a liberação de citocinas pró-inflamatórias (IL-1, IL-6, IL-18 e TNF) 
relacionadas à produção de mediadores inflamatórios finais (CHESSELL et al., 2005; FERRARI 
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et al., 2006; HONORE et al., 2006; LISTER et al., 2007; MINGAM et al., 2008) e durante a 
inflamação induzida pela carragenina, os receptores P2X7 contribuem com a liberação das 
quimiocinas pró-inflamatórias: proteína quimiotática de monócitos-1 (MCP-1), proteína induzida 
por Interferon gama-10 (IP-10) e IL-8, relacionadas à migração e ativação de células 
inflamatórias (FULGENZI et al., 2005). 
Estudos prévios demonstraram que a ativação do receptor P2X7 em células estimuladas 
com LPS, como por exemplo, macrófagos, micróglia e célula de Schwann, promove a conversão 
da pró-IL-1β na forma madura IL-1β (através da ativação da caspase-1, enzima conversora da IL-
1β, THORNBERRY, 1997) e sua liberação para o meio extracelular (SANZ & DI VIRGILIO, 
2000; SOLLE et al., 2001; COLOMAR et al., 2003; KAHLERBERG & DUBYAK, 2004). Além 
disso, foi demonstrado que o efeito anti-hiperalgésico do bloqueio do receptor P2X7 na 
hiperalgesia induzida pelo CFA é mediado pela modulação da atividade da IL-1β (HONORE et 
al., 2009). 
Dados obtidos em nosso laboratório demonstraram que a ativação do receptor P2X7 pelo 
ATP endógeno é essencial para o desenvolvimento da hiperalgesia mecânica induzida pela 
carragenina no tecido subcutâneo da pata de ratos, além de contribuir com a liberação das 
citocinas pró-inflamatórias TNF e IL-6 e da quimiocina CINC-1 no mesmo tecido (TEIXEIRA 
et al., 2010b). Estudos anteriores mostraram que os receptores P2X7 também participam em 
processos de artrite, pois a severidade da artrite induzida por anticorpo monoclonal anti colágeno 
é atenuada em camundongos knockout para receptores P2X7 quando comparados aos animais 
normais (LABASI et al., 2002) e o bloqueio do receptor P2X7 previne a ocorrência de danos 
histopatológicos e o aparecimento de sinais e sintomas da artrite induzida por anti colágeno em 
ratos (BROOM et al., 2008). 
10 
 
Considerando que a articulação do joelho é uma das mais afetadas pelas artropatias 
inflamatórias e que estudos demonstraram que os receptores P2X3 e P2X7 são importantes em 
processos de artrite, o papel desses receptores e os mecanismos periféricos envolvidos na 
hiperalgesia inflamatória induzida pela carragenina na articulação do joelho ainda não eram 
conhecidos. Além disso, estudos têm relatado diferenças sexuais no efeito analgésico de drogas, 
por exemplo, na ação de agonistas kappa opióides (CLEMENTE et al., 2004; CLEMENTE-
NAPIMOGA et al., 2009) e de antagonistas β-adrenérgicos (FAVARO-MOREIRA et al., 2012) 
na nocicepção da ATM entre ratos machos e fêmeas, onde as fêmeas com baixos níveis de 
hormônios ovarianos são mais responsivas à ação analgésica dessas drogas. Por outro lado, ratos 
machos são mais sensíveis aos efeitos antinociceptivos da morfina do que as fêmeas (CICERO et 
al., 1996; CAI et al., 2001). 
Desta forma, o objetivo geral deste trabalho foi investigar a participação dos receptores 
purinérgicos P2X3, P2X2/3 e P2X7 na hiperalgesia inflamatória articular em modelo de artrite na 
articulação do joelho de ratos machos e fêmeas e os mecanismos periféricos envolvidos. Os 
objetivos específicos foram: 
(1) Testar a hipótese de que a ativação dos receptores P2X3 e P2X2/3 através do ATP 
endógeno contribui para a hiperalgesia articular induzida pela carragenina na articulação do 
joelho de ratos machos e fêmeas em estro (níveis baixos de hormônios ovarianos) de forma 
dependente do sexo. Verificar se a inflamação articular induzida pela carragenina aumenta a 
expressão de receptor P2X3 nos condrócitos da cartilagem articular do joelho de ratos. Investigar 
se a contribuição dos receptores P2X3 e P2X2/3 para a hiperalgesia articular induzida pela 
carragenina ocorre através da liberação prévia de citocinas pró-inflamatórias e/ou migração de 
neutrófilos. 
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 (2) Investigar se o ATP endógeno, através da ativação do receptor P2X7, contribui para a 
hiperalgesia articular induzida pela carragenina na articulação do joelho de ratos machos e 
fêmeas em estro e, em caso afirmativo, se essa contribuição depende da liberação prévia de 
citocinas pró-inflamatórias e/ou migração de neutrófilos. Testar a hipótese de que o efeito 
induzido pelo bloqueio do receptor P2X7 na articulação do joelho de ratos machos e fêmeas em 
estro é dependente do sexo. 
(3) Verificar se a ativação dos receptores P2X3 e P2X2/3 na articulação do joelho de ratos 
induz hiperalgesia articular dependente da liberação de mediadores inflamatórios envolvidos na 
hiperalgesia, como a bradicinina, prostaglandinas, aminas simpatomiméticas, citocinas pró-
inflamatórias e migração de neutrófilos. 
 (4) Verificar se a ativação do receptor P2X7 na articulação do joelho de ratos induz 
hiperalgesia articular dependente da liberação de mediadores inflamatórios envolvidos na 
hiperalgesia, como a bradicinina, prostaglandinas, aminas simpatomiméticas, citocinas pró-
inflamatórias e migração de neutrófilos. 
(5) Investigar se a ativação dos receptores P2X3, P2X2/3 e P2X7 contribui para a 
hiperalgesia articular induzida pelos mediadores inflamatórios pertencentes à cascata inflamatório 
da carragenina: bradicinina, TNF-α, IL-1β, IL-6, CINC-1, PGE2 a dopamina. 
 
 
 
 
O presente estudo está apresentado em formato alternativo, conforme deliberação 
da Comissão Central de Pós-graduação (CCPG) da Universidade Estadual de Campinas 
(UNICAMP) nº 002/2013. 
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Abstract 
Osteoarthritis (OA) is a degenerative and progressive disease, characterized by cartilage 
breakdown which covers the bone ends and by synovial membrane inflammation, causing 
different degrees of disability, joint swelling and pain. The P2X3 and P2X2/3 receptors 
contribute to the development of inflammatory hyperalgesia, participate in arthritis processes in 
the knee joint and are expressed in chondrocytes and nociceptive afferent fibers innervating the 
knee joint. In this study, we hypothesized that P2X3 and P2X2/3 receptors activation by 
endogenous ATP induces articular hyperalgesia in the knee joint of males and females rats 
through an indirect sensitization of primary afferent nociceptors dependent on the previous 
release of pro-inflammatory cytokines and/or on neutrophil migration. We found that the 
blockade of articular P2X3 and P2X2/3 receptors attenuates the carrageenan-induced 
hyperalgesia in the knee joint of male and estrus female rats in a similar manner. The 
carrageenan-induced knee joint inflammation increased the expression of the P2X3 receptor in 
the chondrocytes of the articular cartilage. Further, the blockade of articular P2X3 and P2X2/3 
receptors significantly reduced the increase of concentration of TNF-α, IL-6 and CINC-1 and the 
neutrophil migration induced by carrageenan. These findings indicate that P2X3 and P2X2/3 
receptors activation by endogenous ATP is essential to hyperalgesia development in the knee 
joint through an indirect sensitization of primary afferent nociceptors dependent on the previous 
release of pro-inflammatory cytokines and/or on neutrophil migration. 
 
Key words: articular hyperalgesia, P2X3 and P2X2/3 receptors, knee joint, chondrocytes, pro-
inflammatory cytokines, neutrophil migration. 
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Introduction 
 
Osteoarthritis (OA) is the most common form of arthritis. It is a progressive and 
degenerative disease with a higher prevalence in women than in men (Nevitt and Felson, 1996, 
Srikanth et al., 2005, Felson, 2006), characterized by deterioration of the cartilage covering the 
bone ends and by inflammation of the synovial membrane, causing limitation of motion, different 
degree of disability, synovitis and inflammatory pain (Rocha et al., 1999, Hunter, 2009, Sellam 
and Berenbaum, 2010). A better understanding of the peripheral processes linking inflammatory 
pain with OA is necessary for the improvement of the analgesic treatments of OA that have either 
incomplete efficacy, or potentially severe adverse events (Berenbaum, 2011). 
Among the seven P2X purinergic receptor subtypes (P2X1-P2X7) (Buell et al., 1996), the 
P2X3 and P2X2/3 subtypes have been implicated in processes of pain and hyperalgesia in the 
articular tissues of the knee and temporomandibular joint (TMJ) of rats (Shinoda et al., 2005, 
Seino et al., 2006, Teixeira et al., 2010). The P2X3 and P2X2/3 receptors are localized on 
peripheral and central terminals of unmyelinated C-fiber and thinly myelinated Aδ sensory 
afferents, predominantly in the non-peptidergic subpopulation of nociceptors, where they mediate 
sensory neurotransmission (Bradbury et al., 1998, Burnstock and Knight, 2004, Gever et al., 
2006). The expression of these receptors in non-neuronal cells has been weakly explored, but it 
has demonstrated that human epidermal keratinocytes express P2X3 receptors RNAm (Inoue et 
al., 2005) and that endothelial cells of thymus (Glass et al., 2000), urothelial cells (Sun and Chai, 
2004) and chondrocytes (Varani et al., 2008) express P2X3 receptors. Although P2X3 and 
P2X2/3 are expressed on chondrocytes, it is not known whether their expression on these cells is 
increased during inflammation. 
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Studies have been reported that the involvement of some receptors in pain and analgesia 
processes is sex-dependent, for example females with lower levels of ovarian hormones are more 
responsive to some analgesic drugs than males rats (Clemente et al., 2004, Clemente-Napimoga 
et al., 2009, Favaro-Moreira et al., 2012). However, it is not known whether the involvement of 
P2X3 and P2X2/3 receptors in the carrageenan-induced articular hyperalgesia in the knee joint 
differs between male and estrus female rats (low levels of ovarian hormones).   
In this study we used the carrageenan-induced knee joint inflammation model in rats 
(Tonussi and Ferreira, 1992, Ekundi-Valentim et al., 2010, Valenti et al., 2010, Gomis et al., 
2013) to test the hypothesis that (I) the activation of P2X3 and P2X2/3 receptors by endogenous 
ATP contributes to carrageenan-induced articular hyperalgesia in the knee joint of males and 
estrus females (low levels of ovarian hormones) in a sex-dependent manner. (II) the carrageenan-
induced articular inflammation increases the expression of P2X3 receptor in the chondrocytes of 
articular cartilage of the knee joint. (III) the contribution of P2X3 and P2X2/3 receptors 
activation to carrageenan-induced articular hyperalgesia occurs through an indirect sensitization 
of the primary afferent nociceptors dependent on the previous release of pro-inflammatory 
cytokines TNF-α, IL-1β, IL-6 and chemokine-induced chemoattractant-1 (CINC-1, analog to IL-
8 in rats) and/or on the migration of neutrophils to the inflamed knee joint. 
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 Materials and Methods 
 
Animals 
Male and female Wistar rats (200-250g) obtained from the Multidisciplinary Center for 
Biological Research (CEMIB - UNICAMP, SP, Brazil) and from Harlan Laboratories (Madison, 
WI, USA), were used in this study. The animals were housed in plastic cages with soft bedding 
(five/cage) on a 12:12 light cycle (lights on at 06:00 A.M.) with food and water available ad 
libitum. They were maintained in a temperature-controlled room (±23°C) and handled for at least 
one week prior to the experiments. Each animal was used once and the number of animals per 
group was kept to a minimum. Experimental protocols were approved by the Committee on 
Animal Research of the University of Campinas (protocol number: 2049-1) and by the Animal 
Care and Use Committee at the University of Iowa and were conformed to IASP guidelines for 
the study of the pain in animals (Zimmermann, 1983).  
 
General Procedures 
Testing sessions took place during light phase (between 09:00 AM and 5:00 PM) in a 
quiet room maintained at 23ºC (Rosland, 1991). During the tests the animals had no access to 
water or food. The animals were habituated for 1 hour prior to the experiment to minimize stress. 
 
Drugs administration  
Drugs or their vehicle were intra-articularly administrated in the right rat’s knee joint by a 
26-gauge needle that was connected to a catheter of polyethylene and also to a Hamilton syringe. 
The volume of injection was 50 µL.  
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Carrageenan-induced knee joint inflammation (synovitis) 
Under brief inhalation of isoflurane anesthesia, rats were subjected to intra-articular (i.a.) 
injection of λ-carrageenan dissolved in 25μL sterile 0.9% saline solution into their right knee 
joints (Tonussi and Ferreira, 1992, Ekundi-Valentim et al., 2010). The injection site was shaved 
and treated with an antiseptic solution of iodine alcohol. The other drugs were also injected into 
the knee joint in the same manner that the carrageenan and the control animals received vehicle 
or sterile 0.9% saline solution. 
 
Drugs and doses  
The following drugs were used: λ-carrageenan (Cg; 300 µg/knee, i.a., Tonussi and 
Ferreira, 1992, De-Melo et al., 1998, Tonussi and Ferreira, 1999, Ekundi-Valentim et al., 2010) 
and 5-([(3-Phenoxybenzyl) [(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl)-1,2,4-
benzenetricarboxylic acid (A-317491 - the selective P2X3 and P2X2/3 receptor antagonist: 20, 
60, 180, 540 µg/knee, i.a., Oliveira et al., 2009). The drugs were obtained from Sigma-Aldrich 
(MO, USA) and dissolved in 25 μL sterile 0.9% saline solution. 
 
Estrus phase determination of estrous cycle 
Estrus phase in female rats was determined by daily microscope examination of vaginal 
smears taken by gentle lavage, between 9:00 and 10:00 a.m. Estrus phase was identified by the 
predominance (80 %) of anucleated cornified cells in rats with at least two consecutive regular 4-
day cycles (Smith et al., 1975, Marcondes et al., 2002). This phase was chosen because it 
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represent phase of low ovarian hormonal level, 17β-estradiol and progesterone (Butcher et al., 
1974, Spornitz et al., 1999). 
 
Gait disturbance - Rat knee-joint incapacitation test 
We used the rat knee-joint incapacitation test, as described previously (Tonussi and 
Ferreira, 1992). Briefly, 3 hours after carrageenan injection into their right knee joints, rats were 
put to walk on a steel rotary cylinder (30 cm wide x 50 cm diameter), covered with a fine-mesh 
non-oxidizable wire screen, which rotates at 3 rpm. Specially, designed metal gaiters were 
wrapped around both hind paws. After placement of the gaiters, rats were placed to walk in the 
cylinder and the right paw was then connected via a simple circuit to microcomputer data 
input/output port. The paw elevation time (PET) is the total time that the rat walks failing to 
touch the cylinder surface with the injected hindpaw, during a 60 sec period, which is directly 
proportional to the gait disturbance. Incapacitation was quantified as an increase in the PET, 3 
hours after carrageenan injection into the right knee joint. To minimize variations in PET, all rats 
were introduced to the experimental environment and trained on the apparatus to habituation into 
the equipment before the testing sessions. To confirm the local effect of some test agents, they 
were injected into the contralateral rat’s knee joint and the test was performed on the ipsilateral 
knee joint. The rat knee-joint incapacitation test provides automated measurements, which are 
independent of the subjectivity of the observer (Tonussi and Ferreira, 1992). 
 
Tissue Preparation 
 Three hours after the carrageenan (300 μg/knee) or sterile 0.9% saline solution injection, 
the rats were anesthetized with sodium pentobarbital (120 mg/kg i.p.) and fixed with 4 % 
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paraformaldehyde (PFA, in 0.1 M phosphate buffer (PB), pH 7.4) by perfusion through the 
ascending aorta. The whole knee joints were rapidly removed and kept in the same fixative for 24 
hours at 4ºC. The fixed specimens were decalcified for 8 weeks with 10% 
ethylenediaminetetraacetic acid (EDTA) in 0.01 M phosphate buffered saline (PBS) at 4ºC with 
three fresh solution changes per week (Ando et al., 2010). After the complete demineralization, 
the decalcified specimens were then rinsed thoroughly in PBS, placed in 30% sucrose overnight 
and embedded in OCT compound (Sakura Finetek, Torrace, California). All samples were rapidly 
frozen and stored at -80 ºC until being cut on cryostat. Serial sections were then cryosectioned at 
20μm using a cryostat which were obtained at the medial midcondylar region in sagittal plane 
(Hagiwara et al., 2006, Ando et al., 2009). 
 
Immunohistochemistry 
Immunohistochemistry labeling was performed using the immunofluorescence method. 
Nonspecific binding sites were blocked with 10 % NGS (normal goat serum) for 30 minutes. 
Sections were then rinsed twice for 5 minutes in 0.1M PBS and incubated in primary antibody 
(1:1000, guinea pig Anti-P2X3 Receptor, AB5896, Chemicon-Millipore, MA, USA) diluted in 
1% NGS and 0.05% Triton X-100 in 0.1M PBS and applied to the tissues overnight (4ºC) in a 
humid atmosphere. Sections were then rinsed twice for 5 minutes in 0.1M PBS and incubated in 
secondary antibody (1:1000, goat anti-guinea pig IgG-Alexa488, Life Technologies, Grand 
Island, NY, USA) diluted in 1 % NGS and 0.05 % Triton X-100 in 0.1M PBS for 1 hour at room 
temperature. Sections were then rinsed twice for 5 minutes in 0.1M PBS and incubated with TO-
PRO3 (1:4000, 30 minutes; Invitrogen, Carlsbad, CA, USA) for nuclear staining. After a final 
washing, the slides were mounted using Vectashield (Vector Laboratories, Burlingame, CA, 
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USA). Negative controls were prepared without incubation in primary antibody to confirm that 
there was no non-specific binding of the secondary antibody. After staining, sections were 
examined with the Confocal Bio-Rad MRC 1024 Microscope and the images were taken with a 
20× objective lens of the three specific regions of the knee joint: the articular cartilage covering 
the femoral condyle, the articular cartilage covering the tibial plateau and the meniscus. Five 
randomly selected knee sections were chosen for each sample (six samples per group) and were 
digitally imaged and stored for later analysis The density (mean, arbitrary units) of each section 
and the number of positive cells (chondrocytes) were quantified by manually counting total 
numbers in a given area using Image J (National Institutes of Health). Specifically, a standard 
size (average area of 75,190 µm2 for the layer of cartilage covering the femoral condyle, 62,410 
µm2 for the layer of cartilage covering the tibial plateau and 93,630 µm2 for meniscus) was 
applied to each section. Cells (chondrocytes) were counted if they were positively stained for 
P2X3 receptor. 
 
Synovial lavage fluid  
Under deep anaesthesia (induced by the intraperitoneal injection of 80 mg/kg ketamine 
and 20 mg/kg xylazine) the rats were then killed by cervical dislocation, the skin overlying the 
knee was excised, the patellar ligament was dissected and a 26-gauge needle connected to a 100 
µL Hamilton syringe was inserted through the joint capsule. The knee joint cavity was washed 
twice by injecting and immediately aspirating 100 µL of phosphate-buffered saline solution 
(PBS) containing 4 mM EDTA (Ekundi-Valentim et al., 2010).  
 
ELISA procedure 
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An adaptation of ELISA (Enzyme-Linked Immunosorbent Assay) (Safieh-Garabedian et 
al., 1995) was used to quantify the cytokines of the rat’s knee joint. Briefly, the synovial lavage 
fluid was homogenized in solution of phosphate buffered saline (PBS) containing 0.4 M NaCl, 
0.05% Tween 20, 0.5% bovine serum albumine (BSA), 0.1 mM phenyl-methylsulfonyl fluoride, 
0.1 mM benzotonic chloride, 10 mM EDTA, and 20 KL/mL aprotinine (Sigma, USA). The 
samples were centrifuged at 10,000 rpm for 15 minutes at 4ºC and the supernatants were stored at 
-70ºC for posterior use to evaluate the protein levels of TNF-α, IL-1β, IL-6 and CINC-1 in the 
rat’s knee joint. The cytokines were quantified by the following kits: TNF-α: Rat TNF-α/ 
TNFSF1A DuoSet ELISA Kit (R&D Systems, catalog number DY510); IL-1β: Rat IL-1β/IL-1F2 
DuoSet ELISA Kit (R&D Systems, catalog number DY501), IL-6: Rat IL-6 DuoSet ELISA Kit 
(R&D Systems, catalog number: DY506) and CINC-1: Rat CXCL1/CINC-1 DuoSet ELISA Kit 
(R&D Systems, catalog number DY515). All procedures followed the instructions of the 
manufacturer R&D Systems. All samples and standards were run in triplicate and the procedures 
were repeated twice to guarantee the authenticity of the results. In the present study, the levels of 
cytokines (TNF-, IL-1, IL-6 e CINC-1) were assessed three hours after carrageenan 
administration. 
 
Measurement of myeloperoxidase activity 
Myeloperoxidase is one of the enzymes released from neutrophils and directly associated 
to tissue injury. Although monocytes/macrophages and fibroblasts also contain myeloperoxidase, 
neutrophils show the highest intracellular levels of this enzyme, that represents up to 5% of 
neutrophil proteins (Klebanoff, 1991). Therefore, the measurement of myeloperoxidase’s activity 
was used as a marker of neutrophil migration (Klebanoff, 1991) in the knee joint of rats after 
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application of the stimulus. Three hours after carrageenan (300μg/knee) or 0.9% saline solution 
injection in the knee joint, synovial lavage fluid was collected and homogenized in 500μL of 
buffer 1 (0.1 M NaCl, 0.02 M NaPO4,1.015 M Na EDTA, pH 5.4) followed by centrifugation at 
3000 rpm for 15 min. The pellet was resuspended in 500 µL of buffer 1 and subjected to 
hypotonic lyses by the addition of 500 µL of 0.2% NaCl followed 30 seconds later by addition of 
500 µL of 1.6% NaCl in 5% glucose. After a further centrifugation, the pellet was resuspended in 
0.05 M NaPO4 buffer (pH 5.4) containing 0.5% hexadecyl-trimethylammonium bromide 
(HTAB). After that, the samples were snap-frozen in liquid nitrogen and thawed, three times, and 
centrifuged at 10,000 rpm for 15 min.  
The myeloperoxidase kinetic-colorimetric assay was conducted, as previously described 
(Bradley et al., 1982, Torres-Chavez et al., 2012). Fifty microliters of each sample (supernatant) 
and 0.08 M NaPO4 were dropped into wells of a 96-well microplate. 25 µl of 3,3´,3,3´-
tetramethylbenzidine (TMB) was added in each well and the reaction was initiated by the 
addition of 100 µL of  H2O2. The reaction was stopped 5 minutes later by the addition of 50 µL 
of 4M H2SO4. The optical density was read at 450 nm using an Asys UVM340 (3 readings at 
intervals of 30 seconds). Results were calculated by comparing the optical density of rat’s knee 
joint synovial lavage fluid supernatant with a standard curve of neutrophil (>95% purity). All 
procedures were repeated twice to guarantee the authenticity of the results. The results were 
presented as number of neutrophils/knee. 
 
Statistical analysis 
To determine if there were significant differences (p<0.05) between treatment groups, 
One-way ANOVA or T-test was performed. If there was a significant between-subjects main 
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effect of treatment group following One-way ANOVA, post hoc contrasts using the Tukey test 
were performed to determine the basis of the significant difference. For data shown in Fig. 3B a 
Two-way repeated measures ANOVA with one between subjects factor (i.e., treatment) and one 
within-subjects factor (i.e., time) were used to determine whether there were significant (p<0.05) 
differences among the groups. If there was a significant between-subjects main effect of 
treatment group, post hoc contrasts using the Bonferroni test were performed to determine the 
basis of the significant difference. Data are expressed in figures as means ± S.E.M. 
 
Results 
 
Carrageenan-induced articular hyperalgesia in males and estrus females 
In males and estrus females rats, the intra-articular administration of carrageenan (300 
µg/knee) induced hyperalgesia in the rat’s knee joint, measured 3 hours after the carrageenan 
administration (Fig. 1, P<0.05, one-way ANOVA post hoc Tukey test). The PET induced by 
intra-articular administration of 0.9% NaCl (50 µL/knee) was similar to that of untreated animals 
(Naive) (Fig. 1, P>0.05, one-way ANOVA post hoc Tukey test). The hyperalgesic response 
induced by carrageenan (300 µg/knee) in estrus females rats was not significantly different from 
that induced by carrageenan (300 µg/knee) in males rats (Fig. 1, P>0.05, one-way ANOVA post 
hoc Tukey test). Therefore, this equi-hyperalsegic dose of carrageenan (300 µg/knee) was used in 
subsequent experiments.  
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Figure 1 - Articular hyperalgesia induced by carrageenan in males and estrus females rats 
knee joint. Carrageenan (300 μg/knee, i.a.) induced an articular hyperalgesia in the knee joint of 
male and estrus female rats. The symbol "*" indicates a response significantly greater than that 
induced by 0.9% NaCl and Naive groups (p<0.05, Tukey test). The symbol "&" indicates equi-
hyperalsegic responses induced by carrageenan (300 μg/knee, i.a.) in the knee joint of male and 
estrus female rats (p>0.05, Tukey test). In this and in the subsequent figures the articular 
hyperalgesia was measured 3 hours after the intra-articular (i.a.) carrageenan administration and 
the number of rats used are in parentheses.  
 
The blockade of P2X3 and P2X2/3 receptors reduces the carrageenan-induced articular 
hyperalgesia in males and females in the same manner 
 To verify whether the activation of P2X3 and P2X2/3 receptors contributes to 
carrageenan-induced articular hyperalgesia in males and estrus females, and if so, to compare the 
effect of the P2X3 and P2X2/3 receptor antagonist A-317491 between males and estrus females, 
A-317491 was co-administrated with carrageenan (300 µg/knee) into the right knee joint of male 
and estrus female rats, and the hyperalgesic response was evaluated 3 hours after their 
administration. A-317491 at doses of 60, 180 and 540 µg/knee, but not 20µg/knee, significantly 
reduced the carrageenan-induced articular hyperalgesia (Fig. 2A and B, P<0.05, one-way 
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ANOVA post hoc Tukey test) in males and estrus females. The highest dose of A-317491 (540 
µg/knee) did not affect the carrageenan-induced articular hyperalgesia when applied on the 
contralateral knee joint (Fig. 2A and B, P>0.05, one-way ANOVA post hoc Tukey test) of males 
and estrus females, confirming their local peripheral action. When A-317491 plus only 0.9% 
NaCl was applied in the right knee joint, it had no effect by itself (Fig. 2A and B, P>0.05, one-
way ANOVA post hoc Tukey test) in males and estrus females. 
 
 
Figure 2 - Effect of the P2X3 and P2X2/3 receptors antagonist A-317491 on carrageenan-
induced articular hyperalgesia in the knee joint of males and estrus females. Co-
administration of A-317491 (60, 180 and 540 μg/knee) with carrageenan (300 μg/knee) 
significantly reduced carrageenan-induced articular hyperalgesia in males (A) and estrus females 
(B), as indicated by the symbol “#” (p<0.05, Tukey test).  The highest dose of A-317491 (540 
µg/knee) injected in the contralateral knee joint (ct) did not affect the carrageenan-induced 
articular hyperalgesia (p>0.05, Tukey test, A and B). A-317491 injected only with 0.9% NaCl 
had no effect by itself (p>0.05, Tukey test, A and B). The symbol "*" indicates a response 
significantly greater than that induced by 0.9% NaCl (p<0.05, Tukey test, A and B). 
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 Because no differences were found in the effect of the different doses of the P2X3 and 
P2X2/3 receptor antagonist A-317491 on carrageenan-induced articular hyperalgesia between 
males and estrus females, the subsequent experiments were performed only in male rats. 
  
Effect of blockade of articular P2X3 and P2X2/3 receptors on the development of carrageenan-
induced articular hyperalgesia 
 To characterize the period of time at which the activation of P2X3 and P2X2/3 receptors 
contributes to the development of carrageenan-induced hyperalgesia in the knee joint, the A-
317491 was co-administrated (0 hour) with carrageenan or administrated ½, 1, 2 or 3 hours after 
the carrageenan administration. Co-administration of A-317941 (540 μg/knee) with carrageenan 
(300 μg/knee) (Fig. 3A, P<0.05, one-way ANOVA post hoc Tukey test), but not its 
administration ½, 1, 2 or 3 hours after the carrageenan administration (Fig. 3A, P>0.05, one-way 
ANOVA post hoc Tukey test) significantly reduced the carrageenan-induced articular 
hyperalgesia. 
 In another set of experiments, A-317491 (540 µg/knee) was co-administrated with 
carrageenan (300 µg/knee) and the measurements were taken ½, 1, 2, 3, 4, 5, 6 and 24 hours later. 
The carrageenan-induced articular hyperalgesia reached its maximum 3 hours after its 
administration (Fig. 3B). A-317491 blocked the carrageenan-induced articular hyperalgesia 1, 2, 
3, 4, 5 and 6 hours after its co-administration (Fig. 3B, P<0.05, two-way ANOVA post hoc 
Bonferroni test).  
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Figure 3 - Temporal analysis of the effect of the P2X3 and P2X2/3 receptors antagonist A-
317491 on carrageenan-induced articular hyperalgesia. 
A - Co-administration (0 h) of A-317491 (540 μg/knee) with carrageenan (300 μg/knee), but not 
its administration ½, 1, 2 or 3 hours after the carrageenan administration (p>0.05, Tukey test) 
significantly reduced carrageenan-induced articular hyperalgesia, as indicated by the symbol “#” 
(p<0.05, Tukey test). The symbol "*" indicates a response significantly greater than that induced 
by 0.9% NaCl (p<0.05, Tukey test). B - The temporal analysis of the effect of the co-
administration of A-317491 (540 μg/knee) with carrageenan showed that it blocked the 
hyperalgesic response 1, 2, 3, 4, 5 and 6 hours after its co-administration, as indicated by the 
symbol “#” (p<0.05, Tukey test).  
 
Carrageenan increased the expression of the P2X3 receptor on the chondrocytes of the articular 
cartilage of the knee joint 
 To test the hypothesis that the local inflammation induced by carrageenan in the rat’s knee 
joint increases the expression of the P2X3 receptors on the chondrocytes of the articular cartilage 
covering the femoral condyle, the tibial plateau and meniscus cartilage of the knee joint, the 
carrageenan (300 µg/knee) or 0.9% NaCl (50μL) was administered into the rat’s knee joint and 
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the expression of P2X3 receptor was quantified 3 hours after the administration by 
immunofluorescence.  
 The intra-articular administration of carrageenan (300 µg/knee) increased the expression 
of P2X3 receptor on the chondrocytes of the articular cartilage covering the femoral condyle (Fig. 
4, P<0.05, one-way ANOVA post hoc Tukey test), the tibial plateau (Fig. 5, P<0.05, one-way 
ANOVA post hoc Tukey test) and the chondrocytes of the cartilage that forms the meniscus (Fig. 
6, P<0.05, one-way ANOVA post hoc Tukey test) when compared with the 0.9% NaCl treated 
and with untreated animals (Naive). The intra-articular injection of 0.9% NaCl alone (50 
µL/knee) did not affect the expression of P2X3 receptor in the chondrocytes of the three regions 
analyzed when compared with the Naive group (P>0.05, one-way ANOVA post hoc Tukey test). 
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Figure 4 - Effect of intra-articular injection of carrageenan on P2X3 receptors expression in 
the chondrocytes of the articular cartilage of the femoral condyle of the rats knee joint. The 
carrageenan administration (300 μg/knee) significantly increased the expression of P2X3 receptor 
in the chondrocytes of the articular cartilage covering the femoral condyle (A, B and green: C). 
The symbol “*” indicates an expression significantly greater when compared with 0.9% NaCl (A, 
B and green: F) and naive groups (A, B and green: I) rats (p<0.05, Tukey test). Red: TOPRO 3 
(nuclear marker). BM = Bone Marrow. Scale bar of 100 µm. 
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Figure 5 - Effect of intra-articular injection of carrageenan on P2X3 receptors expression in 
the chondrocytes of the articular cartilage of the tibial plateau of the rat’s knee joint. The 
carrageenan administration (300 μg/knee) significantly increased the expression of P2X3 receptor 
in the chondrocytes of the articular cartilage covering the tibial plateau (A, B and green: C). The 
symbol “*” indicates an expression significantly greater when compared with 0.9% NaCl (A, B 
and green: F) and naive groups (A, B and green: I) rats (p<0.05, Tukey test). Red: TOPRO 3 
(nuclear marker). BM = Bone Marrow. Scale bar of 100 µm. 
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Figure 6 - Effect of intra-articular injection of carrageenan on P2X3 receptors expression in 
the chondrocytes of the cartilage that forms the meniscus of the rat’s knee joint. The 
carrageenan administration (300 μg/knee) significantly increased the expression of P2X3 receptor 
in the chondrocytes of the cartilage that forms the meniscus (A, B and green: C). The symbol “*” 
indicates an expression significantly greater when compared with 0.9% NaCl (A, B and green: F) 
and naive groups (A, B and green: I) rats (p<0.05, Tukey test). Red: TOPRO 3 (nuclear marker). 
Scale bar of 100 µm. 
 
The blockade of P2X3 and P2X2/3 receptors reduces the carrageenan-induced local increase 
cytokines concentration 
To test the hypothesis that P2X3 and P2X2/3 receptors activation contributes to the 
carrageenan-induced articular hyperalgesia in the rats knee joint through an indirect sensitization 
of primary afferent nociceptors dependent on the previous release of the pro-inflammatory 
cytokines TNF-α, IL-1β, IL-6 and CINC-1 at the inflamed joint, the selective P2X3 and P2X2/3 
receptor antagonist A-317491 (540 µg/knee), was co-administrated with carrageenan (300 
μg/knee) in the rats knee joint and the local concentration of TNF-α, IL-1β, IL-6 and CINC-1 was 
quantified 3 hours later by ELISA procedure.  
The carrageenan administration (300 μg/knee) significantly increased the local 
concentration of TNF-α (Fig. 7A), IL-1β (Fig. 7B), IL-6 (Fig. 7C) and CINC-1 (Fig. 7D) when 
compared with 0.9% NaCl treated and with untreated rats (Naive) (P<0.05, one-way ANOVA 
post hoc Tukey test). The co-administration of A-317491 (540 µg/knee) with carrageenan 
significantly reduced the local concentration of TNF-α (Fig. 7A), IL-6 (Fig. 7C) and CINC-1 
(Fig. 7D) (P<0.05, one-way ANOVA post hoc Tukey test), but not the local concentration of IL-
1β (Fig. 7B) (P>0.05, one-way ANOVA post hoc Tukey test) induced by carrageenan. The intra-
articular injection of 0.9% NaCl alone did not affect the endogenous concentration of TNF-α, IL-
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1β, IL-6 and CINC-1 when compared with naive rats (P>0.05, one-way ANOVA post hoc Tukey 
test). 
 
Figure 7 - Effect of the P2X3 and P2X2/3 receptors antagonist A-317491 on carrageenan-
induced local increase of pro-inflammatory cytokines concentration. The carrageenan 
administration (300 μg/knee) significantly increased the local concentration of TNF-α (A), IL-1β 
(B), IL-6 (C) and CINC-1 (D) 3 hours after its administration. The co-administration of A-
317491 (540 μg/knee) with carrageenan significantly reduced the local concentration of TNF-α 
(A), IL-6 (C) and CINC-1 (D), as indicated by the symbol “#” (p<0.05, Tukey test), but not the 
local concentration of IL-1β (B) (p>0.05, Tukey test). The intra-articular injection of 0.9% NaCl 
alone did not significantly affect the local endogenous concentration of TNF-α, IL-1β, IL-6 and 
CINC-1 when compared with naive rats (p>0.05, Tukey test). The symbol “*” indicates a 
response significantly greater than that induced by 0.9% NaCl and naive rats (p<0.05, Tukey 
test). 
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The blockade of P2X3 and P2X2/3 receptors reduced the carrageenan-induced local neutrophil 
migration 
 To test the hypothesis that P2X3 and P2X2/3 receptors activation contributes to the 
carrageenan-induced articular hyperalgesia in the rats knee joint through neutrophil migration, 
the A-317491 (540 µg/knee) was co-administrated with carrageenan (300 μg/knee) in the knee 
joint and the myeloperoxidase’s activity was quantified 3 hours after its administration.  
 The carrageenan administration (300 μg/knee) significantly increased the 
myeloperoxidase’s activity when compared with 0.9% NaCl and untreated rats (naive) (Fig. 8, 
P<0.05, one-way ANOVA post hoc Tukey test). The co-administration of A-317491 (540 
µg/knee) with carrageenan significantly reduced the myeloperoxidase’s activity induced by 
carrageenan (Fig. 8, P<0.05, one-way ANOVA post hoc Tukey test). The intra-articular injection 
of 0.9% NaCl alone did not affect the myeloperoxidase’s activity when compared with naive rats 
(Fig. 8, P>0.05, one-way ANOVA post hoc Tukey test). 
 
Figure 8 - Effect of the P2X3 and P2X2/3 receptors antagonist A-317491 on carrageenan-
induced neutrophil migration. The carrageenan administration (300 μg/knee) significantly 
increased the myeloperoxidase’s activity into the rat’s knee joint 3 hours after its administration. 
The co-administration of A-317491 (540 μg/knee) with carrageenan significantly reduced the 
carrageenan-induced increase of myeloperoxidase’s activity, as indicated by the symbol “#” 
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(p<0.05, Tukey test). The symbol “*” indicates a response significantly greater than that induced 
by 0.9% NaCl and naive groups (p<0.05, Tukey test).      
 
 
Discussion 
 
In this study we showed, for the first time, that the activation of P2X3 and P2X2/3 
receptors by endogenous ATP contributes to carrageenan-induced articular hyperalgesia in the 
knee joint of males and estrus females in a similar manner. We also showed that carrageenan-
induced articular inflammation increases the expression of P2X3 receptors in chondrocytes of 
articular cartilage of the knee joint. Finally, we showed that the activation of P2X3 and P2X2/3 
receptors contributes to carrageenan-induced articular hyperalgesia through an indirect 
sensitization of the primary afferent nociceptors dependent on the previous release of pro-
inflammatory cytokines TNF-α, IL-1β, IL-6 and chemokine-induced chemoattractant-1 (CINC-1, 
analog to IL-8 in rats) and on the migration of neutrophils to the inflamed knee joint. 
The intra-articular carrageenan administration (300 µg/knee) induced an articular 
hyperalgesia in the knee joint of males and estrus females rats (low levels of ovarian hormones) 
of similar magnitude. Therefore, the blockade of P2X3 and P2X2/3 receptors in the rat’s knee 
joint attenuated the carrageenan-induced articular hyperalgesia in males and estrus females in a 
similar manner. Although earlier reports have shown sex differences in the action of opioids 
agonists (Cai et al., 2001, Clemente et al., 2004, Clemente-Napimoga et al., 2009) and of β-
adrenoceptor antagonist (Favaro-Moreira et al., 2012) on TMJ nociception between males and 
females, selective kappa opioid agonists are equally powerful to attenuate the edema of 
experimental arthritis in both male and female animals (Binder et al., 2000). Taken together, 
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these findings suggest that sex differences in analgesia depend, at least in part, on the particular 
receptor type under study. 
We showed that the P2X3 and P2X2/3 receptors antagonist A-317491 (Jarvis et al., 2002) 
blocked the carrageenan-induced articular hyperalgesia in the rat knee joint from 1 to 6 hours 
after its administration and did not affect the carrageenan-induced articular hyperalgesia when 
applied in the contralateral paw. Although spinal P2X3 and P2X2/3 receptors also contribute to 
nociception (McGaraughty et al., 2003), the lack of effect of the contralateral administration of 
A-317491 confirmed that only P2X3 and P2X2/3 receptors in the knee joint of male and estrus 
female rats were targeted.  
The presented results reinforce the findings from our research group that during the 
inflammatory process, ATP is released from injured cells such as by macrophages, platelets, 
neutrophils and dying cells (Filippini et al., 1990, Dubyak and el-Moatassim, 1993, Ferrari et al., 
1997, Beigi et al., 1999, Sikora et al., 1999, Mizumoto et al., 2003, Campwala and Fountain, 
2013) to the extracellular milieu and contributes to the development of inflammatory 
hyperalgesia induced by carrageenan in the subcutaneous tissue and in the TMJ region of rats via 
P2X3 and P2X2/3 receptor activation (Oliveira et al., 2005, Oliveira et al., 2009, Teixeira et al., 
2010). Further, they are also consistent with a previous report that the activation of P2X3 receptor 
is involved in the mechanical hypersensitivity induced by Complete Freund's adjuvant (CFA) of 
the inflamed knee joint (Seino et al., 2006) and with the observation that extracellular ATP is 
often found in the synovial fluid of patients with arthropathies (Ryan et al., 1991, Kumahashi et 
al., 2011).  
Similarly to what occurs in the subcutaneous tissue of rat paw (Oliveira et al., 2009), in 
the articular tissue of the knee joint, P2X3 and P2X2/3 receptors seem to be essential to the 
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development, but not to the maintenance of the hyperalgesic response. This is because A-317491 
blocked carrageenan-induced articular hyperalgesia only when it was co-administered with 
carrageenan, but not when it was administered ½, 1, 2 or 3 hours after the carrageenan 
administration.  
It is broadly accepted that carrageenan induces hyperalgesia by two distinct pathways that 
ultimately result in the local release of prostaglandins and sympathomimetic amines (Nakamura 
and Ferreira, 1987, Cunha et al., 1991, Cunha et al., 1992, Cunha et al., 2005). These 
inflammatory mediators directly sensitize the primary afferent nociceptor (Taiwo et al., 1989, 
Gold et al., 1996, Khasar et al., 1999, Rush and Waxman, 2004). Therefore, the blockade of 
carrageenan-induced articular hyperalgesia by the co-administration of P2X3 and P2X2/3 
receptors antagonist with carrageenan, suggests that the articular activation of P2X3 and P2X2/3 
receptors may be crucial to the sensitization of primary afferent nociceptors mediated by PGE2 
and sympathomimetic amines. 
Because the P2X3 receptor is also expressed in chondrocytes (Varani et al., 2008) and in 
degenerative diseases such as OA these cells are associated to cartilage damage, increased 
production of matrix-degrading enzymes and inflammatory mediators such as prostaglandins 
(PGE) (de Mattei et al., 2002, Varani et al., 2008, Lee et al., 2013), we tested the hypothesis that 
the local inflammation induced by carrageenan in the rat knee joint increases the expression of 
the P2X3 receptor in the chondrocytes of the articular cartilage. The current results demonstrated 
that the carrageenan-induced knee joint inflammation increased the expression of the P2X3 
receptor in the chondrocytes of the articular cartilage covering the femoral condyle, tibial plateau 
and meniscus cartilage of the rat’s knee joint.  
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The chondrocytes, the unique cell type residing in cartilage (Picher et al., 2003 
Maldonado and Nam, 2013), can release PGE2 (Chowdhury et al., 2008), a major contributor of 
inflammatory pain in arthritis conditions, that acts through a variety of prostanoids receptors 
expressed in peripheral sensory neurons and spinal cord (Dray and Read, 2007). Previous study 
in vitro showed that ATP and α,β-meATP (P2X3 agonist, Gever et al., 2006) increase the PGE2 
production by chondrocytes in the absence and in the presence of the pro-inflammatory cytokine 
IL-1β, an effect that was blocked by the selective P2X3 and P2X2/3 receptors antagonist 
A317491, indicating a role for P2X3 receptors in PGE2 release by chondrocytes (Varani et al., 
2008). Moreover, previous studies in vitro have been shown that IL-1β stimulates the production 
of pro-inflammatory cytokines by chondrocytes (Guerne et al., 1990, Lotz et al., 1992, Aida et 
al., 2006). Taken together, these findings suggest that the increase on P2X3 receptor expression 
in chondrocytes during articular inflammation and its activation by ATP released from injured or 
dead cells might induce the PGE2 released by chondrocytes, which in turn, activates the 
prostanoids receptors expressed in primary afferent nociceptors. These data suggest that 
activation of P2X3 and P2X2/3 receptors expressed in chondrocytes contributes to carrageenan-
induced articular hyperalgesia in addition to those expressed in the peripheral terminals of 
primary afferent nociceptors that innervate the knee joint, as previously demonstrated (Dowd et 
al., 1998). 
Although the mechanisms involved in the development of articular hyperalgesia resulting 
from OA are not well elucidated, several studies have suggested the involvement of pro-
inflammatory cytokines in articular inflammatory processes (Smith et al., 1997, Fiorito et al., 
2005, Pearle et al., 2007). The increased concentration of pro-inflammatory cytokines such as IL-
1β, TNF-α, IL-6 and IL-8, has been demonstrated in the synovial fluid of joints with experimental 
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OA in rats (Gong et al., 2011, Rocha et al., 2011) and in the knee synovial fluid of patients with 
OA (Orita et al., 2011). A broad array of cytokines, including IL-1, IL-6, IL-18, TNF-α and 
chemokines, are produced by macrophages and fibroblasts of the synovium (Firestein, 2003), as 
well as by chondrocytes (Guerne et al., 1990, Lotz et al., 1992, Aida et al., 2006) that can activate 
either themselves or their neighboring cells.  
It is well known that carrageenan-induced hyperalgesia is mediated by the previous 
release of pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6 and IL-8 (Cunha et al., 1992, 
Lorenzetti et al., 2002). Therefore, we tested the hypothesis that the P2X3 and P2X2/3 receptors 
activation contributes to carrageenan-induced articular hyperalgesia by an indirect sensitization 
of primary afferent nociceptors dependent on the previous release of pro-inflammatory cytokines: 
TNF-α IL-1β, IL-6 and CINC-1.  
The results obtained showed that the peripheral P2X3 and P2X2/3 receptors activation by 
endogenous ATP is important to increase the concentration of TNF-α, IL-6 and CINC-1, but not 
of IL-1β. Previous data from our laboratory demonstrated that the administration of P2X3 and 
P2X2/3 receptors antagonist did not alter the carrageenan-induced increase of IL-1β 
concentration in the subcutaneous tissue of rat paw (Oliveira et al., 2009). Also, in the muscle 
tissue, the carrageenan increases the concentration of IL-1β, but not of TNF-α (Loram et al., 
2007). Therefore, the release of IL-1β does not always depends on the prior release of TNF-α, as 
previously suggested (Cunha et al., 1992). Another possibility is that the residual concentration of 
TNF-α in the knee joint observed after the administration of A-317491, could be enough to keep 
the concentration of IL-1β elevated. 
The importance of TNF-α and IL-6 to the development of arthropathies was demonstrated 
by the ability of anti-TNF-α and anti-IL-6 antibodies to prevent the progression of bone and 
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cartilage damage, relieving pain symptoms in patients (Lipsky et al., 2000, Grunke and Schulze-
Koops, 2006, Garnero et al., 2010, Tanaka et al., 2013) and by their ability in the prevention of 
collagen-induced arthritis in mice (Williams et al., 1992, Takagi et al., 1998). Thus, the findings 
of current study indicate that the essential role of peripheral P2X3 and P2X2/3 receptors 
activation in the development of carrageenan-induced articular hyperalgesia is mediated, at least 
in part, by the release of TNF-a and IL-6.  
The pro-inflammatory chemokine CINC-1 is responsible for stimulating the release of 
sympathomimetic amines (Cunha et al., 1991, Lorenzetti et al., 2002), which directly sensitize 
primary afferent nociceptors (Nakamura and Ferreira, 1987) and contributes to the influx and 
activation of polymorphonuclear cells into the joint (Moon et al., 2010). This leads to the release 
of enzymes that decrease the expression of collagen by fibroblasts, which may result in the 
destruction of cartilage and bone, and consequently pain (Badolato and Oppenheim, 1996). The 
current results also demonstrated that the peripheral P2X3 and P2X2/3 receptors activation is 
important to carrageenan-induced increase of CINC-1 concentration in the knee joint. It explains, 
at least in part, the anti-hyperalgesic effect of the co-administration of P2X3 and P2X2/3 
receptors antagonist in the knee joint of rats, suggesting that blockade of carrageenan-induced 
CINC-1 release by the P2X3 and P2X2/3 receptors antagonist may reduce the release of 
sympathomimetic amines, since the synovium is innervated by sympathetic nerve fibers in OA 
joints (Weidler et al., 2005).  
In patients with OA, it was also demonstrated an intense neutrophil migration (Jones et 
al., 1991). Because neutrophils are involved in the genesis of inflammatory hyperalgesia (Cunha 
et al., 2008), and their infiltration into synovial tissues can cause proteolytic enzymes release 
which contributes significantly to the tissue damage (Edwards and Hallett, 1997), we also 
44 
 
investigated the involvement of articular P2X3 and P2X2/3 receptors activation on neutrophil 
migration induced by intra-articular administration of carrageenan, which induces neutrophil 
recruitment into the knee joint (Ekundi-Valentim et al., 2010).  
Our data demonstrated that the blockade of the P2X3 and P2X2/3 receptors reduced the 
carrageenan-induced neutrophil migration to the rat’s knee joint, showing that the peripheral 
P2X3 and P2X2/3 receptors activation by endogenous ATP is important to induce neutrophil 
migration. This data indicate an important difference between the pathophysiology of 
inflammatory hyperalgesia in the articular and subcutaneous tissues, because although P2X3 
receptor activation by endogenous ATP, is important for the release of CINC-1 in the 
subcutaneous tissue, it has a minor importance for leukocyte migration in this tissue (Oliveira et 
al., 2009).   
In summary, we conclude that the activation of P2X3 and P2X2/3 receptors by 
endogenous ATP plays a crucial role in the development of carrageenan-induced articular 
hyperalgesia in the knee joint of males and estrus females in a similar manner.  Furthermore, 
during knee joint inflammation the expression of P2X3 receptors in chondrocytes is increased, 
suggesting that their activation may contribute to the increased release of inflammatory 
mediators, which in turn, activate the primary afferent nociceptors. This suggestion is supported 
by our findings that the essential role played by P2X3 and P2X2/3 receptors in the development 
of carrageenan-induced articular hyperalgesia is mediated by an indirect sensitization of the 
primary afferent nociceptors dependent on the previous release of pro-inflammatory cytokines 
and on neutrophil migration in the knee joint. Taken together, these findings suggest that 
selective antagonists for the P2X3 and P2X2/3 receptors could be potential targets for drug 
development for inflammatory joint diseases treatment. 
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Abstract 
Knee osteoarthritis (OA) is a common degenerative joint disease which causes physical 
disability, synovitis, joint swelling and inflammatory pain and affects a greater proportion of 
women than men. Although the activation of P2X7 receptor contributes to the development of 
inflammatory hyperalgesia and inflammation, it is not known whether P2X7 receptor plays a role 
in carrageenan-induced inflammatory hyperalgesia in the knee joint. In this study, we 
investigated whether peripheral P2X7 receptor activation by endogenous ATP contributes to 
carrageenan-induced hyperalgesia in the knee joint of rats, and, if so, whether this contribution 
depends on the previous release of the pro-inflammatory cytokines and/or the migration of 
neutrophils to the inflamed knee joint. Because females with lower levels of ovarian hormones 
are more responsive to some analgesic drugs, we also investigated whether the effect induced by 
the blockade of P2X7 receptors in the knee joint differs between male and estrus female rats (low 
levels of ovarian hormones). Blockade of P2X7 in the rat’s knee joint significantly reduced the 
articular hyperalgesia, the increase of concentration of pro-inflammatory cytokines TNF-α, IL-
1β, IL-6 and CINC-1 and the neutrophil migration induced by the carrageenan injection into the 
knee joint of males and estrus females. However, a lower dose of the selective P2X7 receptor 
antagonist A-740003 was sufficient to significantly reduce the hyperalgesic responses, the pro-
inflammatory cytokines concentration and the neutrophil migration in the knee joint of estrus 
females, but not of males. We conclude that activation of P2X7 receptors by endogenous ATP is 
essential to the development of the articular hyperalgesia mediated by the previous release of pro-
inflammatory cytokines and neutrophil migration in both males and females rat knee joint. 
However, estrus females are more responsive than males to the anti-hyperalgesic and anti-
inflammatory effects induced by the blockade of P2X7 receptors in the rat knee joint. 
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Introduction 
 
Knee osteoarthritis (OA) is one of the most common rheumatic disorders. It affects a 
greater proportion of women than men (Nevitt and Felson, 1996, Srikanth et al., 2005, Felson, 
2006) and it is characterized by synovial inflammation and cartilage breakdown due to an 
imbalance between extracellular matrix destruction and repair, which is directly linked to clinical 
symptoms such as physical disability, synovitis, joint swelling and inflammatory pain (Hunter et 
al., 2009, Sellam and Berenbaum, 2010, Orita et al., 2011).   
The P2X purinergic receptors are ligand-gated ionotropic channels, which open in 
response to the binding of extracellular adenosine 5’-triphosphate (ATP). Among the seven P2X 
purinergic receptor subtypes (P2X1-P2X7) (Buell et al., 1996), the P2X7 subtype has been 
implicated in processes of pain and inflammation (Dell'Antonio et al., 2002a, Dell'Antonio et al., 
2002b, Fulgenzi et al., 2005, Donnelly-Roberts and Jarvis, 2007, Lister et al., 2007, 
McGaraughty et al., 2007, Fulgenzi et al., 2008, Honore et al., 2009, Teixeira et al., 2010a and b).  
In the peripheral tissue, the P2X7 receptor is selectively expressed in mast cells, 
lymphocytes, fibroblasts, erythrocytes, monocytes, peripheral macrophages and type B 
synoviocytes (FLS cells) (Surprenant et al., 1996, Collo et al., 1997, Mancino et al., 2001, 
Caporali et al., 2008), where it plays an important role in the development of the inflammatory 
processes by modulating the production of inflammatory mediators, such as IL-1, IL-6, IL-8, 
TNF, monocyte chemoattractant protein-1 (MCP-1) and  interferon gamma-induced protein (IP-
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10) (Chessell et al., 2005, Fulgenzi et al., 2005, Ferrari et al., 2006, Honore et al., 2006, Lister et 
al., 2007, Mingam et al., 2008). Although the occurrence of OA is very common in the knee joint 
(Hunter and Eckstein, 2009), it is not known whether P2X7 receptor play a role in carrageenan-
induced inflammatory hyperalgesia in this joint. In the temporomandibular joint (TMJ) they do 
not, whereas functional P2X7 receptors are expressed in the TMJ region (Teixeira et al., 2010a).  
In this study, we investigated whether the P2X7 receptor activation by endogenous ATP 
contributes to carrageenan-induced articular hyperalgesia in rats knee joint, and, if so, whether 
this contribution depends on the previous release of the pro-inflammatory cytokines TNF-α, IL-
1β, IL-6 and chemokine-induced chemoattractant-1 (CINC-1, analog to IL-8 in rats) and/or 
migration of neutrophils to the inflamed joint. Because the involvement of some receptors in pain 
and analgesia processes is sex-dependent, for example females with lower levels of ovarian 
hormones are more responsive to some analgesic drugs than males rats (Clemente et al., 2004, 
Clemente-Napimoga et al., 2009, Favaro-Moreira et al., 2012), we also investigated whether the 
effect induced by the blockade of P2X7 receptors in the knee joint differs between male and 
estrus female rats  (low levels of ovarian hormones).   
 
Materials and Methods 
 
Animals 
Male and female Wistar rats (200-250g) obtained from the Multidisciplinary Center for 
Biological Research (CEMIB - UNICAMP, SP, Brazil) were used in this study. The animals were 
housed in plastic cages with soft bedding (five/cage) on a 12:12 light cycle (lights on at 06:00 
A.M.) with food and water available ad libitum. They were maintained in a temperature-
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controlled room (±23°C) and handled for at least one week prior to the experiments. Each animal 
was used once and the number of animals per group was kept to a minimum. Experimental 
protocols were approved by the Committee on Animal Research of the University of Campinas 
(protocol number: 2049-1) and were conformed to IASP guidelines for the study of the pain in 
animals (Zimmermann, 1983). 
 
General Procedures 
Testing sessions took place during light phase (between 09:00 AM and 5:00 PM) in a 
quiet room maintained at 23ºC (Rosland, 1991). During the tests the animals had no access to 
water or food. The animals were habituated for 1 hour prior to the experiment to minimize stress. 
 
Drugs administration  
Drugs or their vehicle were intra-articularly administrated in the right rat’s knee joint by a 
26-gauge needle that was connected to a catheter of polyethylene and also to a Hamilton syringe. 
The volume of injection was 50 µL.   
 
Carrageenan-induced knee joint inflammation (synovitis) 
Under brief inhalation of isoflurane anesthesia, rats were subjected to intra-articular (i.a.) 
injection of λ-carrageenan dissolved in 25 μL sterile 0.9% saline solution into their right knee 
joints (Tonussi and Ferreira, 1992, Ekundi-Valentim et al., 2010). The injection site was shaved 
and treated with an antiseptic solution of iodine alcohol. The other drugs were also injected into 
the knee joint in the same manner that the carrageenan and the control animals received vehicle 
or sterile 0.9% saline solution. 
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Drugs and doses  
The following drugs were used: λ-carrageenan (Cg; 300 µg/knee, i.a., Tonussi and 
Ferreira, 1992, Tonussi and Ferreira, 1999) obtained from Sigma-Aldrich (MO, USA) and [N-(1-
{[(Cyanoimino)(5-quinolinylamino)methyl]amino}-2,2-dimethylpropyl)-2-(3,4-
dimethoxyphenyl) acetamide] (A-740003 - the selective P2X7 receptor antagonist: 142, 284, 568 
µg/knee, i.a., Honore et al., 2006), dissolved in 25 μL of dimethyl sulfoxide (DMSO, 50%) and 
propylene glycol (50%), obtained from Tocris Bioscience (Ellisville, MO). 
 
Estrus phase determination 
Estrus phase in female rats was determined by daily microscope examination of vaginal 
smears taken by gentle lavage, between 9:00 and 10:00 a.m. Estrus phase was identified by the 
predominance (80 %) of anucleated cornified cells in rats with at least two consecutive regular 4-
day cycles (Smith et al., 1975, Marcondes et al., 2002). This phase was chosen because it 
represent phase of low levels of ovarian hormones, 17β-estradiol and progesterone (Butcher et 
al., 1974, Spornitz et al., 1999). 
 
Gait disturbance - Rat knee joint incapacitation test 
We used the rat knee-joint incapacitation test, as described previously (Tonussi and 
Ferreira, 1992). Briefly, 3 hours after carrageenan injection into their right knee joints, rats were 
put to walk on a steel rotary cylinder (30 cm wide x 50 cm diameter), covered with a fine-mesh 
non-oxidizable wire screen, which rotates at 3 rpm. Specially, designed metal gaiters were 
wrapped around both hind paws. After placement of the gaiters, rats were placed to walk in the 
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cylinder and the right paw was then connected via a simple circuit to microcomputer data 
input/output port. The paw elevation time (PET) is the total time that the rat walks failing to 
touch the cylinder surface with the injected hindpaw, during a 60 sec period, which is directly 
proportional to the gait disturbance. Incapacitation was quantified as an increase in the PET, 3 
hours after carrageenan injection into the right knee joint. To minimize variations in PET, all rats 
were introduced to the experimental environment and trained on the apparatus to habituation into 
the equipment before the testing sessions. To confirm the local effect of some test agents, they 
were injected into the contralateral rat’s knee joint and the test was performed on the ipsilateral 
knee joint. The rat knee-joint incapacitation test provides automated measurements, which are 
independent of the subjectivity of the observer (Tonussi and Ferreira, 1992). 
 
Synovial lavage fluid  
Under deep anaesthesia (induced by the intraperitoneal injection of 80 mg/kg ketamine 
and 20 mg/kg xylazine) the rats were then killed by cervical dislocation, the skin overlying the 
knee was excised, the patellar ligament was dissected and a 26-gauge needle connected to a 100 
µL Hamilton syringe was inserted through the joint capsule. The knee joint cavity was washed 
twice by injecting and immediately aspirating 100 µL of phosphate-buffered saline solution 
(PBS) containing 4 mM EDTA (Ekundi-Valentim et al., 2010).  
 
ELISA procedure 
An adaptation of ELISA (Enzyme-Linked Immunosorbent Assay) (Safieh-Garabedian et 
al., 1995) was used to quantify the cytokines of the rat’s knee joint. Briefly, the synovial lavage 
fluid was homogenized in solution of phosphate-buffered saline (PBS) containing 0.4 M NaCl, 
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0.05 % Tween 20, 0.5 % bovine serum albumine (BSA), 0.1 mM phenyl-methylsulfonyl fluoride, 
0.1 mM benzotonic chloride, 10 mM EDTA, and 20 KL/mL aprotinine (Sigma, USA). The 
samples were centrifuged at 10000 rpm for 15 minutes at 4ºC and the supernatants were stored at 
-70ºC for posterior use to evaluate the protein levels of TNF-α, IL-1β, IL-6 and CINC-1 in the 
rat’s knee joint. The cytokines were quantified by the following kits: TNF-α: Rat TNF-α/ 
TNFSF1A DuoSet ELISA Kit (R&D Systems, catalog number DY510); IL-1β: Rat IL-1β/IL-1F2 
DuoSet ELISA Kit (R&D Systems, catalog number DY501), IL-6: Rat IL-6 DuoSet ELISA Kit 
(R&D Systems, catalog number: DY506) and CINC-1: Rat CXCL1/CINC-1 DuoSet ELISA Kit 
(R&D Systems, catalog number DY515). All procedures followed the instructions of the 
manufacturer R&D Systems. All samples and standards were run in triplicate and the procedures 
were repeated twice to guarantee the authenticity of the results. In the present study, the levels of 
cytokines (TNF-, IL-1, IL-6 e CINC-1) were assessed three hours after carrageenan 
administration. 
 
Measurement of myeloperoxidase activity 
Myeloperoxidase is one of the enzymes released from neutrophils and directly associated 
to tissue injury. Although monocytes/macrophages and fibroblasts also contain myeloperoxidase, 
neutrophils show the highest intracellular levels of this enzyme, that represents up to 5 % of 
neutrophil proteins (Klebanoff, 1991). Therefore, the measurement of myeloperoxidase’s activity 
was used as a marker of neutrophil migration (Klebanoff, 1991) in the rat’s knee joint after 
application of the stimulus. Three hours after injection of the inflammatory agent in the knee 
joint, synovial lavage fluid was collected and homogenized in 500μL of buffer 1 (0.1 M NaCl, 
0.02 M NaPO4,1.015 M Na EDTA, pH 5.4) followed by centrifugation at 3000 rpm for 15 min. 
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The pellet was resuspended in 500 µL of buffer 1 and subjected to hypotonic lyses by the 
addition of 500 µL of 0.2 % NaCl followed 30 seconds later by addition of 500 µL of 1.6% NaCl 
in 5% glucose. After a further centrifugation, the pellet was resuspended in 0.05 M NaPO4 buffer 
(pH 5.4) containing 0.5% hexadecyl-trimethylammonium bromide (HTAB). After that, the 
samples were snap-frozen in liquid nitrogen and thawed, three times, and centrifuged at 10,000 
rpm for 15 min.  
The myeloperoxidase kinetic-colorimetric assay was conducted, as previously described 
(Bradley et al., 1982, Torres-Chavez et al., 2012). Fifty microliters of each sample (supernatant) 
and 0.08 M NaPO4 were dropped into wells of a 96-well microplate. 25 µL of 3,3´,3,3´-
tetramethylbenzidine (TMB) was added in each well and the reaction was initiated by the 
addition of 100 µL of  H2O2. The reaction was stopped 5 min later by the addition of 50 µL of 
4M H2SO4. The optical density was read at 450 nm using an Asys UVM340 (3 readings at 
intervals of 30 seconds). Results were calculated by comparing the optical density of rat’s knee 
joint synovial lavage fluid supernatant with a standard curve of neutrophil (>95% purity). All 
procedures were repeated twice to guarantee the authenticity of the results. The results were 
presented as number of neutrophils/knee. 
 
Statistical analysis 
 To determine if there were significant differences (p<0.05) between treatment groups, 
One-way ANOVA or T-test was performed. If there was a significant between-subjects main 
effect of treatment group following One-way ANOVA, post hoc contrasts using the Tukey test 
were performed to determine the basis of the significant difference. For data shown in Fig. 2B a 
Two-way repeated measures ANOVA with one between subjects factor (i.e., treatment) and one 
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within-subjects factor (i.e., time) were used to determine whether there were significant (p<0.05) 
differences among the groups. If there was a significant between-subjects main effect of 
treatment group, post hoc contrasts using the Bonferroni test were performed to determine the 
basis of the significant difference. Data are expressed in figures as means ± S.E.M.  
 
Results 
 
Effect of blockade of P2X7 receptors on carrageenan-induced articular hyperalgesia  
The hyperalgesic and inflammatory responses of males and estrus females administered 
carrageenan (300 µg/knee) were not significantly different from each other (Fig. 1, 3 and 4, 
P>0.05, t test). Therefore, this equi-hyperalgesic and equi-inflammatory dose of carrageenan was 
used to compare the effect of P2X7 receptor blockade into the knee joint among males and estrus 
females.  
Co-administration of the selective P2X7 receptor antagonist A-740003 with carrageenan 
into the rat’s knee joint significantly reduced carrageenan-induced articular hyperalgesia (Fig. 1, 
P<0.05, one-way ANOVA post hoc Tukey test) measured 3 hours after the carrageenan 
administration in both males and females and in a dose related fashion. However, the lowest dose 
of A-740003 (142 µg/knee) significantly reduced the carrageenan-induced articular hyperalgesia 
in females but not in males, suggesting that carrageenan-induced hyperalgesia is significantly 
more responsive to P2X7 receptor antagonist A-740003 in females than in males. 
The highest dose of A-740003 (568 µg/knee) did not affect the carrageenan-induced 
articular hyperalgesia when administered on the contralateral knee joint in both males and estrus 
females (Fig. 1A and B, P>0.05, one-way ANOVA post hoc Tukey test), confirming its local 
65 
 
action. Co-administration of the highest dose of A-740003 (568 µg/knee) with the vehicle of 
carrageenan (0.9% NaCl) had no effect by itself (Fig. 1A and B, P>0.05, one-way ANOVA post 
hoc Tukey test) in both males and estrus females. Furthermore, the co-administration of 0.9% 
NaCl with the vehicle of A-740003 [dimethyl sulfoxide (50 %, DMSO) plus propylene glycol (50 
%)] had no effect by itself either (Fig. 1A and B, P>0.05, one-way ANOVA post hoc Tukey test). 
 
Figure 1 - Effect of the P2X7 receptor antagonist on carrageenan-induced articular 
hyperalgesia in males and estrus females rat’s knee joint. Co-administration of A-740003 in 
males (A, 284 and 568 μg/knee) and in estrus females (B, 142, 284 and 568 μg/knee) with 
carrageenan (300 μg/knee) significantly reduced carrageenan-induced articular hyperalgesia, as 
indicated by the symbol “#” (p<0.05, Tukey test).  The highest dose of A-740003 (568 µg/knee) 
injected in the contralateral knee joint (ct) did not affect the carrageenan-induced articular 
hyperalgesia (p>0.05, Tukey test, A and B). A-740003 injected only plus 0.9% NaCl did not 
induce articular hyperalgesia by itself (p>0.05, Tukey test, A and B). The administration of 
DMSO (50%) plus propylene glycol (50%) did not induce articular hyperalgesia by itself 
(p>0.05, Tukey test, A and B) in males and estrus females knee joint. The symbol "*" indicates a 
response significantly greater than that induced by 0.9% NaCl group (p<0.05, Tukey test, A and 
B). 
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Effect of blockade of articular P2X7 receptors on the development of carrageenan-induced 
articular hyperalgesia 
Co-administration of A-740003 (568 µg/knee) with carrageenan (300 μg/knee), but not its 
administration ½, 1, 2 and 3 hours after the carrageenan administration, significantly reduced 
carrageenan-induced hyperalgesia measured 3 hours after the carrageenan administration (Fig. 
2A, P<0.05, one-way ANOVA post hoc Tukey test). The carrageenan-induced articular 
hyperalgesia reached its maximum 3 hours after its administration (Fig. 2B). Co-administration 
of A-740003 (568 µg/knee) with carrageenan (300 μg/paw) blocked the hyperalgesic responses 1, 
2, 3, 4, 5 and 6 hours after the carrageenan administration (Fig. 2B, P<0.05, two-way ANOVA 
post hoc Bonferroni test).  
 
Figure 2 - Effect of P2X7 receptor antagonist co-administered or administrated ½, 1, 2, and 
3 hours after the carrageenan administration on carrageenan-induced articular 
hyperalgesia and the temporal analysis. (A) Co-administration (0 h) of A-740003 (568 
μg/knee) with the carrageenan (Cg, 300 μg/knee), but not its administration ½, 1, 2 or 3 hours 
after carrageenan administration (p>0.05, Tukey test) significantly reduced carrageenan-induced 
articular hyperalgesia in the males rat’s knee joint, as indicated by the symbol “#” (p<0.05, 
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Tukey test). The symbol "*" indicates a response significantly greater than that induced by 0.9% 
NaCl group (p<0.05, Tukey test). (B) The temporal analysis of the effect of the co-administration 
of A-740003 (568 μg/knee) with carrageenan showed that it blocked the hyperalgesic response 1, 
2, 3, 4, 5 and 6 hours after its co-administration, as indicated by the symbol “#”  (p<0.05, Tukey 
test).  
 
Effect of blockade of articular P2X7 receptors on carrageenan-induced local increase in 
cytokines concentration 
To verify whether the activation of P2X7 receptor by endogenous ATP contributes to the 
release of pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and CINC-1 induced by carrageenan 
at the knee joint, A-740003 (142 and 568 µg/knee for males and 142 µg/knee for estrus females) 
was co-administered with carrageenan (300 μg/knee) into the knee joint and the local 
concentrations of TNF-α, IL-1β, IL-6 and CINC-1 were quantified 3 hours after the carrageenan 
administration.  
The carrageenan administration (300 μg/knee) significantly increased the local 
concentration of TNF-α (Fig. 3A and B), IL-1β (Fig. 3C and D), IL-6 (Fig. 3E and F) and CINC-
1 (Fig. 3G and H) 3 hours after its administration into the knee joint of males and estrus females 
rats (P<0.05, one-way ANOVA post hoc Tukey test) when compared with the 0.9% NaCl 
administration and with untreated animals (Naive). Co-administration of A-740003 (568 μg/knee, 
but not 142 μg/knee) with carrageenan significantly reduced the local concentration of TNF-α 
(Fig. 3A), IL-1β (Fig. 3C), IL-6 (Fig. 3E) and CINC-1 (Fig. 3G) (P<0.05, one-way ANOVA post 
hoc Tukey test) induced by carrageenan into the knee joint of male rats. However, in estrus 
females the co-administration of the lowest dose of A-740003 (142 μg/knee) with carrageenan 
was sufficient to significantly reduce the local concentration of TNF-α (Fig. 3B), IL-6 (Fig. 3F) 
and CINC-1 (Fig. 3H) (P<0.05, one-way ANOVA post hoc Tukey test), but not of IL-1β (Fig. 
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3D) (P>0.05, one-way ANOVA post hoc Tukey test) induced by carrageenan into the knee joint. 
The intra-articular injection either the vehicle of carrageenan (0.9% NaCl) or the vehicle of A-
740003 [DMSO (50%) plus propylene glycol (50%)] did not affect the concentrations of TNF-α, 
IL-1β, IL-6 and CINC-1 when compared with those of the knee joint of untreated males and 
estrus females (Fig. 3, P>0.05, one-way ANOVA post hoc Tukey test). 
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Figure 3 - Effect of P2X7 receptor antagonist on carrageenan-induced local increase of pro-
inflammatory cytokines concentration in males and estrus females rat’s knee joint. The 
carrageenan administration (300 μg/knee) significantly increased the local concentration of TNF-
α (A and B), IL-1β (C and D), IL-6 (E and F) and CINC-1 (G and H) in the knee joint of males 
and estrus females rats 3 hours after its administration. In males rats, the co-administration of A-
740003 (568 μg/knee, but not 142 μg/knee) with carrageenan significantly reduced the local 
concentration of TNF-α (A), IL-1β (C), IL-6 (E) and CINC-1 (G) in the knee joint, as indicated 
by the symbol “#” (p<0.05, Tukey test). In estrus females rats, the co-administration of A-740003 
(142 μg/knee) with carrageenan significantly reduced the local concentration TNF-α (B), IL-6 (F) 
and CINC-1 (G) in the knee joint, as indicated by the symbol “#” (p<0.05, Tukey test), but not 
the local concentration of IL-1β (D) (p>0.05, Tukey test). The intra-articular injection in both 
males and estrus females knee joint of either 0.9% NaCl alone or DMSO (50%) plus propylene 
glycol (50%) did not significantly affect the local endogenous concentration of TNF-α, IL-1β, IL-
6 and CINC-1 when compared with naive group (p>0.05, Tukey test). The symbol “*” indicates a 
response significantly greater than that induced by naïve and vehicle groups (p<0.05, Tukey test). 
 
Effect of blockade of articular P2X7 receptors on carrageenan-induced local neutrophil 
migration  
To verify whether the activation of P2X7 receptor by endogenous ATP contributes to the 
neutrophil migration induced by carrageenan at the knee joint, A-740003 (142 and 568 µg/knee 
for males and 142 µg/knee for estrus females) was co-administrated with carrageenan (300 
μg/knee) in the knee joint of males and estrus females and the myeloperoxidase’s activity was 
quantified 3 h after the carrageenan administration. 
The carrageenan administration (300 μg/knee) significantly increased the 
myeloperoxidase’s activity in males (Fig. 4A) and in estrus females (Fig. 4B) when compared 
with the 0.9% NaCl administration and with untreated animals (Naive) (P<0.05, one-way 
ANOVA post hoc Tukey test). Co-administration of A-740003 (568 μg/knee, but not 142 
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μg/knee) with carrageenan significantly reduced the myeloperoxidase’s activity induced by 
carrageenan in the knee joint of male rats (Fig. 4A, P<0.05, one-way ANOVA post hoc Tukey 
test). However, in estrus females, the co-administration of the lowest dose of A-740003 (142 
μg/knee) with carrageenan was also sufficient to significantly reduce the myeloperoxidase’s 
activity induced by carrageenan in the knee joint of estrus female rats (P<0.05, one-way ANOVA 
post hoc Tukey test). The intra-articular injection of either the vehicle of carrageenan (0.9% 
NaCl) or the vehicle of A-740003 [DMSO (50 %) plus propylene glycol (50 %)] did not affect 
the basal myeloperoxidase’s activity when compared with untreated males and estrus females 
(naive groups) (P>0.05, one-way ANOVA post hoc Tukey test). 
 
 
Figure 4 - Effect of P2X7 receptor antagonist on carrageenan-induced neutrophil migration 
in males and estrus females rat’s knee joint. The carrageenan administration (Cg, 300μg/knee) 
significantly increased the myeloperoxidase’s activity in the knee joint of males (A) and estrus 
females rats (B). The co-administration of A-740003 in males (A, 568 μg/knee, but not 142 
μg/knee) and in estrus females (B, 142 μg/knee) with carrageenan significantly reduced the 
carrageenan-induced increase of myeloperoxidase’s activity, as indicated by the symbol “#” 
(p<0.05, Tukey test). The intra-articular injection in both males and estrus females knee joint of 
either 0.9% NaCl alone or DMSO (50 %) plus propylene glycol (50 %) did not affect the 
myeloperoxidase’s activity when compared with naive group (p>0.05, Tukey test). The symbol 
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“*” indicates a response significantly greater than that induced by vehicle and naive groups 
(p<0.05, Tukey test). 
 
 
Discussion 
 
In this study, we showed that blockade of P2X7 receptors in the rat knee joint 
significantly reduces the articular hyperalgesia mediated by the previous release of pro-
inflammatory cytokines and neutrophil migration in the rat knee joint of both males and estrus 
females. However, estrus females are more responsive than males to the anti-hyperalgesic and 
anti-inflammatory effects induced by the blockade of P2X7 receptor in the rat knee joint. 
The activation of P2X7 receptor by endogenous ATP during inflammation, not only 
contributes but it is essential to the development, but not to the maintenance of the articular 
hyperalgesia in the knee joint of males and estrus females.  This is because the selective P2X7 
receptor antagonist A-740003 (Honore et al., 2006) blocked carrageenan-induced articular 
hyperalgesia when it was co-administered with carrageenan, but not when it was administered ½, 
1, 2 or 3 hours after the carrageenan administration.   
A-740003 blocked the carrageenan-induced articular hyperalgesia in the rat knee joint 
from 1 to 6 hours after its administration and did not affect the carrageenan-induced articular 
hyperalgesia when applied in the contralateral paw. Although the activation of spinal P2X7 
receptor contributes to the mechanical hyperalgesia (Clark et al., 2010), the finding that the 
administration of A-740003 in the contralateral knee joint did not affect carrageenan-induced 
articular hyperalgesia, confirms that only articular P2X7 receptors of the knee joint were targeted. 
These findings are consistent with the involvement of peripheral P2X7 receptors in collagen-
73 
 
induced arthritis (Labasi et al., 2002, Broom et al., 2008) and in carrageenan-induced mechanical 
hyperalgesia in the subcutaneous tissue (Teixeira et al., 2010b). However, these receptors are not 
involved in processes of pain and inflammation in all joints. Although functional P2X7 receptors 
are expressed in the temporomandibular joint, they do not play a role in the carrageenan-induced 
inflammatory hyperalgesia in this joint (Teixeira et al., 2010a). 
The mechanisms involved in the development of articular pain resulting from OA are not 
well elucidated. However, in patients with OA (Orita et al., 2011) and in rats with experimental 
OA (Gong et al., 2011, Rocha et al., 2011), the concentration of pro-inflammatory cytokines such 
as IL-1β, TNF-α, IL-6 and CINC-1 (or IL-8 in human) is increased in the synovial fluid. These 
pro-inflammatory cytokines contribute to the destruction of cartilage and bone, and consequently 
to pain development in the joints (Goldring et al., 1994, Attur et al., 1998, Mengshol et al., 2000).  
In addition, it has been demonstrated in the carrageenan model, that TNF-α triggers the 
release of IL-1β, IL-6 and CINC-1, that ultimately induce the synthesis of the final inflammatory 
mediators prostaglandins and sympathomimetic amines, respectively (Cunha et al., 1991, Cunha 
et al., 1992, Ferreira et al., 1993) which sensitize the primary afferent nociceptor (Taiwo et al., 
1989, Gold et al., 1996, Khasar et al., 1999, Rush and Waxman, 2004). Therefore, our findings 
that the administration of the P2X7 receptor antagonist A-740003 significantly reduced the 
increase of concentration of pro-inflammatory cytokines induced by carrageenan in the knee joint 
of males and females, suggest that the essential role that the peripheral P2X7 receptor activation 
plays in the development of carrageenan-induced articular hyperalgesia in males and females, is 
mediated, in part, by the previous release of pro-inflammatory cytokines.  
This interpretation is in accordance with the finding that the anti-hyperalgesic effect of 
P2X7 receptor antagonists in the CFA-induced hyperalgesia (Complete Freund’s Adjuvant) is 
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mediated by modulation of IL-1β activity (Honore et al., 2009). In the articular tissue, pro-
inflammatory cytokines such as IL-1β, TNF-α, IL-6 and CINC-1 (or IL-8 in human) are produced 
by synovial macrophages (Firestein, 2003) and by type B synoviocytes (Guerne et al., 1989, Pap 
et al., 2000, Hayashida et al., 2001), which express the P2X7 receptor  (Caporali et al., 2008). 
Therefore, the high concentration of extracellular ATP released due to the extensive cell injury in 
the inflamed joints, may activate the P2X7 receptor expressed on these cells, resulting in the 
release of pro-inflammatory cytokines that contribute to synovitis, to cartilage and bone 
destruction and to inflammatory pain development in the arthropathies. There is an important 
difference in the inflammatory response mediated by the activation of P2X7 receptor located in 
the knee joint and in the subcutaneous tissue. The P2X7 receptor activation by endogenous ATP 
released during inflammation increases the concentration of IL-1β in the knee joint, but not in the 
subcutaneous tissue of male rats (Teixeira et al., 2010b).  
In patients with OA, in addition to the increased levels of pro-inflammatory cytokines in 
the synovial fluid, there is also an intense neutrophil migration into the knee joint (Jones et al., 
1991). The pro-inflammatory chemokine CINC-1 contributes to the influx and to the activation of 
polymorphonuclear cells into the joint (Moon et al., 2010), leading to the release of enzymes that 
decrease the expression of collagen by fibroblasts, which may result in destruction of cartilage 
and bone and, consequently, pain development (Badolato and Oppenheim, 1996). 
The intra-articular administration of the P2X7 receptor antagonist A-740003 significantly 
reduced the carrageenan-induced neutrophil migration in the knee joint of males and estrus 
females. This finding suggests that the peripheral P2X7 receptor activation by endogenous ATP 
is important in the recruitment of neutrophil to the injured joint and is in agreement with those 
showing that the blockade of P2X7 receptor reduces neutrophil migration in different tissues 
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(Kim et al., 2010, Martins et al., 2012). Because neutrophils are involved in the genesis of 
inflammatory hyperalgesia (Cunha et al., 2008), the anti-hyperalgesic effect of the P2X7 receptor 
antagonist A-740003 on the knee joint, may be mediated, in part, by a decreased concentration of 
the chemokine CINC-1 into the joint tissue, and by the subsequent decrease of neutrophil 
migration.  
In this study, we showed for the first time, that while males and females respond to the 
anti-hyperalgesic and anti-inflammatory effects of the P2X7 receptor antagonist A-740003 in the 
inflamed knee joint, estrus females are more responsive to these effects than males. The evidence 
is that, the lowest dose of the P2X7 receptor antagonist A-740003 (142 μg) was sufficient to 
reduce the articular hyperalgesia, the local concentration of the pro-inflammatory cytokines TNF-
α, IL-6 and CINC-1, and the neutrophil migration induced by carrageenan in estrus females, but 
not in males, which responded only to the two highest doses of A-740003. 
These findings are of clinical relevance, because OA is more prevalent in women than 
men (Nevitt and Felson, 1996, Srikanth et al., 2005, Felson, 2006). They are also in accordance 
with previous reports that the administration of a kappa opioid agonist (Clemente et al., 2004) or 
of a β-adrenoceptor antagonist (Favaro-Moreira et al., 2012) induces greater TMJ analgesia in 
females than in males, and especially in females with lower levels of ovarian hormones, such as 
estrus or diestrus females. On the other hand, we have demonstrated that males and females are 
similarly responsive to the anti-hyperalgesic effect of P2X3 and P2X2/3 receptor antagonists in 
the inflamed knee joint (Teixeira et al., 2014 in press). Taken together, these findings reinforce 
the previous suggestion that sex differences in analgesia depend, at least in part, on the particular 
receptor type under study (Binder et al., 2000, Clemente et al., 2004, Favaro-Moreira et al., 
2012). 
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The peripheral mechanism involved in the greater responsiveness of estrus females to the 
anti-hyperalgesic effect induced by the P2X7 receptor antagonist A-740003 may be mediated, at 
least in part, by the greater ability of this antagonist in reducing the release of the pro-
inflammatory cytokines TNF-α, IL-6 and CINC-1 and the neutrophil migration induced by 
carrageenan in the knee joint of estrus females than males.  In estrus females, a higher dose of the 
P2X7 receptor antagonist A-740003 may be necessary to significantly reduce the release of IL-1β 
induced by carrageenan. 
The physiological mechanisms involved in the sex-related differences in the anti-
hyperalgesic and anti-inflammatory responses mediated by the blockade of P2X7 receptors in the 
knee joint are not presently known. However, our findings that estrus females are more 
responsive to the anti-hyperalgesic and anti-inflammatory effect of the P2X7 receptor antagonist 
A-740003 than males, suggest that testosterone might attenuate the anti-hyperalgesic effect 
induced by this antagonist, as previously showed in the antinociceptive effects induced by opiods 
agonist (Clemente et al., 2004) and by β-blockers (Favaro-Moreira et al., 2012) on the TMJ of 
male rats. 
In summary, we have shown that activation of P2X7 receptors by endogenous ATP is 
essential to the development of the articular hyperalgesia dependent on the previous release of 
pro-inflammatory cytokines and neutrophil migration in both males and females rat’s knee joint. 
However, estrus females are more responsive than males to the anti-hyperalgesic and anti-
inflammatory effects induced by the blockade of P2X7 receptors in the rat knee joint. The greater 
responsiveness of estrus females to the anti-hyperalgesic effect induced by the blockade of P2X7 
receptors in the rat knee joint, may result from their greater responsiveness to the anti-
inflammatory effect induced by the articular blockade of this purinergic receptor. Taken together, 
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these findings indicate that the P2X7 receptors are a novel anti-inflammatory and anti-
hyperalgesic therapeutic target in the treatment of the symptoms of OA in the knee joint, 
especially in women, who are more affected than men by this disease. 
 
Acknowledgements 
This work was supported by grants from Fundação de Amparo à Pesquisa do Estado de 
São Paulo - FAPESP, Brazil (2009/16854-3 and 2010/05381-4). 
 
 
References 
 
Attur MG, Patel IR, Patel RN, Abramson SB, Amin AR (Autocrine production of IL-1 beta by 
human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, 
IL-6, prostaglandin E2, and IL-8. Proc Assoc Am Physicians 110:65-72.1998). 
Badolato R, Oppenheim JJ (Role of cytokines, acute-phase proteins, and chemokines in the 
progression of rheumatoid arthritis. Semin Arthritis Rheum 26:526-538.1996). 
Bradley PP, Priebat DA, Christensen RD, Rothstein G (Measurement of cutaneous inflammation: 
estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206-209.1982). 
Binder W, Carmody J, Walker J (Effect of gender on anti-inflammatory and analgesic actions of 
two kappa-opioids. J Pharmacol Exp Ther 292:303-309.2000). 
Broom DC, Matson DJ, Bradshaw E, Buck ME, Meade R, Coombs S, Matchett M, Ford KK, Yu 
W, Yuan J, Sun SH, Ochoa R, Krause JE, Wustrow DJ, Cortright DN (Characterization of N-
(adamantan-1-ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl)methyl]-2-chloro-ben zamide, a P2X7 
antagonist in animal models of pain and inflammation. J Pharmacol Exp Ther 327:620-
633.2008). 
Buell G, Collo G, Rassendren F (P2X receptors: an emerging channel family. Eur J Neurosci 
8:2221-2228.1996). 
78 
 
Butcher RL, Collins WE, Fugo NW (Plasma concentration of LH, FSH, prolactin, progesterone 
and estradiol-17beta throughout the 4-day estrous cycle of the rat. Endocrinology 94:1704-
1708.1974). 
Caporali F, Capecchi PL, Gamberucci A, Lazzerini PE, Pompella G, Natale M, Lorenzini S, Selvi 
E, Galeazzi M, Laghi Pasini F (Human rheumatoid synoviocytes express functional P2X7 
receptors. J Mol Med (Berl) 86:937-949.2008). 
Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, 
Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN 
(Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic 
pain. Pain 114:386-396.2005). 
Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB, Malcangio M (P2X7-dependent 
release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. J 
Neurosci 30:573-582.2010). 
Clemente-Napimoga JT, Pellegrini-da-Silva A, Ferreira VH, Napimoga MH, Parada CA, Tambeli 
CH (Gonadal hormones decrease temporomandibular joint kappa-mediated antinociception 
through a down-regulation in the expression of kappa opioid receptors in the trigeminal 
ganglia. European journal of pharmacology 617:41-47.2009). 
Clemente JT, Parada CA, Veiga MC, Gear RW, Tambeli CH (Sexual dimorphism in the 
antinociception mediated by kappa opioid receptors in the rat temporomandibular joint. 
Neurosci Lett 372:250-255.2004). 
Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G (Tissue distribution of 
the P2X7 receptor. Neuropharmacology 36:1277-1283.1997). 
Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH (Interleukin-8 as a mediator of sympathetic pain. 
Br J Pharmacol 104:765-767.1991). 
Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH (The pivotal role of tumour necrosis factor alpha 
in the development of inflammatory hyperalgesia. Br J Pharmacol 107:660-664.1992). 
Cunha TM, Verri WA, Jr., Schivo IR, Napimoga MH, Parada CA, Poole S, Teixeira MM, 
Ferreira SH, Cunha FQ (Crucial role of neutrophils in the development of mechanical 
inflammatory hypernociception. J Leukoc Biol 83:824-832.2008). 
79 
 
Dell'Antonio G, Quattrini A, Cin ED, Fulgenzi A, Ferrero ME (Relief of inflammatory pain in 
rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis and 
rheumatism 46:3378-3385.2002a). 
Dell'Antonio G, Quattrini A, Dal Cin E, Fulgenzi A, Ferrero ME (Antinociceptive effect of a new 
P(2Z)/P2X7 antagonist, oxidized ATP, in arthritic rats. Neurosci Lett 327:87-90.2002b). 
Donnelly-Roberts DL, Jarvis MF (Discovery of P2X7 receptor-selective antagonists offers new 
insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 
151:571-579.2007). 
Ekundi-Valentim E, Santos KT, Camargo EA, Denadai-Souza A, Teixeira SA, Zanoni CI, Grant 
AD, Wallace J, Muscara MN, Costa SK (Differing effects of exogenous and endogenous 
hydrogen sulphide in carrageenan-induced knee joint synovitis in the rat. Br J Pharmacol 
159:1463-1474.2010). 
Favaro-Moreira NC, Parada CA, Tambeli CH (Blockade of beta(1)-, beta(2)- and beta(3)-
adrenoceptors in the temporomandibular joint induces antinociception especially in female 
rats. Eur J Pain 16:1302-1310.2012). 
Felson DT (Clinical practice. Osteoarthritis of the knee. N Engl J Med 354:841-848.2006). 
Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F (The 
P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176:3877-3883.2006). 
Ferreira SH, Lorenzetti BB, Cunha FQ, Poole S (Bradykinin release of TNF-alpha plays a key 
role in the development of inflammatory hyperalgesia. Agents Actions 38 Spec No:C7-
9.1993). 
Firestein GS (Evolving concepts of rheumatoid arthritis. Nature 423:356-361.2003). 
Fulgenzi A, Dell'Antonio G, Foglieni C, Dal Cin E, Ticozzi P, Franzone JS, Ferrero ME 
(Inhibition of chemokine expression in rat inflamed paws by systemic use of the 
antihyperalgesic oxidized ATP. BMC Immunol 6:18.2005). 
Fulgenzi A, Ticozzi P, Gabel CA, Dell Antonio G, Quattrini A, Franzone JS, Ferrero ME 
(Periodate oxidized ATP (OATP) reduces hyperalgesia in mice: involvement of P2X7 
receptors and implications for therapy. Int J Immunopathol Pharmacol 21:61-71.2008). 
Gold MS, Shuster MJ, Levine JD (Role of a Ca(2+)-dependent slow afterhyperpolarization in 
prostaglandin E2-induced sensitization of cultured rat sensory neurons. Neurosci Lett 
205:161-164.1996). 
80 
 
Goldring MB, Birkhead JR, Suen LF, Yamin R, Mizuno S, Glowacki J, Arbiser JL, Apperley JF 
(Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J Clin 
Invest 94:2307-2316.1994). 
Gong K, Shao W, Chen H, Wang Z, Luo ZJ (Rat model of lumbar facet joint osteoarthritis 
associated with facet-mediated mechanical hyperalgesia induced by intra-articular injection of 
monosodium iodoacetate. Journal of the Formosan Medical Association = Taiwan yi zhi 
110:145-152.2011). 
Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M (Synovium as a source of interleukin 6 
in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 83:585-
592.1989). 
Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, Lipsky PE (Synovial stromal cells from 
rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res 
3:118-126.2001). 
Honore P, Donnelly-Roberts D, Namovic M, Zhong C, Wade C, Chandran P, Zhu C, Carroll W, 
Perez-Medrano A, Iwakura Y, Jarvis MF (The antihyperalgesic activity of a selective P2X7 
receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav Brain Res 
204:77-81.2009). 
Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, 
Zhong C, Gauvin DM, Chandran P, Harris R, Medrano AP, Carroll W, Marsh K, Sullivan JP, 
Faltynek CR, Jarvis MF (A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) 
methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and 
selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J 
Pharmacol Exp Ther 319:1376-1385.2006). 
Hunter DJ, Eckstein F (Exercise and osteoarthritis. J Anat 214:197-207.2009). 
Hunter DJ, McDougall JJ, Keefe FJ (The symptoms of osteoarthritis and the genesis of pain. Med 
Clin North Am 93:83-100, xi.2009). 
Jones AK, al-Janabi MA, Solanki K, Sobnack R, Greenwood A, Doyle DV, Britton KE, 
Huskisson EC (In vivo leukocyte migration in arthritis. Arthritis and rheumatism 34:270-
275.1991). 
81 
 
Khasar SG, McCarter G, Levine JD (Epinephrine produces a beta-adrenergic receptor-mediated 
mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol 81:1104-
1112.1999). 
Kim JE, Ryu HJ, Yeo SI, Kang TC (P2X7 receptor regulates leukocyte infiltrations in rat 
frontoparietal cortex following status epilepticus. J Neuroinflammation 7:65.2010). 
Klebanoff SJ (Myeloperoxidase: Occurrence and biological function. In: Peroxidases in 
chemistry and biology (Everse, J. et al., eds), pp 1-35 Boca Raton, FL, EUA: CRC 
Press.1991). 
Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, 
Audoly L, Gabel CA (Absence of the P2X7 receptor alters leukocyte function and attenuates 
an inflammatory response. J Immunol 168:6436-6445.2002). 
Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, Rossi AG, Finlayson K (The 
role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond) 4:5.2007). 
Mancino G, Placido R, Di Virgilio F (P2X7 receptors and apoptosis in tuberculosis infection. J 
Biol Regul Homeost Agents 15:286-293.2001). 
Marcondes FK, Bianchi FJ, Tanno AP (Determination of the estrous cycle phases of rats: some 
helpful considerations. Braz J Biol 62:609-614.2002). 
Martins JP, Silva RB, Coutinho-Silva R, Takiya CM, Battastini AM, Morrone FB, Campos MM 
(The role of P2X7 purinergic receptors in inflammatory and nociceptive changes 
accompanying cyclophosphamide-induced haemorrhagic cystitis in mice. Br J Pharmacol 
165:183-196.2012). 
McGaraughty S, Chu KL, Namovic MT, Donnelly-Roberts DL, Harris RR, Zhang XF, Shieh CC, 
Wismer CT, Zhu CZ, Gauvin DM, Fabiyi AC, Honore P, Gregg RJ, Kort ME, Nelson DW, 
Carroll WA, Marsh K, Faltynek CR, Jarvis MF (P2X7-related modulation of pathological 
nociception in rats. Neuroscience 146:1817-1828.2007). 
Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE (Interleukin-1 induction 
of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, 
c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 
and collagenase 3. Arthritis and rheumatism 43:801-811.2000). 
82 
 
Mingam R, De Smedt V, Amedee T, Bluthe RM, Kelley KW, Dantzer R, Laye S (In vitro and in 
vivo evidence for a role of the P2X7 receptor in the release of IL-1 beta in the murine brain. 
Brain Behav Immun 22:234-244.2008). 
Moon SJ, Park MK, Oh HJ, Lee SY, Kwok SK, Cho ML, Ju JH, Park KS, Kim HY, Park SH 
(Engagement of toll-like receptor 3 induces vascular endothelial growth factor and interleukin-
8 in human rheumatoid synovial fibroblasts. Korean J Intern Med 25:429-435.2010). 
Nevitt MC, Felson DT (Sex hormones and the risk of osteoarthritis in women: epidemiological 
evidence. Annals of the rheumatic diseases 55:673-676.1996). 
Orita S, Koshi T, Mitsuka T, Miyagi M, Inoue G, Arai G, Ishikawa T, Hanaoka E, Yamashita K, 
Yamashita M, Eguchi Y, Toyone T, Takahashi K, Ohtori S (Associations between 
proinflammatory cytokines in the synovial fluid and radiographic grading and pain-related 
scores in 47 consecutive patients with osteoarthritis of the knee. BMC musculoskeletal 
disorders 12:144.2011). 
Pap T, Muller-Ladner U, Gay RE, Gay S (Fibroblast biology. Role of synovial fibroblasts in the 
pathogenesis of rheumatoid arthritis. Arthritis Res 2:361-367.2000). 
Rocha FA, Silva FS, Jr., Leite AC, Leite AK, Girao VC, Castro RR, Cunha FQ (Tadalafil 
analgesia in experimental arthritis involves suppression of intra-articular TNF release. Br J 
Pharmacol 164:828-835.2011). 
Rosland JH (The formalin test in mice: the influence of ambient temperature. Pain 45:211-
216.1991). 
Rush AM, Waxman SG (PGE2 increases the tetrodotoxin-resistant Nav1.9 sodium current in 
mouse DRG neurons via G-proteins. Brain Res 1023:264-271.2004). 
Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ (Contribution of interleukin-1 
beta to the inflammation-induced increase in nerve growth factor levels and inflammatory 
hyperalgesia. Br J Pharmacol 115:1265-1275.1995). 
Sellam J, Berenbaum F (The role of synovitis in pathophysiology and clinical symptoms of 
osteoarthritis. Nature reviews Rheumatology 6:625-635.2010). 
Smith MS, Freeman ME, Neill JD (The control of progesterone secretion during the estrous cycle 
and early pseudopregnancy in the rat: prolactin, gonadotropin and steroid levels associated 
with rescue of the corpus luteum of pseudopregnancy. Endocrinology 96:219-226.1975). 
83 
 
Spornitz UM, Socin CD, Dravid AA (Estrous stage determination in rats by means of scanning 
electron microscopic images of uterine surface epithelium. Anat Rec 254:116-126.1999). 
Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G (A meta-analysis of sex 
differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage 
13:769-781.2005). 
Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (The cytolytic P2Z receptor for 
extracellular ATP identified as a P2X receptor (P2X7). Science 272:735-738.1996). 
Taiwo YO, Bjerknes LK, Goetzl EJ, Levine JD (Mediation of primary afferent peripheral 
hyperalgesia by the cAMP second messenger system. Neuroscience 32:577-580.1989). 
Teixeira JM, Oliveira MC, Nociti FH, Jr., Clemente-Napimoga JT, Pelegrini-da-Silva A, Parada 
CA, Tambeli CH (Involvement of temporomandibular joint P2X3 and P2X2/3 receptors in 
carrageenan-induced inflammatory hyperalgesia in rats. European journal of pharmacology 
645:79-85.2010a). 
Teixeira JM, Oliveira MC, Parada CA, Tambeli CH (Peripheral mechanisms underlying the 
essential role of P2X7 receptors in the development of inflammatory hyperalgesia. European 
journal of pharmacology 644:55-60.2010b). 
Teixeira JM, Bobinski F, Athie MCP, Parada CA, Sluka KA, Tambeli CH (P2X3 and P2X2/3 
receptors play a crucial role in hyperalgesia development through inflammatory mechanisms 
in the knee joint experimental osteoarthritis. in press. 2014). 
Tonussi CR, Ferreira SH (Rat knee-joint carrageenin incapacitation test: an objective screen for 
central and peripheral analgesics. Pain 48:421-427.1992). 
Tonussi CR, Ferreira SH (Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint 
incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain 
82:81-87.1999). 
Torres-Chavez KE, Sanfins JM, Clemente-Napimoga JT, Pelegrini-Da-Silva A, Parada CA, 
Fischer L, Tambeli CH (Effect of gonadal steroid hormones on formalin-induced 
temporomandibular joint inflammation. Eur J Pain 16:204-216.2012). 
Zimmermann M (Ethical guidelines for investigations of experimental pain in conscious animals. 
Pain 16:109-110.1983). 
 
 
84 
 
85 
 
IV. CAPÍTULO 03 
 
P2X3 and P2X2/3 receptors activation induces articular hyperalgesia by an indirect 
sensitization of the primary afferent nociceptor in the rat’s knee joint 
 
 
 
Juliana Maia Teixeira 
Carlos Amílcar Parada 
Cláudia Herrera Tambeli* 
 
 
 
Department of Structural and Functional Biology, Institute of Biology, State University of 
Campinas – UNICAMP 
 
 
 
* Corresponding author: 
Rua Monteiro Lobato, 255 - Campinas - SP - Brasil - CEP 13083-862 - Brazil 
Tel: + 55-19-3521-6195 
E-mail address: tambeli@unicamp.br (C.H. Tambeli) 
86 
 
Abstract 
P2X3 and P2X2/3 receptors activation plays an important role in articular hyperalgesia 
mediated by inflammatory agent in the knee joint. In this study, we verify the mechanism by 
which the activation of the P2X3 and P2X2/3 receptors exclusively by their agonist α,β-meATP 
contributes to the articular hyperalgesia. The data of this study demonstrated that the 
administration of α,β-meATP in rat’s knee joint induces a dose-dependent articular hyperalgesia 
that was blocked by the selective P2X3 and P2X2/3 receptors antagonist A-317491. Co-
administration of selective antagonists for bradykinin B1- (DALBK) or B2-receptors (Bradyzide), 
β1- (Atenolol) or β2-adrenoceptors (ICI 118,551) and the local pre-treatment with cyclooxygenase 
inhibitor (Indomethacin) or with the nonspecific selectin inhibitor (Fucoidan) significantly 
reduced α,β-meATP-induced articular hyperalgesia in the rat’s knee joint. Local administration of 
α,β-meATP also induced the release of pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and 
CINC-1, that was significantly decrease by A-317491. Moreover, the systemic treatment with 
fucoidan blocked α,β-meATP-induced  neutrophil migration and articular hyperalgesia. Taken 
together, these findings suggest that peripheral P2X3 and P2X2/3 receptors activation induces 
articular hyperalgesia by an indirect mechanism that involves release of bradykinin, 
prostaglandins, sympathomimetic amines, pro-inflammatory cytokines and neutrophil migration.   
 
Keywords: α,β-meATP, P2X3 and P2X2/3 receptors, articular hyperalgesia, knee joint, 
inflammatory mediators, neutrophil migration. 
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Introduction 
 
  Osteoarthritis (OA) is a degenerative joint disease which causes physical disability, 
inflammatory pain and synovitis and affects the whole joint including cartilage, synovial 
membrane, bone, muscle and tendons (Woolf and Pfleger, 2003). Although the mechanisms 
underlying the OA is not yet clear, evidences suggest that adenosine triphosphate (ATP) is an 
important inflammatory mediator involved in the development of hyperalgesia during OA (Dowd 
et al., 1998, Seino et al., 2006, Kumahashi et al., 2011, Teixeira et al., 2014b in press). Indeed, 
extracellular ATP is frequently found in synovial fluid of patients with arthropathies (Ryan et al., 
1991, Park et al., 1996, Kumahashi et al., 2011).  
P2X purinergic receptors (P2X1-P2X7) are membrane ligand-gated ion channels which 
open in response to ATP (Dubyak and el-Moatassim, 1993, Valera et al., 1994). In particular, the 
P2X3 receptor is involved in pain mechanisms including inflammatory articular hyperalgesia. For 
example, it has been demonstrated that the activation of P2X3 receptor, as a consequence of ATP 
release in inflamed articular tissue, is important to development of articular hyperalgesia in 
temporomandibular joint (TMJ) (Shinoda et al., 2005, Teixeira et al., 2010) and knee joint (Seino 
et al., 2006) of rats. 
In addition to ATP, others inflammatory mediators, such as bradykinin, prostaglandins, 
sympathomimetic amines and the pro-inflammatory cytokines released after tissue injury are 
essential to induce and to maintain the inflammatory hyperalgesia (Cunha et al., 1992, Ferreira et 
al., 1993a, Verri et al., 2006, Loram et al., 2007, Luiz et al., 2010, Petho and Reeh, 2012, 
Villarreal et al., 2013). However, inflammatory mediators are released in a subsequent way, in 
which the release of ATP and P2X3 receptor activation induces the release of TNF-α (de Oliveira 
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Fusaro et al., 2010), that ultimately induces prostaglandins and sympathomimetic amines release, 
which directly sensitize primary afferent nociceptors (Gold et al., 1996, Khasar et al., 1999, Rush 
and Waxman, 2004).  
Although P2X3 receptor is expressed on terminals of primary afferent neurons, 
particularly in the non-peptidergic subpopulation (Bradbury et al., 1998, Burnstock and Knight, 
2004, Gever et al., 2006), it has been demonstrated that this purinergic receptor is also expressed 
in chondrocytes (Varani et al., 2008). Furthermore, we have recently showed that endogenous 
ATP, via P2X3 and P2X2/3 receptors is essential to development of carrageenan-induced 
articular hyperalgesia in the rat’s knee joint, and that the P2X3 receptor expression in 
chondrocytes of cartilage is increased during carrageenan-induced articular inflammation 
(Teixeira et al, 2014b in press). Once chondrocytes can release inflammatory mediators (Guerne 
et al., 1990, Lotz et al., 1992, Aida et al., 2006), it is plausible to hypothesize that P2X3 receptor 
activation in knee joint induces articular hyperalgesia not only by directly sensitizing primary 
afferent nociceptor, but also by an indirect mechanism that involves the release of inflammatory 
mediators.  
Therefore, the aim of this study was to verify whether the administration of P2X3 and 
P2X2/3 receptor agonist α,β-meATP in the rat’s knee joint induces articular hyperalgesia which 
depends on release of bradykinin, prostaglandins, sympathomimetic amines, pro-inflammatory 
cytokines and on neutrophil migration.  
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Materials and Methods 
 
Animals 
Male Wistar rats (200-250g) obtained from the Multidisciplinary Center for Biological 
Research (CEMIB) - University of Campinas, were used in this study. The animals were housed 
in plastic cages with soft bedding (five/cage) on a 12:12 light cycle (lights on at 06:00 A.M.) with 
food and water available ad libitum. They were maintained in a temperature-controlled room 
(±23°C) and handled for at least one week prior to the experiments. Each animal was used once 
and the number of animals per group was kept to a minimum. Experimental protocols were 
approved by the Committee on Animal Research of the University of Campinas (protocol 
number: 2049-1) and conformed to IASP guidelines for the study of the pain in animals 
(Zimmermann, 1983).  
 
General Procedures 
Testing sessions took place during light phase (between 09:00 AM and 5:00 PM) in a 
quiet room maintained at 23ºC (Rosland, 1991). During the tests the animals had no access to 
water or food. The animals were habituated for 1 hour prior to the experiment to minimize stress. 
 
Drugs administration  
Drugs or their vehicle were intra-articularly administrated in the right rat’s knee joint by a 
26-gauge needle that was connected to a catheter of polyethylene and also to a Hamilton syringe 
(50 µL). The volume of injection was 50 µL. 
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α,β-meATP-induced knee joint inflammation  
Under brief inhalation of isoflurane anesthesia, rats were subjected to intra-articular (i.a.) 
injection of α,β-meATP dissolved in 25 μL sterile 0.9% saline solution into their right knee 
joints, in the same manner as demonstrated in carrageenan-induced knee joint inflammation 
(Tonussi and Ferreira, 1992). The injection site was shaved and treated with an antiseptic solution 
of iodine alcohol. The other drugs were also injected into the knee joint in that the α,β-meATP 
and the control animals received vehicle. 
 
Drugs and doses  
The following drugs were used: the P2X3 and P2X2/3 receptor agonist α,β-
methyleneATP lithium salt (Gever et al., 2006) (α,β-meATP: 10, 30, 100, 300 e 900 µg/knee, i.a., 
Oliveira-Fusaro et al., 2014 in press); the selective P2X3 and P2X2/3 receptor antagonist 5-([(3-
Phenoxybenzyl)[ (1S)-1,2,3,4-tetrahydro-1-naphthalenyl] amino]carbonyl)-1,2,4-
benzenetricarboxylic acid (Jarvis et al., 2002) (A-317491: 540 µg/knee, i.a., Teixeira et al., 2014b 
in press); the selective bradykinin B1 receptor antagonist des-Arg9-[Leu8]-BK - DALBK (Ferreira 
et al., 2008) (3.0 g/knee, i.a., Teixeira et al., 2014a in press); the selective bradykinin B2 
receptor antagonist Bradyzide (Burgess et al., 2000) (1.5 g/knee, i.a., Teixeira et al., 2014a in 
press); the selective β1 receptor antagonist Atenolol (Allibardi et al., 1999) (6.0 g/knee, i.a., 
Teixeira et al., 2014a in press); the selective β2 receptor antagonist ICI 118,551 (Yalcin et al., 
2009) (1.5 g/knee, i.a., Teixeira et al., 2014a in press); the cyclooxygenase inhibitor 
Indomethacin (Summ and Evers, 2013) (100 g/knee, i.a., Teixeira et al., 2014a in press) and the 
nonspecific selectin inhibitor Fucoidan (Ley et al., 1993) (25 mg/kg, i.v., Teixeira et al., 2014a in 
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press). The drugs were obtained from Sigma-Aldrich (MO, USA). All drugs were dissolved in 
sterile saline (0.9% NaCl).  
 
Gait disturbance - Rat knee-joint incapacitation test 
We used the rat knee-joint incapacitation test, as described previously (Tonussi and 
Ferreira, 1992). Briefly, 3 hours after α,β-meATP injection into their right knee joints, rats were 
put to walk on a steel rotary cylinder (30 cm wide x 50 cm diameter), covered with a fine-mesh 
non-oxidizable wire screen, which rotates at 3 rpm. Specially, designed metal gaiters were 
wrapped around both hind paws. After placement of the gaiters, rats were placed to walk in the 
cylinder and the right paw was then connected via a simple circuit to microcomputer data 
input/output port. The paw elevation time (PET) is the total time that the rat walks failing to 
touch the cylinder surface with the injected hindpaw, during a 60 sec period, which is directly 
proportional to the gait disturbance. Incapacitation was quantified as an increase in the PET, 3 
hours after carrageenan injection into the right knee joint. To minimize variations in PET, all rats 
were introduced to the experimental environment and trained on the apparatus to habituation into 
the equipment before the testing sessions. To confirm the local effect of some test agents, they 
were injected into the contralateral rat’s knee joint and the test was performed on the ipsilateral 
knee joint. The rat knee-joint incapacitation test provides automated measurements, which are 
independent of the subjectivity of the observer (Tonussi and Ferreira, 1992). 
 
Synovial lavage fluid  
Under deep anaesthesia (induced by the intraperitoneal injection of 80 mg/kg ketamine 
and 20 mg/kg xylazine) the rats were then killed by cervical dislocation, the skin overlying the 
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knee was excised, the patellar ligament was dissected and a 30-gauge needle connected to a 100 
µL Hamilton syringe was inserted through the joint capsule. The knee joint cavity was washed 
twice by injecting and immediately aspirating 100 µL of phosphate-buffered saline solution 
(PBS) containing 4 mM EDTA (Ekundi-Valentim et al., 2010).  
 
ELISA procedure 
An adaptation of ELISA (Enzyme-Linked Immunosorbent Assay) (Safieh-Garabedian et 
al., 1995) was used to determine whether α,β-meATP was able to increase the local concentration 
of TNF-α, IL-1β, IL-6 and CINC-1 in the rat’s knee joint. Briefly, the synovial lavage fluid was 
homogenized in solution of phosphate buffered saline (PBS) containing 0.4 M NaCl, 0.05% 
Tween 20, 0.5% bovine serum albumine (BSA), 0.1 mM phenyl-methylsulfonyl fluoride, 0.1 mM 
benzotonic chloride, 10 mM EDTA, and 20 KL/mL aprotinine (Sigma, USA). The samples were 
centrifuged at 10,000 rpm for 15 minutes at 4ºC and the supernatants were stored at -70ºC for 
posterior use to evaluate the protein levels of TNF-α, IL-1β, IL-6 and CINC-1 in the rat’s knee 
joint. The cytokines were quantified by the following kits: TNF-α: Rat TNF-α/ TNFSF1A 
DuoSet ELISA Kit (R&D Systems, catalog number DY510); IL-1β: Rat IL-1β/IL-1F2 DuoSet 
ELISA Kit (R&D Systems, catalog number DY501), IL-6: Rat IL-6 DuoSet ELISA Kit (R&D 
Systems, catalog number: DY506) and CINC-1: Rat CXCL1/CINC-1 DuoSet ELISA Kit (R&D 
Systems, catalog number DY515). All procedures followed the instructions of the manufacturer 
R&D Systems. All procedures were repeated twice to guarantee the authenticity of the results. In 
the present study, the levels of cytokines (TNF-, IL-1, IL-6 e CINC-1) were assessed three 
hours after α,β-meATP administration. 
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Measurement of myeloperoxidase activity 
Myeloperoxidase is one of the enzymes released from neutrophils and directly associated 
to tissue injury. Although monocytes/macrophages and fibroblasts also contain myeloperoxidase, 
neutrophils show the highest intracellular levels of this enzyme, that represents up to 5% of 
neutrophil proteins (Klebanoff, 1991). Therefore, the measurement of myeloperoxidase’s activity 
was used as a marker of neutrophil migration (Klebanoff, 1991) in the knee joint of rats after 
application of the stimulus. Three hours after α,β-meATP injection in the knee joint, synovial 
lavage fluid was collected and homogenized in 500μL of buffer 1 (0.1 M NaCl, 0.02 M 
NaPO4,1.015 M Na EDTA, pH 5.4) followed by centrifugation at 3000 rpm for 15 min. The 
pellet was resuspended in 500 µL of buffer 1 and subjected to hypotonic lyses by the addition of 
500 µL of 0.2% NaCl followed 30 seconds later by addition of 500 µL of 1.6% NaCl in 5% 
glucose. After a further centrifugation, the pellet was resuspended in 0.05 M NaPO4 buffer (pH 
5.4) containing 0.5% hexadecyl-trimethylammonium bromide (HTAB). After that, the samples 
were snap-frozen in liquid nitrogen and thawed, three times, and centrifuged at 10,000 rpm for 15 
min.  
The myeloperoxidase kinetic-colorimetric assay was conducted, as previously described 
(Bradley et al., 1982, Perin-Martins et al., 2013). Fifty microliters of each sample (supernatant) 
and 0.08 M NaPO4 were dropped into wells of a 96-well microplate. 25 µl of 3,3´,3,3´-
tetramethylbenzidine (TMB) was added in each well and the reaction was initiated by the 
addition of 100 µL of H2O2. The reaction was stopped 5 min later by the addition of 50 µL of 4M 
H2SO4. The optical density was read at 450 nm using an Asys UVM340 (3 readings at intervals 
of 30 seconds). Results were calculated by comparing the optical density of rat’s knee joint 
synovial lavage fluid supernatant with a standard curve of neutrophil (>95% purity). All 
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procedures were repeated twice to guarantee the authenticity of the results. The results were 
presented as number of neutrophils/knee.  
 
Statistical analysis 
To determine if there were significant differences (p<0.05) between treatment groups, 
One-way ANOVA or T-test was performed. If there was a significant between-subjects main 
effect of treatment group following One-way ANOVA, post hoc contrasts using the Tukey test 
were performed to determine the basis of the significant difference. For data shown in Fig. 1B a 
Two-way repeated measures ANOVA with one between subjects factor (i.e., treatment) and one 
within-subjects factor (i.e., time) were used to determine whether there were significant (p<0.05) 
differences among the groups. If there was a significant between-subjects main effect of 
treatment group, post hoc contrasts using the Bonferroni test were performed to determine the 
basis of the significant difference. Data are expressed in figures as means ± S.E.M.  
 
Results 
 
α,β-meATP-induced articular hyperalgesia in the rat’s knee joint 
To investigate whether the P2X3 and P2X2/3 receptors activation induces articular 
hyperalgesia, the P2X3 and P2X2/3 receptors agonist α,β-meATP was administrated in the rat’s 
knee joint. The intra-articular administration of α,β-meATP (10, 30, 100, 300 and 900 µg/knee) 
induced articular hyperalgesia in a dose-response manner. The dose of 300 µg/knee (submaximal 
dose) was used in all subsequent experiments (Fig. 1A, P<0.05, two-way ANOVA post hoc 
Bonferroni test). As showed in figure 1B, the α,β-meATP-induced articular hyperalgesia (300 
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µg/knee) reached its maximum effect 3 hours after its administration and was completely 
resolved 24 hours later when compared with 0.9% NaCl control group (P<0.05, two-way 
ANOVA post hoc Bonferroni test). The subsequent experiments was performed 3 hours after α,β-
meATP administration. 
To confirm that α,β-meATP-induced articular hyperalgesia was mediated by P2X3 and 
P2X2/3 receptors, the selective P2X3 and P2X2/3 receptors antagonist A-317491 was co-
administered with α,β-meATP. A-317491 (540 µg/knee) reduced the α,β-meATP-induced 
articular hyperalgesia (Fig. 1C, P<0.05, one-way ANOVA post hoc Tukey test). To rule out the 
systemic effect of A-317491 (540 µg/knee), it was administrated in contralateral knee joint and 
did not affect the articular hyperalgesia induced by α,β-meATP administrated in ipsilateral knee 
joint (Fig. 1C, P>0.05, one-way ANOVA post hoc Tukey test). In addition, to confirm the 
selectivity of α,β-meATP (300 μg/knee) as a P2X3 and P2X2/3 agonist, it was co-administrated 
with the selective P2X7 receptors antagonist A-740003 (568 µg/knee), which did not affect the 
α,β-meATP-induced articular hyperalgesia (Fig. 1C, P>0.05, one-way ANOVA post hoc Tukey 
test).  
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Figure 1 - Articular hyperalgesia induced by α,β-meATP administration in the rat knee 
joint. (A) Intra-articular administration of α,β-meATP (30, “∞”; 100, “$”; 300, “*” and 900 
µg/knee, “#”) in the rat knee joint induced a dose-dependent articular hyperalgesia when 
compared with 0.9% NaCl control group (P<0.05, Bonferroni test). (B) The α,β-meATP-induced 
articular hyperalgesia (300 µg/knee) in the rat’s knee joint reached its maximum effect 3 hours 
after its administration. The symbol “*” indicates responses significantly greater than that 
induced by 0.9% NaCl group (P<0.05, Bonferroni test). (C) The α,β-meATP-induced articular 
hyperalgesia (300 µg/knee) was significantly reduced by the co-administration of A-317491 (A-
317, 540 µg/knee, P<0.05, Tukey test) as indicated by the symbol “#”, but not by the co-
administration of A-740003 (A-74, 568 µg/knee, P>0.05, Tukey test). A-317491 (540 µg/knee) 
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applied in the contralateral knee joint (ct) did not affect the α,β-meATP-induced articular 
hyperalgesia. The symbol “*” indicates responses significantly greater than that induced by 0.9% 
NaCl or naive groups (P<0.05, Tukey test). In this and in subsequent figures the hyperalgesia was 
measured 3 hours after α,β-meATP administration and the numbers of rats used are shown in 
parentheses. 
 
Blockade of local bradykinin B1- or B2-receptor reduced the articular hyperalgesia induced by 
α,β-meATP.  
To verify whether α,β-meATP-induced articular hyperalgesia depends on bradykinin 
release, the bradykinin B1- or B2-receptor antagonist DALBK or Bradyzide, respectively, was co-
administered with α,β-meATP. DALBK (3.0 µg/knee, Fig. 2A) or Bradyzide (0.5 µg/knee, Fig. 
2B) reduced the α,β-meATP-induced articular hyperalgesia (P<0.05, one-way ANOVA post hoc 
Tukey test) and they did not affect the articular hyperalgesia when administered in the 
contralateral knee joint (P>0.05, one-way ANOVA post hoc Tukey test) confirming their local 
action. The co-administration of DALBK (3.0 µg/knee) or Bradyzide (0.5 µg/knee) with 0.9% 
NaCl did not change the paw elevation time (PET) when compared with 0.9% NaCl or naive 
control groups (P>0.05, one-way ANOVA post hoc Tukey test). 
 
Blockade of local β1- or β2-adrenoceptors reduced the articular hyperalgesia induced by α,β-
meATP  
To verify whether α,β-meATP-induced articular hyperalgesia depends on 
sympathomimetics amines release, the β1- or β2-adrenoceptor antagonist Atenolol or ICI 118,551, 
respectively, was co-administered with α,β-meATP. As showed in figure 2, Atenolol (6.0 
µg/knee, C) or ICI 118,551 (1.5 µg/knee, D) significantly reduced α,β-meATP-induced articular 
hyperalgesia (P<0.05, one-way ANOVA post hoc Tukey test) and they did not affect the articular 
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hyperalgesia when administered in the contralateral knee joint (P>0.05, one-way ANOVA post 
hoc Tukey test) confirming their local action. The co-administration of Atenolol (6.0 µg/knee) or 
ICI 118,551 (1.5 µg/knee) with 0.9% NaCl did not change the paw elevation time (PET) when 
compared with 0.9% NaCl or naive control groups (P>0.05, one-way ANOVA post hoc Tukey 
test). 
 
Blockade of local prostaglandins synthesis reduced the articular hyperalgesia induced by α,β-
meATP  
To verify whether α,β-meATP-induced articular hyperalgesia depends on prostaglandins 
release, rats were treated with local administration of Indomethacin 30 minutes before α,β-
meATP administration. Indomethacin (100 µg/knee, Fig. 2E) significantly reduced α,β-meATP-
induced articular hyperalgesia (P<0.05, one-way ANOVA post hoc Tukey test) and did not affect 
the articular hyperalgesia when administered on the contralateral knee joint (P>0.05, one-way 
ANOVA post hoc Tukey test) confirming its local action. The co-administration of Indomethacin 
(100 µg/knee) with 0.9% NaCl did not change the paw elevation time (PET) when compared with 
0.9% NaCl or naive control groups (P>0.05, one-way ANOVA post hoc Tukey test). 
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Figure 2 - Effect of B1- or B2-receptors antagonists, β1- or β2- adrenoceptors antagonists and 
the blockade of prostaglandins synthesis on the α,β-meATP-induced articular hyperalgesia 
in rat’s knee joint. The co-administration of B1 receptor antagonist DALBK (3.0 µg/knee, A), 
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B2 receptor antagonist Bradyzide (0.5 µg/knee, B), β1 adrenoceptor antagonist Atenolol (6.0 
µg/knee, C), β2 adrenoceptor antagonist ICI 118,551 (1.5 µg/knee, D) or cyclooxygenase 
inhibitor Indomethacin (100 µg/knee, 30 min pre-treatment, E) with α,β-meATP (300 µg/knee) 
significantly reduced the α,β-meATP-induced articular hyperalgesia, as indicated by the symbol 
“#” (P<0.05, Tukey test). DALBK (3.0 µg/knee, A), Bradyzide (0.5 µg/knee, B), Atenolol (6.0 
µg/knee, C), ICI 118,551 (1.5 µg/knee, D) or Indomethacin (100 µg/knee, E) administrated in the 
contralateral knee joint (ct) or co-administrated with 0.9% NaCl did not affect the articular 
hyperalgesia induced by α,β-meATP or the paw elevation time, when compared with α,β-meATP 
alone or naive groups, respectively (P>0.05, Tukey test). The symbol “*” indicates responses 
significantly greater than that induced by 0.9% NaCl or naive groups (P<0.05, Tukey test). 
 
Local administration of α,β-meATP increases the concentration of pro-inflammatory cytokines in 
rat’s knee joint.  
This set of experiments was performed to verify whether α,β-meATP induces local 
increase of concentration of TNF-α, IL-1β, IL-6 and CINC-1. Intra-articular administration of 
α,β-meATP (300 µg/knee) significantly increased the concentration of TNF-α (Fig. 3A), IL-1β 
(Fig. 3B), IL-6 (Fig. 3C) and CINC-1 (Fig. 3D) 3 hours later when compared with 0.9% NaCl 
administration or naive control groups (P<0.05, one-way ANOVA post hoc Tukey test). The co-
administration of the selective P2X3 and P2X2/3 receptors antagonist A-317491 (540 µg/knee) 
with α,β-meATP reduced (P<0.05, one-way ANOVA post hoc Tukey test) the local concentration 
of TNF-α (Fig. 3A), IL-1β (Fig. 3B) and CINC-1 (Fig. 3D) but not IL-6 (Fig. 3C) (P>0.05, one-
way ANOVA post hoc Tukey test). The intra-articular injection of 0.9% NaCl (50µL) alone did 
not affect the endogenous concentration of TNF-α, IL-1β, IL-6 and CINC-1 when compared with 
naive group (P>0.05, one-way ANOVA post hoc Tukey test). 
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Figure 3 - Effect of α,β-meATP on the local concentration of pro-inflammatory cytokines in 
the rat’s knee joint. The intra-articular administration of α,β-meATP (300 µg/knee) induced an 
increase of TNF-α (A), IL-1β (B), IL-6 (C) and CINC-1 (D) concentrations. The co-
administration of A-317491 (540µg/knee) with α,β-meATP significantly reduced the α,β-
meATP-induced increase of TNF-α (A), IL-1β (B) and CINC-1 (D) (P<0.05, Tukey test), but not 
IL-6 (C) (P>0.05, Tukey test) concentrations, as indicated by the symbol “#”. The intra-articular 
injection of 0.9% NaCl did not affect the endogenous concentration of TNF-α, IL-1β, IL-6 and 
CINC-1 when compared with naive group (P>0.05, Tukey test). The symbol “*” indicated a 
cytokines concentrations significantly greater than that induced by 0.9% NaCl or by naive control 
groups (P<0.05, ANOVA, pos hoc Tukey test). 
 
Neutrophil migration contributes to α,β-meATP-induced articular hyperalgesia 
To verify whether local administration of α,β-meATP (300 μg/knee) induces neutrophil 
migration and if this is important to development of articular hyperalgesia, rats were treated with 
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Fucoidan (25 mg/kg, i.v.) 20 minutes before the α,β-meATP administration. As showed in figure 
4A, the articular hyperalgesia measured 3 hours later α,β-meATP administration was reduced by 
the pre-treatment with Fucoidan (P<0.05, one-way ANOVA post hoc Tukey test). Intra-articular 
administration of α,β-meATP (300 µg/knee) increased the myeloperoxidase’s activity when 
compared with 0.9% NaCl control group which was blocked by Fucoidan (Fig. 4B, P<0.05, one-
way ANOVA post hoc Tukey test). The intra-articular injection of 0.9% NaCl alone did not 
affect the myeloperoxidase’s activity when compared with naive rats (P>0.05, one-way ANOVA 
post hoc Tukey test). 
 
Figure 4 - Effect of Fucoidan on α,β-meATP-induced articular hiperalgesia and neutrophil 
migration in the rat’s knee joint. 
(A) The pre-treatment with Fucoidan (25 mg/kg, i.v.) significantly decreased α,β-meATP-induced 
articular hyperalgesia, as indicated by the symbol “#” (P<0.05, Tukey test). The symbol “*” 
indicates an articular hyperalgesia significantly greater than that induced by 0.9% NaCl or naive 
groups (P<0.05, Tukey test). (B) The intra-articular administration of α,β-meATP (300 µg/knee) 
induced an increase of myeloperoxidase’s activity which was blocked by the pre-treatment with 
Fucoidan (25 mg/kg, i.v.), as indicated by the symbol “#” (P<0.05, Tukey test). The symbol “*” 
indicates a myeloperoxidase’s activity significantly greater than that induced by 0.9% NaCl or 
naive groups (P<0.05, Tukey test). 
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Discussion 
 
This study demonstrated that peripheral P2X3 and P2X2/3 receptors activation induce 
articular hyperalgesia, at least in part, by an indirect sensitization of the primary afferent 
nociceptors once it depends on release of bradykinin, prostaglandins, sympathomimetic amines, 
pro-inflammatory cytokines and on neutrophil migration. 
Although α,β-meATP is a non-selective P2X3 receptor agonist once it also bind to P2X1 
and P2X2/3 receptor, the involvement of P2X1 in hyperalgesia seems to be unlikely, since it has 
been demonstrated that IP5I, a potent and selective P2X1 receptor antagonist, is ineffective in 
reducing inflammatory pain (Honore et al., 2002) or mechanical hypersensitivity (Dai et al., 
2004), in addition it has been shown that the P2X1 receptor does not contribute to hyperalgesia in 
the temporomandibular joint (Shinoda et al., 2005).  
While in this study we assumed the involvement of both P2X3 and P2X2/3 receptor 
activation in articular hyperalgesia induced by α,β-meATP, the involvement of P2X2/3 in this 
mechanism is not clear. Studies demonstrate that nociceptive behaviors and thermal hyperalgesia 
produced by α,β-meATP may primarily reflect P2X3 receptor activation because the responses to 
α,β-meATP were completely eliminated in P2X3 receptor deficient animals (Cockayne et al., 
2000, Souslova et al., 2000, Zhong et al., 2001). Moreover, oligodeoxynucleotide antisense 
against P2X3 receptor prevents inflammatory hyperalgesia at same magnitude than the selective 
P2X3 and P2X2/3 receptor antagonist A-317491 (Oliveira et al., 2009). Indeed, α,β-meATP is the 
most used agonist for P2X3 and P2X2/3 receptors available (Gever et al., 2006). In this study we 
also demonstrated that the articular hyperalgesia induced by α,β-meATP was prevented by the 
P2X3 and P2x2/3 receptor antagonist A-317491 (Jarvis et al., 2002), but was unaffected by the 
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selective P2X7 receptors antagonist A-740003 (Honore et al., 2006), strengthening previous data 
showing that α,β-meATP has not agonist activity in P2X7 receptors (Bianchi et al., 1999). 
In agreement with the findings of this study, the activation of P2X3 and P2X2/3 receptors 
in knee joint induces articular hyperalgesia which depends on the subsequent activation of B1 and 
B2 receptors. Bradykinin is an inflammatory mediator rapidly generated after tissue injury 
(Ferreira et al., 1993a, Ferreira et al., 1993b) and modulates most of the events observed during 
the inflammatory processes, including increase of vascular permeability, cell migration, 
nociception and inflammatory hyperalgesia (Marceau et al., 1998, Calixto et al., 2000, Couture et 
al., 2001). Also, studies suggest that the mechanical hyperalgesia induced by bradykinin depends 
on release of endogenous ATP and P2X3 receptor activation (de Oliveira Fusaro et al., 2010). 
Similarly to cutaneous tissue (Ferreira et al., 1993a), this study confirm that bradykinin 
plays a crucial role in the development of articular hyperalgesia in rat’s knee joint. Considering 
that bradykinin is an inflammatory mediator released at the early phase of inflammatory 
hyperalgesia (Ferreira et al., 1993a, Ferreira et al., 1993b), data of this study suggest that the 
release of ATP and the subsequent P2X3 receptor activation is a inflammatory process upstream 
to release of bradykinin.  
It has been described that bradykinin induces hyperalgesia by two distinct pathways that 
ultimately result in the local prostaglandins synthesis and sympathomimetic amines release 
(Ferreira et al., 1993a, Ferreira et al., 1993b), which directly sensitize the primary afferent 
nociceptor (Gold et al., 1996, Khasar et al., 1999, Rush and Waxman, 2004). Data of this study 
also showed that β-adrenoceptors antagonists or the cyclooxygenase inhibitor indomethacin 
reduced the α,β-meATP-induced articular hyperalgesia. These results demonstrated that articular 
hyperalgesia induced local activation of P2X3 and P2X2/3 receptors ultimately depends on the 
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production of prostaglandins and release of sympathomimetic amines, which in turn act directly 
on primary afferent nociceptors. 
The synovium is innervated by postganglionic sympathetic fibers which are between half 
and two-thirds of the nerve fibers in the synovium (Hildebrand et al., 1991). Noradrenaline is co-
released with ATP from sympathetic nerves, and both agents contribute to sympathetically 
mediated autonomic responses (Burnstock, 1995). Thus, the current data are consistent with 
earlier studies which demonstrated strong synergistic effect between the noradrenergic system 
(sympathetic postganglionic neurons) and P2X3 receptor in neuropathic and thermal pain 
(Waldron and Sawynok, 2004, Meisner et al., 2007, Meisner et al., 2008).  
It is interesting to point out that, although the activation of P2X3 and P2X2/3 receptors in 
knee joint induces articular hyperalgesia by two independent pathways, one mediated by 
prostaglandins and other by sympathomimetic amines, the blockage of just one pathway 
completely prevented the articular hyperalgesia induced by α,β-meATP. These data suggest that 
the articular hyperalgesia induced by P2X3 and P2X2/3 receptor activation in knee joint tissue 
may involve the activation of more than one type of receptor and consequently more than one 
signaling pathway activation in primary afferent nociceptor.  
Although P2X3 and P2X2/3 receptors are predominantly distributed on terminals of 
primary afferent neurons (Bradbury et al., 1998, Burnstock and Knight, 2004, Gever et al., 2006), 
they are also expressed in chondrocytes (Varani et al., 2008) and during joint inflammation 
occurs an increase of P2X3 receptor expression in the chondrocytes of rat’s knee joint articular 
cartilage (Teixeira et al., 2014b in press). Studies in vitro demonstrated that α,β-meATP increases 
the synthesis of prostaglandin E2 (PGE2) by chondrocytes via P2X3 and P2X2/3 receptor 
106 
 
activation (Varani et al., 2008). This data suggest that, at least PGE2 is released by chondrocytes 
as a result of P2X3 and P2X2/3 receptors receptor activation. 
Therefore, our data suggest that extracellular ATP, in addition to directly activation of 
P2X3 and P2X2/3 receptors in primary afferent nociceptor in the rat knee joint, as previously 
demonstrated (Dowd et al., 1998), it can also activates these receptors in articular chondrocytes 
that releases inflammatory mediators, which in turn, ultimately sensitize the primary afferent 
nociceptors.  
Because the prostaglandins synthesis and sympathomimetic amines release usually 
depends on prior pro-inflammatory cytokines release (Cunha et al., 1991, Cunha et al., 1992, 
Ferreira et al., 1993a), we also investigated whether P2X3 and P2X2/3 receptor activation 
induces release of TNF-α, IL-1β, IL-6 and CINC-1. The current results demonstrated that P2X3 
and P2X2/3 receptor activation increases the concentration of TNF-α, IL-1β, IL-6 and CINC-1 in 
the rat’s knee joint, suggesting that P2X3 and P2X2/3 activation initiates the release of pro-
inflammatory cytokines during articular inflammation. Indeed, pro-inflammatory cytokines 
participate in the development and maintenance of articular hyperalgesia (Williams et al., 1992, 
Lewthwaite et al., 1995, Ohtani et al., 2012). 
Different resident cells can release pro-inflammatory cytokines in knee joint tissue, such 
as synoviocytes (Firestein, 2003), however chondrocytes should be a key candidate to release 
these cytokines by P2X3 and P2X2/3 receptor activation. In fact, it has been demonstrated in 
vitro that stimulated chondrocytes can release TNF-α, IL-1β, IL-6, IL-8 and IL-11 (Guerne et al., 
1990, Lotz et al., 1992, Aida et al., 2006). It is important to note, however, that the activation of 
P2X3 receptor on primary afferent nociceptor induces release of ATP (Kirkpatrick and 
Burnstock, 1994) which in turn, can activate P2X7 receptor. This purinergic receptor is expressed 
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in inflammatory cells and synovial fibroblast (Surprenant et al., 1996, Collo et al., 1997, Mancino 
et al., 2001, Caporali et al., 2008). Therefore, P2X7 receptor activation by ATP release can 
collaborate to increase of pro-inflammatory cytokines induced by ,-meATP.  
Neutrophil migration to synovial fluid is another important sign during joint inflammation 
and it correspond to about 90% of the leukocytic infiltrate in synovial fluid of patients with 
arthritis (Mohr, 1995). It has been demonstrated that neutrophils play an important role in the 
arthropathies pathogenesis, because their interaction with resident cells and local inflammatory 
mediators amplify the inflammatory response contributing to the chronic and acute inflammation 
(Kasama et al., 2005). Based on that, we also investigated whether P2X3 and P2X2/3 receptors 
activation induces neutrophil migration to rat’s knee joint, contributing to the articular 
hyperalgesia. 
According with the data of this study, the activation of P2X3 and P2X2/3 receptor induces 
neutrophil migration to the rat’s knee joint, because the pre-treatment with fucoidan, which 
inhibit neutrophil rolling (Ley et al., 1993, Cunha et al., 2008), prevented articular hyperalgesia 
and neutrophil migration induced by administration of ,-meATP in knee joint. Therefore, the 
neutrophil migration induced by P2X3 and P2X2/3 receptors activation probably results from the 
release of the chemokine CINC-1, which induces chemotaxis and leukocytes activation (Romano 
et al., 1997, Moon et al., 2010). Although, the release of prostaglandins by P2X3 and P2X2/3 
receptors activation could be resulted from the chondrocytes activation (Varani et al., 2008), 
neutrophils may contribute to the release of prostaglandins (Cunha et al., 2008) and consequently 
to development of articular hyperalgesia.   
In conclusion, the findings of the present study suggest that P2X3 and P2X2/3 receptors 
activation induces articular inflammatory hyperalgesia by an indirect mechanism that involves 
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release of bradykinin and pro-inflammatory cytokines, neutrophil migration with and the 
subsequently release of prostaglandins and sympathomimetic amines which ultimately sensitize 
primary afferent nociceptors in joint tissue. The data of this study also suggest that P2X3 and 
P2X2/3 receptors activation has an important participation on inflammation of the knee joint and 
could be an interesting target to control arthropathies. 
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Abstract 
Recently we have demonstrated that endogenous ATP, via P2X7 receptor activation is 
essential to development of carrageenan-induced articular hyperalgesia in the rats knee joint. In 
this study, we hypothesized that P2X7 receptor activation induces articular hyperalgesia in the 
rat’s knee joint and, if so, whether depends on release of inflammatory mediators such as 
bradykinin, prostaglandins, sympathomimetic amines, pro-inflammatory cytokines and neutrophil 
migration. We found that BzATP, a P2X7 receptor agonist, induced a dose-dependent articular 
hyperalgesia that was blocked by the selective P2X7 receptor antagonist A-740003, but not by 
the selective P2X3 and P2X2/3 receptors antagonist A-317491. These findings confirm that 
although BzATP also acts at P2X3 receptor, BzATP-induced articular hyperalgesia was mediated 
by P2X7 receptor activation. Co-administration of selective antagonists for bradykinin B1- 
(DALBK) or B2-receptors (Bradyzide), β1- (Atenolol) or β2-adrenoceptors (ICI 118,551) and the 
local pre-treatment with cyclooxygenase inhibitor (Indomethacin) significantly reduced BzATP-
induced articular hyperalgesia in the rat’s knee joint. BzATP also induced the pro-inflammatory 
cytokines release TNF-α, IL-1β, IL-6 and CINC-1, an effect that was significantly reduced by A-
740003. Moreover, BzATP induced the neutrophil migration to the knee joint that was 
significantly reduced by the nonspecific selectin inhibitor (Fucoidan). On the other hand, the pre-
treatment with Fucoidan did not reduced BzATP-induced articular hyperalgesia in the rat’s knee 
joint. Taken together, these findings suggest that peripheral P2X7 receptor activation induces 
articular hyperalgesia by an indirect sensitization of the primary afferent nociceptor of the rat’s 
knee joint which depends on release of bradykinin, prostaglandins, sympathomimetic amines and 
pro-inflammatory cytokines.  
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Introduction 
 
The P2X7 purinergic receptor subtype belongs to the family of ATP-sensitive ionotropic 
P2X receptors (P2X1-P2X7) (Buell et al., 1996, North, 2002) and have been implicated in 
processes of pain and hyperalgesia in several tissues, including articular tissues such as the 
temporomandibular joint (TMJ), ankle and knee joints of rodents (Labasi et al., 2002, Broom et 
al., 2008, Teixeira et al., 2010).  
Osteoarthritis (OA) is a common disease of aged population and one of most important 
causes of pain and physical disability, affecting the quality of life of patients. Affects the whole 
joint including cartilage, synovial membrane, muscle and bones and its occurrence is most 
common in the knees, hips and hands (Woolf and Pfleger, 2003, Heidari, 2011). Although the 
cause of pain in OA patients is not yet clear, evidences suggest the involvement of ATP in the 
development of hyperalgesia during OA (Dowd et al., 1998, Seino et al., 2006, Kumahashi et al., 
2011, Teixeira et al., 2014b in press). Indeed, extracellular ATP is frequently found in synovial 
fluid of patients with arthropathies (Ryan et al., 1991, Park et al., 1996, Kumahashi et al., 2011). 
During inflammation, ATP released from injured cells (Filippini et al., 1990, Dubyak and 
el-Moatassim, 1993, Beigi et al., 1999, Sikora et al., 1999, Mizumoto et al., 2003 Campwala and 
Fountain, 2013) can activates the P2X7 receptor, which is predominantly found on macrophages, 
mast cells, erythrocytes, monocytes, fibroblasts, peripheral macrophages, T and B lymphocytes 
and in type B synoviocytes (fibroblasts like-synoviocytes - FLS cells (Chiozzi et al., 1997, Collo 
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et al., 1997, Kim et al., 2001, Greig et al., 2003, Caporali et al., 2008), where it can triggers 
cellular responses such as membrane permeabilization, caspases activation, pro-inflammatory 
cytokine release and cell proliferation (Panenka et al., 2001, Chakfe et al., 2002, North, 2002, 
Verhoef et al., 2003, Kahlenberg and Dubyak, 2004), contributing to inflammatory hyperalgesia. 
In addition to ATP, others inflammatory mediators, such as bradykinin, prostaglandins, 
sympathomimetic amines and pro-inflammatory cytokine are released after tissue injury and are 
essential to induce and maintain the inflammatory hyperalgesia (Cunha et al., 1992, Ferreira et 
al., 1993a, Loram et al., 2007 Luiz et al., 2010, Petho and Reeh, 2012, Villarreal et al., 2013). 
Also, neutrophil migration is essential to the development of inflammatory hyperalgesia (Jain et 
al., 2001, Tambeli et al., 2006, Oliveira et al., 2007, Cunha et al., 2008, Guerrero et al., 2008, 
Carreira et al., 2013). We have showed that endogenous ATP via P2X7 receptor activation is 
essential to development of articular hyperalgesia, pro-inflammatory cytokines release, and 
neutrophil migration induced by carrageenan in the rat’s knee joint (Teixeira et al., 2014b in 
press).  
Therefore, the aim of this study was to verify whether the administration of P2X7 receptor 
agonist BzATP in the rat’s knee joint induces articular hyperalgesia and, if so, whether depends 
on release of inflammatory mediators involved in hyperalgesia, such as bradykinin, 
prostaglandins, sympathomimetic amines, pro-inflammatory cytokines and neutrophil migration.   
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Materials and Methods 
 
Animals 
Male Wistar rats (200-250g) obtained from the Multidisciplinary Center for Biological 
Research (CEMIB) - University of Campinas, were used in this study. The animals were housed 
in plastic cages with soft bedding (five/cage) on a 12:12 light cycle (lights on at 06:00 A.M.) with 
food and water available ad libitum. They were maintained in a temperature-controlled room 
(±23°C) and handled for at least one week prior to the experiments. Each animal was used once 
and the number of animals per group was kept to a minimum. Experimental protocols were 
approved by the Committee on Animal Research of the University of Campinas (protocol 
number: 2049-1) and conformed to IASP guidelines for the study of the pain in animals 
(Zimmermann, 1983).  
 
General Procedures 
Testing sessions took place during light phase (between 09:00 AM and 5:00 PM) in a 
quiet room maintained at 23ºC (Rosland, 1991). During the tests the animals had no access to 
water or food. The animals were habituated for 1 hour prior to the experiment to minimize stress. 
 
Drugs administration  
Drugs or their vehicle were intra-articularly administrated in the right rats knee joint by a 
26-gauge needle that was connected to a catheter of polyethylene and also to a Hamilton syringe 
(50 µL). The volume of injection was 50 µL.  
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BzATP-induced knee joint inflammation  
Under brief inhalation of isoflurane anesthesia, rats were subjected to intra-articular (i.a.) 
injection of BzATP dissolved in 25 μL sterile 0.9% saline solution into their right knee joint, in 
the same manner as demonstrated in carrageenan-induced articular hyperalgesia (Tonussi and 
Ferreira, 1992). The injection site was shaved and treated with an antiseptic solution of iodine 
alcohol. The other drugs were also injected into the knee joint in the same manner that the 
BzATP and the control animals received vehicle. 
 
Drugs and doses  
 The following drugs were used: the P2X7 receptor agonist 2′(3′)-O-(4-
Benzoylbenzoyl)adenosine 5′-triphosphate Triethylammonium salt (Jacobson et al., 2002) 
(BzATP: 25, 75, 225 and 675 g/knee, (Jarvis et al., 2001); the selective P2X7 receptor 
antagonist [N-(1-{[(Cyanoimino) (5-quinolinylamino) methyl] amino}-2,2-dimethylpropyl)- 2-
(3,4-dimethoxyphenyl)acetamide] (Honore et al., 2006) (A-740003: 568 µg/knee, i.a., Teixeira et 
al., 2014b in press); the selective bradykinin B1 receptor antagonist des-Arg9-[Leu8]-BK - 
DALBK (Ferreira et al., 2008) (3.0 g/knee, i.a., Teixeira et al., 2014a in press);  the selective 
bradykinin B2 receptor antagonist Bradyzide (Burgess et al., 2000) (1.5 g/knee, i.a. Teixeira et 
al., 2014a in press); the selective β1 receptor antagonist Atenolol (Allibardi et al., 1999) (6.0 
g/knee, i.a., Teixeira et al., 2014a in press); the selective β2 receptor antagonist ICI 118,551 
(Yalcin et al., 2009) (1.5 g/knee, i.a., Teixeira et al., 2014a in press); the cyclooxygenase 
inhibitor Indomethacin (Summ and Evers, 2013) (100 g/knee, i.a., Teixeira et al., 2014a in 
press) and the nonspecific selectin inhibitor Fucoidan (Ley et al., 1993) (25 mg/kg, i.v., Teixeira 
et al., 2014a in press). A-740003 was obtained from Tocris Bioscience (Ellisville, MO) and all 
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other drugs were obtained from Sigma-Aldrich (MO, USA). A-740003 was dissolved in 25 μL of 
dimethyl sulfoxide (DMSO, 50%) and propylene glycol (50%) and all other drugs were dissolved 
in sterile saline (0.9% NaCl). 
 
Gait disturbance - Rat knee-joint incapacitation test 
We used the rat knee-joint incapacitation test, as described previously (Tonussi and 
Ferreira, 1992). Briefly, 3 hours after BzATP injection into their right knee joints, rats were put 
to walk on a steel rotary cylinder (30 cm wide x 50 cm diameter), covered with a fine-mesh non-
oxidizable wire screen, which rotates at 3 rpm. Specially, designed metal gaiters were wrapped 
around both hind paws. After placement of the gaiters, rats were placed to walk in the cylinder 
and the right paw was then connected via a simple circuit to microcomputer data input/output 
port. The paw elevation time (PET) is the total time that the rat walks failing to touch the cylinder 
surface with the injected hindpaw, during a 60 sec period, which is directly proportional to the 
gait disturbance. Incapacitation was quantified as an increase in the PET, 3 hours after 
carrageenan injection into the right knee joint. To minimize variations in PET, all rats were 
introduced to the experimental environment and trained on the apparatus to habituation into the 
equipment before the testing sessions. To confirm the local effect of some test agents, they were 
injected into the contralateral rat’s knee joint and the test was performed on the ipsilateral knee 
joint. The rat knee-joint incapacitation test provides automated measurements, which are 
independent of the subjectivity of the observer (Tonussi and Ferreira, 1992). 
 
Synovial lavage fluid  
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Under deep anaesthesia (induced by the intraperitoneal injection of 80 mg/kg ketamine 
and 20 mg/kg xylazine) the rats were then killed by cervical dislocation, the skin overlying the 
knee was excised, the patellar ligament was dissected and a 30-gauge needle connected to a 100 
µL Hamilton syringe was inserted through the joint capsule. The knee joint cavity was washed 
twice by injecting and immediately aspirating 100 µL of phosphate-buffered saline solution 
(PBS) containing 4 mM EDTA (Ekundi-Valentim et al., 2010).  
 
ELISA procedure 
An adaptation of ELISA (Enzyme-Linked Immunosorbent Assay) (Safieh-Garabedian et 
al., 1995) was used to determine whether BzATP was able to increase the local concentration of 
TNF-α, IL-1β, IL-6 and CINC-1 in the rat’s knee joint. Briefly, the synovial lavage fluid was 
homogenized in solution of phosphate-buffered saline (PBS) containing 0.4 M NaCl, 0.05% 
Tween 20, 0.5% bovine serum albumine (BSA), 0.1 mM phenyl-methylsulfonyl fluoride, 0.1 mM 
benzotonic chloride, 10 mM EDTA, and 20 KL/mL aprotinine (Sigma, USA). The samples were 
centrifuged at 10000 rpm for 15 minutes at 4ºC and the supernatants were stored at -70ºC for 
posterior use to evaluate the protein levels of TNF-α, IL-1β, IL-6 and CINC-1 in the rats knee 
joint. The cytokines were quantified by the following kits: TNF-α: Rat TNF-α/ TNFSF1A 
DuoSet ELISA Kit (R&D Systems, catalog number DY510); IL-1β: Rat IL-1β/IL-1F2 DuoSet 
ELISA Kit (R&D Systems, catalog number DY501), IL-6: Rat IL-6 DuoSet ELISA Kit (R&D 
Systems, catalog number: DY506) and CINC-1: Rat CXCL1/CINC-1 DuoSet ELISA Kit (R&D 
Systems, catalog number DY515). All procedures followed the instructions of the manufacturer 
R&D Systems. All procedures were repeated twice to guarantee the authenticity of the results. In 
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the present study, the levels of cytokines (TNF-, IL-1, IL-6 e CINC-1) were assessed three 
hours after BzATP administration. 
 
Measurement of myeloperoxidase activity 
Myeloperoxidase is one of the enzymes released from neutrophils and directly associated 
to tissue injury. Although monocytes/macrophages and fibroblasts also contain myeloperoxidase, 
neutrophils show the highest intracellular levels of this enzyme, that represents up to 5% of 
neutrophil proteins (Klebanoff, 1991). Therefore, the measurement of myeloperoxidase activity 
was used as a marker of neutrophil migration (Klebanoff, 1991) in the knee joint of rats after 
application of the stimulus. Three hours after BzATP injection in the knee joint, synovial lavage 
fluid was collected and homogenized in 500μL of buffer 1 (0.1 M NaCl, 0.02 M NaPO4,1.015 M 
Na EDTA, pH 5.4) followed by centrifugation at 3000 rpm for 15 min. The pellet was 
resuspended in 500 µL of buffer 1 and subjected to hypotonic lyses by the addition of 500 µL of 
0.2% NaCl followed 30 seconds later by addition of 500 µL of 1.6% NaCl in 5% glucose. After a 
further centrifugation, the pellet was resuspended in 0.05 M NaPO4 buffer (pH 5.4) containing 
0.5% hexadecyl-trimethylammonium bromide (HTAB). After that, the samples were snap-frozen 
in liquid nitrogen and thawed, three times, and centrifuged at 10,000 rpm for 15 min.  
The myeloperoxidase kinetic-colorimetric assay was conducted, as previously described 
(Bradley et al., 1982, Perin-Martins et al., 2013). Fifty microliters of each sample (supernatant) 
and 0.08 M NaPO4 were dropped into wells of a 96-well microplate. 25 µl of 3,3´,3,3´-
tetramethylbenzidine (TMB) was added in each well and the reaction was initiated by the 
addition of 100 µL of  H2O2. The reaction was stopped 5 min later by the addition of 50 µL of 
4M H2SO4. The optical density was read at 450 nm using an Asys UVM340 (3 readings at 
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intervals of 30 seconds). Results were calculated by comparing the optical density of rats knee 
joint synovial lavage fluid supernatant with a standard curve of neutrophil (>95% purity). The 
results were presented as number of neutrophils/knee. 
 
Statistical analysis 
 To determine if there were significant differences (p<0.05) between treatment groups, 
One-way ANOVA or T-test was performed. If there was a significant between-subjects main 
effect of treatment group following One-way ANOVA, post hoc contrasts using the Tukey test 
were performed to determine the basis of the significant difference. For data shown in Fig. 1B a 
Two-way repeated measures ANOVA with one between subjects factor (i.e., treatment) and one 
within-subjects factor (i.e., time) were used to determine whether there were significant (p<0.05) 
differences among the groups. If there was a significant between-subjects main effect of 
treatment group, post hoc contrasts using the Bonferroni test were performed to determine the 
basis of the significant difference. Data are expressed in figures as means ± S.E.M.  
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Results 
 
BzATP-induced articular hyperalgesia in the rats knee joint 
To investigate whether the P2X7 receptor activation induces articular hyperalgesia, the 
P2X7 receptor agonist BzATP was administrated in the rats knee joint. As showed in the figure 
1A, the intra-articular administration of BzATP (25, 75, 225 and 675 µg/knee) induced articular 
hyperalgesia in a dose-response manner. The dose of 225 µg/knee (submaximal dose) was used 
in all the subsequent experiments (P<0.05, two-way ANOVA post hoc Bonferroni test). As 
showed in figure 1B, the BzATP-induced articular hyperalgesia (225 µg/knee) reached its 
maximum effect 3 hours after its administration and was completely resolved 6 hours later when 
compared with 0.9% NaCl control group (P<0.05, two-way ANOVA post hoc Bonferroni test). 
The subsequent experiments were performed 3 hours after BzATP administration.  
To confirm that BzATP-induced articular hyperalgesia was mediated by P2X7 receptors, 
the selective P2X7 receptors antagonist A-740003 was co-administered with BzATP. A-740003 
(568 µg/knee) reduced the BzATP-induced articular hyperalgesia (Fig. 1C, P<0.05, one-way 
ANOVA post hoc Tukey test). To rule out the systemic effect of A-740003 (568 µg/knee), it was 
administrated in contralateral knee joint and did not affect the articular hyperalgesia induced by 
BzATP administrated in ipsilateral knee joint (Fig. 1C, P>0.05, one-way ANOVA post hoc 
Tukey test). In addition, to confirm the selectivity of BzATP (225 µg/knee) as a P2X7 agonist, it 
was co-administrated with the selective the selective P2X3 and P2X2/3 receptors antagonist A-
317491 (540 µg/knee) which did not affect the BzATP-induced articular hyperalgesia (Fig. 1C, 
P>0.05, one-way ANOVA post hoc Tukey test). 
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Figure 1 - Articular hyperalgesia induced by BzATP administration in the rat knee joint. 
(A) Intra-articular administration of BzATP (225 µg/knee, “*” and 675 µg/knee, “#”) in the rats 
knee joint induced a dose-dependent articular hyperalgesia when compared with 0.9% NaCl 
control group (P<0.05, Tukey test). (B) The BzATP-induced articular hyperalgesia (225µg/knee) 
in the rat’s knee joint reached its maximum effect 3 hours after its administration. The symbol 
“*” indicates responses significantly greater than that induced by 0.9% NaCl group (P<0.05, 
Bonferroni test). (C) The BzATP-induced articular hyperalgesia (225 µg/knee) was significantly 
reduced by the co-administration of A-740003 (A-74, 568 µg/knee, P<0.05, Tukey test) as 
indicated by the symbol “#”, but not by the co-administration of A-317491 (A-317, 540 µg/knee, 
P>0.05, Tukey test). A-740003 (568 µg/knee) administrated in the contralateral knee joint (ct) did 
not affect the BzATP-induced articular hyperalgesia. The symbol “*” indicates responses 
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significantly greater than that induced by 0.9% NaCl or naive groups (P<0.05, Tukey test). In this 
and in subsequent figures the hyperalgesia was measured 3 hours after BzATP administration and 
the numbers of rats used are shown in parentheses. 
 
Blockade of local bradykinin B1- or B2-receptors reduced the articular hyperalgesia induced by 
BzATP. 
To verify whether BzATP-induced articular hyperalgesia depends on bradykinin release, 
the bradykinin B1- or B2-receptor antagonist DALBK or Bradyzide, respectively, was co-
administered with BzATP. DALBK (3.0 µg/knee, Fig. 2A) or Bradyzide (0.5 µg/knee, Fig. 2B) 
reduced the BzATP-induced articular hyperalgesia (P<0.05, one-way ANOVA post hoc Tukey 
test) and they did not affect the articular hyperalgesia when administered on the contralateral 
knee joint (P>0.05, one-way ANOVA post hoc Tukey test) confirming their local action. The co-
administration of DALBK (3.0 µg/knee) or Bradyzide (0.5 µg/knee) with 0.9% NaCl did not 
change the paw elevation time (PET) when compared with 0.9% NaCl or naive control groups 
(P>0.05, one-way ANOVA post hoc Tukey test). 
 
Blockade of local β1- or β2-adrenoceptors reduced the articular hyperalgesia induced by BzATP. 
To verify whether BzATP-induced articular hyperalgesia depends on sympathomimetics 
amines release, the β1- or β2-adrenoceptor antagonist Atenolol or ICI 118,551, respectively, was 
co-administered with BzATP. Atenolol (6.0 µg/knee, Fig. 2C) and ICI 118,551 (1.5 µg/knee, Fig. 
2D) significantly reduced BzATP-induced articular hyperalgesia (P<0.05, one-way ANOVA post 
hoc Tukey test) and they did not affect the articular hyperalgesia when administered on the 
contralateral knee joint (P>0.05, one-way ANOVA post hoc Tukey test) confirming their local 
action. Co-administration of Atenolol (6.0 µg/knee) or ICI 118,551 (1.5 µg/knee) with 0.9% 
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NaCl did not change the paw elevation time (PET) when compared with 0.9% NaCl group or 
naive control groups (P>0.05, one-way ANOVA post hoc Tukey test). 
 
Blockade of local prostaglandins synthesis reduced the articular hyperalgesia induced by BzATP. 
To verify whether BzATP-induced articular hyperalgesia depends on prostaglandins 
release, rats were treated with local administration of Indomethacin 30 minutes before BzATP 
administration. Indomethacin (100 µg/knee, Fig. 2E) significantly reduced BzATP-induced 
articular hyperalgesia (P<0.05, one-way ANOVA post hoc Tukey test) and did not affect the 
articular hyperalgesia when administered on the contralateral knee joint (P>0.05, one-way 
ANOVA post hoc Tukey test) confirming its local action. The co-administration of Indomethacin 
(100 µg/knee) with 0.9% NaCl did not change the paw elevation time (PET) when compared with 
0.9% NaCl or naive control groups (P>0.05, one-way ANOVA post hoc Tukey test). 
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Figure 2 - Effect of B1- or B2-receptors antagonists, β1- or β2- adrenoceptors antagonists and 
the blockade of prostaglandins synthesis on the BzATP-induced articular hyperalgesia in 
rat’s knee joint. The co-administration of B1 receptor antagonist DALBK (3.0 µg/knee, A), B2 
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receptor antagonist Bradyzide (0.5 µg/knee, B), β1 adrenoceptor antagonist Atenolol (6.0 
µg/knee, C), β2 adrenoceptor antagonist ICI 118,551 (1.5 µg/knee, D) or cyclooxygenase 
inhibitor Indomethacin (100 µg/knee, 30 min pre-treatment, E) with BzATP (225 µg/knee) 
significantly reduced the BzATP-induced articular hyperalgesia, as indicated by the symbol “#” 
(P<0.05, Tukey test). DALBK (3.0 µg/knee, A), Bradyzide (0.5 µg/knee, B), Atenolol (6.0 
µg/knee, C), ICI 118,551 (1.5 µg/knee, D) or Indomethacin (100 µg/knee, E) administrated in the 
contralateral knee joint (ct) or co-administrated with 0.9% NaCl did not affect the articular 
hyperalgesia induced by BzATP or the paw elevation time, when compared with BzATP alone or 
naive groups, respectively (P>0.05, Tukey test). The symbol “*” indicates responses significantly 
greater than that induced by 0.9% NaCl or naive groups (P<0.05, Tukey test). 
 
Local administration of BzATP increases the concentration of pro-inflammatory cytokines in rats 
knee joint 
This set of experiments was performed to verify whether BzATP induces the increase of 
concentration of TNF-α, IL-1β, IL-6 and CINC-1. Intra-articular administration of BzATP (225 
µg/knee) significantly increased the concentration of TNF-α (Fig. 3A), IL-1β (Fig. 3B), IL-6 
(Fig. 3C) and CINC-1 (Fig. 3D) 3 hours later when compared with 0.9% NaCl administration or 
naive control groups (P<0.05, one-way ANOVA post hoc Tukey test).  The co-administration of 
the selective P2X7 receptor antagonist A-740003 (568 µg/knee) with BzATP reduced the local 
concentration of TNF-α (Fig. 3A), IL-1β (Fig. 3B), IL-6 (Fig. 3C) and CINC-1 (Fig. 3D) 
(P<0.05, one-way ANOVA post hoc Tukey test). The intra-articular injection of 0.9% NaCl (50 
µL) alone did not affect the endogenous concentration of TNF-α, IL-1β, IL-6 and CINC-1 when 
compared with naive group (P>0.05, one-way ANOVA post hoc Tukey test). 
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Figure 3 – Effect of BzATP on the local concentration of pro-inflammatory cytokines in the 
rat’s knee joint. The intra-articular administration of BzATP (225 µg/knee) induced an increase 
of TNF-α (A), IL-1β (B), IL-6 (C) and CINC-1 (D) concentrations. The co-administration of A-
740003 (568 µg/knee) with BzATP significantly reduced the BzATP-induced increase of TNF-α 
(A), IL-1β (B), IL-6 (C) and CINC-1 (D) concentrations, as indicated by the symbol “#” (P<0.05, 
Tukey test). The intra-articular injection of 0.9% NaCl did not affect the endogenous 
concentration of TNF-α, IL-1β, IL-6 and CINC-1 when compared with naive group (P>0.05, 
Tukey test). The symbol “*” indicated a cytokines concentrations significantly greater than that 
induced by 0.9% NaCl and by naive groups (p<0.05, ANOVA, pos hoc Tukey test). 
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Involvement of neutrophil migration on BzATP-induced articular hyperalgesia 
To verify whether local administration of BzATP (225 µg/knee) induces neutrophil 
migration and if this is important to development of articular hyperalgesia, rats were treated with 
Fucoidan (25 mg/kg, i.v.) 20 minutes before BzATP administration. As showed in figure 4A, the 
articular hyperalgesia measured 3 hours later BzATP administration was not reduced by the pre-
treatment with Fucoidan (P>0.05, one-way ANOVA post hoc Tukey test). The intra-articular 
administration of BzATP (225 µg/knee) increased the myeloperoxidase’s activity when compared 
with 0.9% NaCl control group which was blocked by Fucoidan (Fig. 4B, P<0.05, one-way 
ANOVA post hoc Tukey test). The intra-articular injection of 0.9% NaCl alone did not affect the 
myeloperoxidase’s activity when compared with naive rats (P>0.05, one-way ANOVA post hoc 
Tukey test). 
 
Figure 4 - Effect of Fucoidan on BzATP-induced articular hiperalgesia and neutrophil 
migration in rat knee joint. (A) The pre-treatment with Fucoidan (25mg/kg, i.v.) did not 
decreased BzATP-induced articular hyperalgesia (P>0.05, Tukey test). (B) The intra-articular 
administration of BzATP (225µg/knee) induced an increase of myeloperoxidase’s activity which 
was blocked by the pre-treatment with Fucoidan (25mg/kg, i.v.), as indicated by the symbol “#” 
(P<0.05, Tukey test). The symbol “*” indicates a neutrophil migration significantly greater than 
that induced by 0.9% NaCl group (P<0.05, Tukey test). 
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Discussion 
 
 Recently, we have demonstrated that activation of P2X7 receptor by endogenous ATP 
release in inflamed articular tissue is essential to the development of the articular inflammatory 
hyperalgesia induced by carrageenan mediated by an indirect sensitization of the primary afferent 
nociceptors which depends on the previous pro-inflammatory cytokines release and neutrophil 
migration (Teixeira et al., 2014b in press). In the current study, we have showed that peripheral 
P2X7 receptor activation by its agonist induces articular hyperalgesia by an indirect sensitization 
of the primary afferent nociceptors, once it depends on inflammatory mediators release: 
bradykinin, prostaglandins, sympathomimetic amines and pro-inflammatory cytokines.  
Although BzATP is a non-selective P2X7 receptor agonist once it also bind to P2X1 and 
P2X3 receptor (Bianchi et al., 1999, Jacobson et al., 2002), the involvement of P2X1 seems to be 
unlikely, since it has been demonstrated that IP5I, a potent and selective P2X1 receptor 
antagonist, is ineffective in reducing inflammatory pain (Honore et al., 2002) or mechanical 
hypersensitivity (Dai et al., 2004). Morevover, it has been shown that the P2X1 receptor does not 
contribute to hyperalgesia in temporomandibular joint (Shinoda et al., 2005). 
In addition, BzATP is the most potent agonist for P2X7 receptor available (Jacobson et 
al., 2002). In this study we demonstrated that the articular hyperalgesia induced by BzATP was 
prevented by the P2X7 receptor antagonist A-740003 (Honore et al., 2006) but was unaffected by 
the selective P2X3 and P2X2/3 receptors antagonist, A-317491 (Jarvis et al., 2002), suggesting 
that BzATP-induced articular hyperalgesia was mediated by P2X7 receptor activation. Our data 
are consistent with previous studies showing that BzATP induces nociceptive and hyperalgesic 
behaviors by P2X7 receptor activation (Teixeira et al., 2010, Ito et al., 2013, Teixeira et al., 
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2014a). Because the activation of spinal P2X7 receptor contributes to mechanical hyperalgesia 
(Clark et al., 2010), the finding that the administration of A-740003 in the contralateral knee joint 
did not affect BzATP-induced articular hyperalgesia confirms that only local P2X7 receptors of 
the peripheral tissue were targeted. 
Agreeing with the results of this study, P2X7 receptor activation in knee joint can induces 
the release of bradykinin, an inflammatory mediator which has been pointed out as a key target in 
arthropathies models (Valenti et al., 2010, Valenti et al., 2012, Gomis et al., 2013). It has been 
described that the bradykinin is rapidly generated after tissue injury and modulates most of the 
events observed during the inflammatory processes, including increase of vascular permeability 
and vasodilatation, producing local heating and oedema, leukocyte recruitment, excitation and 
sensitization of sensory nerves, evoking pain and hyperalgesia (Marceau et al., 1998, Calixto et 
al., 2000, Couture et al., 2001, Pawlak et al., 2008). In addition, in the arthritic joints bradykinin 
has also been involved in endothelial cell proliferation, cartilage matrix homeostasis and bone 
resorption, potentially affecting, therefore, the synovial angiogenesis and cartilage destruction 
(Colman, 2006, Brechter and Lerner, 2007, Meini and Maggi, 2008).  
Our results showed that bradykinin also plays a crucial role in the development of 
articular hyperalgesia in rats knee joint, because the bradykinin B1 and B2-receptors antagonists 
greatly reduced BzATP-induced articular hyperalgesia. This result is similar to that occurs in 
subcutaneous tissue (Teixeira et al., 2014a in press). Considering that bradykinin is an 
inflammatory mediator released during earlier phase of inflammation (Ferreira et al., 1993a, 
Ferreira et al., 1993b), it is plausible to suggest that P2X7 receptor activation in the knee joint 
initiates the articular inflammatory process.  
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Bradykinin induces hyperalgesia by two distinct pathways that result in the local 
production of prostaglandins and release of sympathomimetic amines (Ferreira et al., 1993a, 
Ferreira et al., 1993b), which directly sensitize the primary afferent nociceptor (Gold et al., 1996, 
Khasar et al., 1999, Rush and Waxman, 2004). The synovium of knee joint is innervated by both 
postganglionic sympathetic fibers and afferent C-fibers. Sympathetic postganglionic fibers 
constitute between half and two-thirds of the nerve fibers in the synovium (Hildebrand et al., 
1991).  The results of this study demonstrate that the articular hyperalgesia induced by local 
activation of P2X7 receptor depends on both pathways: the production of prostaglandins and 
release of sympathomimetic amines, which act directly on primary afferent nociceptors. 
Specifically, both β-adrenoceptor antagonists and inhibitor of cyclooxygenase indomethacin 
reduced the BzATP-induced articular hyperalgesia. These results showed that the blockade of one 
pathway completely reverses the BzATP-induced articular hyperalgesia.  
The data of this study demonstrated that local P2X7 receptor activation in the rat’s knee 
joint induces release of TNF-α, IL-1β, IL-6 and CINC-1.  These findings are consistent with 
recent data which demonstrated that P2X7 receptor activation in the subcutaneous tissue also 
triggered pro-inflammatory cytokines release (Teixeira et al., 2014a in press).  
It has been systematically demonstrated that P2X7 receptor is selectively expressed in 
peripheral macrophages, mast cells, lymphocytes, fibroblasts, erythrocytes, monocytes and FLS 
cells (Surprenant et al., 1996, Collo et al., 1997, Mancino et al., 2001, Caporali et al., 2008) and 
these cells produce and secrete pro-inflammatory cytokines (Guerne et al., 1989, Dubravec et al., 
1990, Mekori and Metcalfe, 2000, Hayashida et al., 2001, Shakoory et al., 2004, Mor et al., 
2005). Thus, our results suggest that the pro-inflammatory cytokines release in knee joint 
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mediated by activation of P2X7 receptors expressed in resident cells, especially peripheral 
macrophages and FLS cells. 
In fact, it has been demonstrated a role of P2X7 receptor activation in IL-6 release by FLS 
cells (Caporali et al., 2008). Moreover, ATP induces the release of IL-1β, TNF-α and IL-6 via 
P2X7 receptor activation (Ferrari et al., 1997, Hide et al., 2000, Solle et al., 2001, Colomar et al., 
2003, Chessell et al., 2005, Gourine et al., 2005, Mingam et al., 2008). Several studies have been 
demonstrated the ability of P2X7 receptor activation increases IL-1β.   Experiments performed in 
vitro show that the activation of P2X7 receptor stimulates caspase-1, triggering IL-1β release in 
LPS stimulation models (Ferrari et al., 1996, Sanz and Di Virgilio, 2000, Kahlenberg and 
Dubyak, 2004, Ferrari et al., 2006). Also, the activation of P2X7 receptors by the BzATP did not 
stimulate the IL-1β production by macrophages obtained from P2X7 knockout mice when 
compared with wild type (Basso et al., 2009). 
Therefore, our results suggested that P2X7 activation-induced articular hyperalgesia 
depends on the prior release of pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and CINC-1, 
with subsequent prostaglandins synthesis and sympathomimetic amines release in the rat’s knee 
joint, which in turn directly sensitize the primary afferent nociceptor. 
Another important sign involved in inflammatory hyperalgesia is the migration of 
neutrophils to the site of inflammation. Neutrophils are present in higher quantity, about 90% of 
the leukocytic infiltrate in synovial fluid of patients with arthritis (Mohr, 1995) and play an 
important role in the arthropathies pathogenesis, because they interact with resident cells and 
local inflammatory mediators. This interaction amplify the inflammatory response, contributing 
directly to the chronic and acute inflammation and release of nociceptive mediators (Kasama et 
al., 2005). Neutrophils induce the release of proteolytic enzymes which contribute tissue damage 
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(Edwards and Hallett, 1997). Studies from our laboratory have showed that ATP released in the 
site of inflammation via P2X7 receptor activation induces articular hyperalgesia that is mediated 
by neutrophil migration. Thus, in this study we also investigated whether the P2X7 receptor 
activation induces neutrophil migration to the rats knee joint, contributing to P2X7 activation-
induced articular hyperalgesia. 
Surprisingly, our results demonstrate that neutrophils do not contribute to the 
development of BzATP-mediated articular hyperalgesia in the rat’s knee joint, because the pre-
treatment with Fucoidan does not reduces the BzATP-induced articular hyperalgesia. Fucoidan 
was used as a pharmacological tool to investigate this issue, as it binds to L- and P-selectins and 
consequently, inhibits neutrophil rolling (Ley et al., 1993, Cunha et al., 2008). This data indicates 
a difference between the pathophysiology of articular inflammatory hyperalgesia and 
subcutaneous tissue inflammatory hyperalgesia, because data from our laboratory demonstrated 
that in the rats paw subcutaneous tissue BzATP-induced mechanical hyperalgesia depends on 
neutrophils migration (Teixeira et al., 2014a in press). 
 By the other hand, our results showed that BzATP induces neutrophil migration to the 
rat’s knee joint, which was blocked by Fucoidan. We can hypothesize that the neutrophil 
migration induced by BzATP probably results from its ability to induce the pro-inflammatory 
cytokines release, mainly CINC-1 which induces chemotaxis and leukocytes recruitment 
(Romano et al., 1997, Ramos et al., 2003, Moon et al., 2010).  
In conclusion, the findings of the present study suggest that peripheral mechanisms 
involved in the articular hyperalgesia induced by P2X7 receptors activation in the rat knee joint 
involve previous release of bradykinin, prostaglandins, sympathomimetic amines and pro-
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inflammatory cytokines. Therefore, P2X7 receptor antagonist may be an interesting target to 
control articular inflammatory hyperalgesia.   
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Abstract 
Activation of P2X3, P2X2/3 and P2X7 receptors by endogenous ATP plays an essential 
role in the development of carrageenan-induced hyperalgesia in the rat’s knee joint through the 
previous release of pro-inflammatory cytokines and neutrophil migration. Moreover, P2X3, 
P2X2/3 and P2X7 activation by their agonists, induces articular hyperalgesia mediated by 
bradykinin, prostaglandins, sympathomimetic amines, pro-inflammatory cytokines and neutrophil 
migration in the rat’s knee joint. In this study, we asked whether the activation of P2X3, P2X2/3 
and P2X7 receptors, contributes to the articular hyperalgesia induced by the inflammatory 
mediators belonging to carrageenan inflammatory cascade, such as bradykinin, tumor necrosis 
factor alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), chemokine-induced 
chemoattractant-1 (CINC-1), prostaglandin E2 (PGE2) and dopamine. We found that the co-
administration of the selective P2X3 and P2X2/3 receptors antagonist A-317491 or of the 
selective P2X7 receptor antagonist A-740003 significantly reduced the articular hyperalgesia 
induced by bradykinin, and dopamine, but not by TNF-α, IL-1β and CINC-1. The co-
administration of the selective P2X3 and P2X2/3 receptors antagonist A-317491 also 
significantly reduced the articular hyperalgesia induced by PGE2. These results indicate the 
activation of P2X3, P2X2/3 and P2X7 receptors contributes to bradykinin- and dopamine-
induced hyperalgesia and that the activation of P2X3 and P2X2/3, but not P2X7 receptors, 
contributes to PGE2-induced hyperalgesia. Further, they also indicate that these purinergic 
receptors contribute to the hyperalgesia induced by bradykinin, dopamine and PGE2, through a 
previous release of endogenous ATP induced by these inflammatory mediators. 
Keywords: ATP, P2X3 and P2X2/3 receptors, P2X7 receptor, articular inflammatory 
hyperalgesia, rat knee joint, inflammatory mediators. 
153 
 
Introduction 
 
Extracellular ATP released from damaged cells such as macrophages, platelets, 
keratinocytes, neutrophils and dying cells (Filippini et al., 1990, Dubyak and el-Moatassim, 1993, 
Beigi et al., 1999, Sikora et al., 1999, Mizumoto et al., 2003, Campwala and Fountain, 2013) 
plays an important role in the development of inflammatory pain by activating P2X receptors. 
The P2X3, P2X2/3 and P2X7 purinergic receptors subtypes belongs to the family of ATP-
sensitive ionotropic P2X receptors (P2X1-P2X7) (Buell et al., 1996, North, 2002) and are 
involved in pain and hiperalgesia mechanisms in several tissues, including articular tissues 
(Labasi et al., 2002, Shinoda et al., 2005, Seino et al., 2006, Broom et al., 2008, Teixeira et al., 
2010, Teixeira et al., 2014a in press, Teixeira et al., 2014b in press). 
The P2X3 and P2X2/3 receptors are localized on terminals of primary sensory afferents 
fibers where they mediate sensory neurotransmission (Bradbury et al., 1998, Burnstock and 
Knight, 2004, Gever et al., 2006), on endothelial cells of thymus (Glass et al., 2000), urothelial 
cells (Sun and Chai, 2004), human epidermal keratinocytes (Inoue et al., 2005) and chondrocytes 
(Varani et al., 2008, Teixeira et al., 2014a in press). The P2X7 receptors are found predominantly 
in cells of immunological origin such as mast cells, erythrocytes, monocytes, fibroblasts, 
peripheral macrophages, T and B lymphocytes (Chiozzi et al., 1997, Collo et al., 1997, Kim et al., 
2001, Mancino et al., 2001, North, 2002, Greig et al., 2003, Surprenant and North, 2009) and in 
type B synoviocytes (fibroblasts like-synoviocytes - FLS cells,  Caporali et al., 2008). 
In addition to ATP, many inflammatory mediators such as bradykinin, prostaglandins, 
sympathomimetic amines and the pro-inflammatory cytokines are released after tissue injury 
induce and/or maintain the inflammatory hyperalgesia (Cunha et al., 1991, Cunha et al., 1992, 
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Ferreira et al., 1993a, Loram et al., 2007, Luiz et al., 2010, Petho and Reeh, 2012, Villarreal et 
al., 2013). All of these inflammatory mediators play an important role in pain development in the 
arthropathies (Attur et al., 1998, Kasama et al., 2005, Colman, 2006, Brechter and Lerner, 2007, 
Meini and Maggi, 2008, Moon et al., 2010, Tanaka et al., 2013). 
We have recently demonstrated that peripheral P2X3, P2X2/3 and P2X7 receptors 
activation by endogenous ATP, not only contributes, but it is essential to the development of 
carrageenan-induced articular hyperalgesia in the rat’s knee joint through an indirect sensitization 
of the primary afferent nociceptors, dependent on the previous release of pro-inflammatory 
cytokines and neutrophil migration (Teixeira et al., 2014a in press, Teixeira et al., 2014b in 
press). Further, we have also demonstrated that the activation of P2X3, P2X2/3 and P2X7 
receptors by their agonists, induces articular hyperalgesia mediated by bradykinin, 
prostaglandins, sympathomimetic amines, pro-inflammatory cytokines and neutrophil migration 
in the rat’s knee joint (Teixeira et al., 2014c in press, Teixeira et al., 2014d in press). However, it 
is not known whether the P2X3, P2X2/3 and P2X7 receptors contribute to the articular 
hyperalgesia induced by inflammatory mediators belonging to carrageenan cascade (Ferreira et 
al., 1993a, Ferreira et al., 1993b).  
In this study, we asked whether the activation of P2X3, P2X2/3 and P2X7 receptors, 
contributes to the articular hyperalgesia induced by the inflammatory mediators bradykinin, TNF-
α, IL-1β, IL-6, CINC-1, PGE2 and dopamine. For this study, we explored the ability of the 
selective P2X3, P2X2/3 and P2X7 receptors antagonists, A-317491 and A-740003, respectively, 
to reduce the articular hyperalgesia induced by each one of these inflammatory mediators. 
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Materials and Methods 
 
Animals 
Male Wistar rats (200-250g) obtained from the Multidisciplinary Center for Biological 
Research (CEMIB) - University of Campinas, were used in this study. The animals were housed 
in plastic cages with soft bedding (five/cage) on a 12:12 light cycle (lights on at 06:00 A.M.) with 
food and water available ad libitum. They were maintained in a temperature-controlled room 
(±23°C) and handled for at least one week prior to the experiments. Each animal was used once 
and the number of animals per group was kept to a minimum. Experimental protocols were 
approved by the Committee on Animal Research of the University of Campinas (protocol 
number: 2049-1) and conformed to IASP guidelines for the study of the pain in animals 
(Zimmermann, 1983).  
 
General Procedures 
Testing sessions took place during light phase (between 09:00 AM and 5:00 PM) in a 
quiet room maintained at 23ºC (Rosland, 1991). During the tests the animals had no access to 
water or food. The animals were habituated for 1 hour prior to the experiment to minimize stress. 
 
Drugs administration  
Drugs or their vehicle were intra-articularly administrated in the right rat’s knee joint by a 
26-gauge needle that was connected to a catheter of polyethylene and also to a Hamilton syringe 
(50 µL). The volume of injection was 50 µL.  
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Knee joint inflammation induced by inflammatory mediators 
Under brief inhalation of isoflurane anesthesia, rats were subjected to intra-articular (i.a.) 
injection of inflammatory mediators (bradykinin, TNF-α, IL-1β, IL-6, CINC-1, PGE2 and 
dopamine) dissolved in 25μL sterile 0.9% saline or PBS solution into their right knee joints 
(Tonussi and Ferreira, 1992). The injection site was shaved and treated with an antiseptic solution 
of iodine alcohol. The other drugs were also injected into the knee joint in the same manner that 
the inflammatory mediators and the control animals received vehicle. 
 
Drugs and doses  
 The following drugs were used: bradykinin (1.5, 4.5, 13.5 and 40.5 μg/knee, i.a., de 
Oliveira Fusaro et al., 2010); tumor necrosis factor alpha (TNF: 0.8, 2.4 and 7.2 pg/knee, i.a, de 
Oliveira Fusaro et al., 2010); interleukin-1 beta (IL-1: 0.5, 1.5 and 4.5 pg/knee, i.a., Cunha et 
al., 2008);  interleukin-6 (IL-6: 0.1, 0.3 and 0.9 ng/knee, i.a., de Oliveira Fusaro et al., 2010); 
chemokine-induced chemoattractant-1 (CINC-1: 1.0, 3.0 and 9.0 pg/knee, i.a., de Oliveira Fusaro 
et al., 2010); prostaglandin E2 (PGE2: 100, 300 and 900 ng/knee, i.a., de Oliveira Fusaro et al., 
2010); dopamine (10, 30 and 90 g/knee, i.a., de Oliveira Fusaro et al., 2010); the selective P2X3 
and P2X2/3 receptor antagonist 5-([(3-Phenoxybenzyl)[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] 
amino]carbonyl)-1,2,4-benzenetricarboxylic acid (Jarvis et al., 2002) (A-317491: 540 µg/knee, 
i.a., Teixeira et al., 2014a in press); the selective P2X7 receptor antagonist [N-(1-{[(Cyanoimino) 
(5-quinolinylamino) methyl] amino}-2,2-dimethylpropyl)- 2-(3,4-dimethoxyphenyl)acetamide] 
(Honore et al., 2006) (A-740003: 568 µg/knee, i.a., Teixeira et al., 2014b in press). TNF-, IL-
1, IL-6 and CINC-1 were obtained from R&D Systems (Minneapolis, USA) and dissolved in 
phosphate-buffered saline (PBS, Sigma Chemicals, St. Louis, Missouri, USA). A-740003 was 
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obtained from Tocris Bioscience (Ellisville, MO) and dissolved in 25μL of dimethyl sulfoxide 
(DMSO, 50%) and propylene glycol (50%). All other drugs were obtained from Sigma-Aldrich 
(MO, USA) and dissolved in sterile 0.9% saline (0.9% NaCl). 
 
Gait disturbance - Rat knee-joint incapacitation test 
We used the rat knee-joint incapacitation test, as described previously (Tonussi and 
Ferreira, 1992). Briefly, after drugs injection into their right knee joints, rats were put to walk on 
a steel rotary cylinder (30 cm wide x 50 cm diameter), covered with a fine-mesh non-oxidizable 
wire screen, which rotates at 3 rpm. Specially, designed metal gaiters were wrapped around both 
hind paws. After placement of the gaiters, rats were placed to walk in the cylinder and the right 
paw was then connected via a simple circuit to microcomputer data input/output port. The paw 
elevation time (PET) is the total time that the rat walks failing to touch the cylinder surface with 
the injected hindpaw, during a 60 sec period, which is directly proportional to the gait 
disturbance. Incapacitation was quantified as an increase in the PET, 3 hours after carrageenan 
injection into the right knee joint. To minimize variations in PET, all rats were introduced to the 
experimental environment and trained on the apparatus to habituation into the equipment before 
the testing sessions. To confirm the local effect of some test agents, they were injected into the 
contralateral rat’s knee joint and the test was performed on the ipsilateral knee joint. The rat 
knee-joint incapacitation test provides automated measurements, which are independent of the 
subjectivity of the observer (Tonussi and Ferreira, 1992). 
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Statistical analysis 
 To determine if there were significant differences (p<0.05) between treatment groups, 
One-way ANOVA was performed. If there was a significant between-subjects main effect of 
treatment group following One-way ANOVA, post hoc contrasts using the Tukey test were 
performed to determine the basis of the significant difference. Data are expressed in figures as 
means ± S.E.M.  
 
Results 
 
Bradykinin, TNF-α, IL-1β, CINC-1, PGE2 or dopamine-induced articular hyperalgesia in the 
rat’s knee joint 
The intra-articular administration of bradykinin (13.5 and 40.5 μg/knee, Fig. 1A and 2A), 
TNF-α (2.4 pg/knee, Fig. 1B and 2B), IL-1β (1.5 and 4.5 pg/knee, Fig. 1C and 2C), CINC-1 (3.0 
and 9.0 pg/knee, Fig. 1D and 2D), PGE2 (300 and 900 ng/knee, Fig. 1E and 2E) or dopamine (30 
and 90 μg/knee, Fig. 1F and 2F) into the rat’s knee joint induced a dose-dependent articular 
hyperalgesia 3 hours after their administration when compared with vehicle administration and 
naive rats (P<0.05, one-way ANOVA post hoc Tukey test). Intra-articular administration of IL-6 
(0.1, 0.3 and 0.9 ng/knee Fig. 3) into the rat’s knee joint did not induce articular hyperalgesia 
(P>0.05, one-way ANOVA post hoc Tukey test). 
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Blockade of P2X3 and P2X2/3 receptors prevented bradykinin, PGE2 and dopamine-induced 
hyperalgesia in the rat’s knee joint 
To verify whether P2X3 and P2X2/3 receptors activation mediates the articular 
hyperalgesia induced by bradykinin, TNF-α, IL-1β, CINC-1, PGE2 or dopamine, the selective 
P2X3 and P2X2/3 receptors antagonist A-317491 was co-administered with each one of these 
inflammatory mediators. Co-administration of A-317491 (540 μg/knee) significantly reduced the 
articular hyperalgesia induced by bradykinin (13.5 μg/knee, Fig. 1A), PGE2 (300 ng/knee, Fig. 
1E) and dopamine (30 μg/knee, Fig. 1F) (P<0.05, one-way ANOVA post hoc Tukey test) but not 
the articular hyperalgesia induced by TNF-α (2.4 pg/knee, Fig. 1B), IL-1β (1.5 pg/knee, Fig. 1C) 
and CINC-1 (3.0 pg/knee, Fig. 1D) (P>0.05, one-way ANOVA post hoc Tukey test). The 
administration of A-317491 (540 μg/knee) in the contralateral knee joint did not affect the 
articular hyperalgesia induced by bradykinin, PGE2 or dopamine, ruling out a possible systemic 
effect. The administration of A317491 (540 μg/knee) with 0.9% NaCl did not induce articular 
hyperalgesia by itself (P>0.05, one-way ANOVA post hoc Tukey test, Fig 1A, 1E and 1F). These 
findings suggest that P2X3 and P2X2/3 receptors mediate the articular hyperalgesia induced by 
bradykinin, PGE2 and dopamine, but not by TNF-α, IL-1β, CINC-1. 
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Figure 1 - Effect of P2X3 and P2X2/3 receptors antagonist on bradykinin, TNF-α, IL-1β, 
CINC-1, PGE2 or dopamine-induced articular hyperalgesia in the rat’s knee joint. The co-
administration of A-317491 (A-317, 540 μg/knee) significantly reduced the hyperalgesic 
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response of Bradykinin (13.5 μg/knee, A), PGE2 (300 ng/knee, E) and Dopamine (30 μg/knee, F) 
(P<0.05, Tukey test) but not the hyperalgesic response induced by TNF-α (2.4 pg/knee, B), IL-1β 
(1.5 pg/knee, C) and CINC-1 (3.0 pg/knee, D) (P>0.05, Tukey test). The intra-articular 
administration of A-317491 (A-317, 540 μg/knee) in the contralateral knee joint did not affect the 
articular hyperalgesia induced by Bradykinin, PGE2 or Dopamine (P>0.05, Tukey test). The 
administration of A-317491 (A-317, 540 μg/knee) plus 0.9% NaCl had no effect (P>0.05, Tukey 
test). The symbol “*” indicates responses significantly higher than that induced by vehicle and 
naive groups (P<0.05, Tukey test). The symbol “#” indicates responses significantly lower than 
that induced by Bradykinin, PGE2 and Dopamine (P<0.05, Tukey test). In this and in the 
subsequent figures, measurements were taken 3 hour after injections and the number of rats used 
is between parentheses. 
 
Blockade of P2X7 receptors reduces bradykinin and dopamine-induced hyperalgesia in the rat’s 
knee joint 
To investigate whether P2X7 receptor activation mediates the articular hyperalgesia 
induced by bradykinin, TNF-α, IL-1β, CINC-1, PGE2 or dopamine, the selective P2X7 receptor 
antagonist A-740003 was co-administered with each one of these inflammatory mediators. Co-
administration of A-740003 (568 μg/knee) significantly reduced the articular hyperalgesia 
induced by bradykinin (13.5 μg/knee, Fig. 2A) and dopamine (30 μg/knee, Fig. 2F) (P<0.05, one-
way ANOVA post hoc Tukey test) but not the articular hyperalgesia induced by TNF-α (2.4 
pg/knee, Fig. 2B), IL-1β (1.5 pg/knee, Fig. 2C), CINC-1 (3.0 pg/knee, Fig. 2D) and PGE2 (300 
ng/knee, Fig. 2E) (P>0.05, one-way ANOVA post hoc Tukey test). The administration of A-
740003 (568 μg/knee) in the contralateral rat’s knee joint did not affect the articular hyperalgesia 
induced by bradykinin or dopamine, ruling out a systemic effect.  The administration of A-
740003 (568 μg/knee) with 0.9% NaCl into the knee joint, did not induce articular hyperalgesia 
by itself (P>0.05, one-way ANOVA post hoc Tukey test, Fig 2A and 2F). These findings suggest 
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that P2X7 receptor mediates the articular hyperalgesia induced by bradykinin and dopamine, but 
not by TNF-α, IL-1β, CINC-1 and PGE2. 
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Figure 2 - Effect of P2X7 receptor antagonist on bradykinin, TNF-α, IL-1β, CINC-1, PGE2 
or dopamine-induced articular hyperalgesia in the rat’s knee joint.  
Co-administration of A-740003 (A-74, 568 μg/knee) significantly reduced the hyperalgesic 
response of Bradykinin (13.5 μg/knee, A) and Dopamine (30 μg/knee, F) (P<0.05, Tukey test) 
but not the hyperalgesic response of  TNF-α (2.4 pg/knee, B), IL-1β (1.5 pg/knee, C), CINC-1 
(3.0 pg/knee, D) and PGE2 (300 ng/knee, E) (P>0.05, Tukey test). The intra-articular 
administration of A-740003 (A-74, 568 μg/knee) in the contralateral knee joint did not affect the 
articular hyperalgesia induced by Bradykinin or Dopamine (P>0.05, Tukey test). The 
administration of A-740003 (A-74, 568 μg/knee) plus 0.9% NaCl had no effect(P>0.05, Tukey 
test). The symbol “*” indicates responses significantly higher than that induced by vehicle and 
naive groups (P<0.05, Tukey test). The symbol “#” indicates responses significantly lower than 
that induced by Bradykinin or Dopamine (P<0.05, Tukey test).  
 
 
 
Figure 3 - Effect of IL-6 administration into the rat’s knee joint. The intra-articular 
administration of IL-6 (0.1, 0.3 and 0.9ng/knee) did not induce articular hyperalgesia when 
compared with naive and vehicle (PBS) administered rats (P>0.05, Tukey test). 
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Discussion 
 
This study shows that in the knee joint of rats, the activation of P2X3, P2X2/3 and P2X7 
receptors contributes to the hyperalgesic response of bradykinin and dopamine through a 
previous release of endogenous ATP induced by these inflammatory mediators. However, the 
activation of P2X3 and P2X2/3, but not P2X7 receptor, contributes to PGE2-induced 
hyperalgesia.  
The evidences are that the selective P2X3 and P2X2/3 receptor antagonist A-317491 
(Jarvis et al., 2002) prevented the articular hyperalgesia induced by bradykinin, PGE2 and 
dopamine, and that the selective P2X7 receptor antagonist A-740003 (Honore et al., 2006) 
prevented the articular hyperalgesia induced by bradykinin and dopamine. However, neither A-
317491 nor A-740003 significantly affected the hyperalgesia induced by TNF-α, IL-1β, and 
CINC-1. Because the activation of spinal P2X3, P2X2/3 and P2X7 receptors contribute to the 
inflammatory hyperalgesia (McGaraughty et al., 2003, Clark et al., 2010), the lack of effect of the 
administration of A-740003 or A-317491 in the contralateral knee joint, confirms that only P2X3, 
P2X2/3 and P2X7 receptors of the articular tissue were targeted.  
In fact, P2X3 and P2X2/3 receptors expressed on terminals of primary sensory afferents 
fibers (Bradbury et al., 1998, Dowd et al., 1998, Burnstock and Knight, 2004, Gever et al., 2006) 
and chondrocytes (Varani et al., 2008) and P2X7 receptors expressed on macrophages, mast cells, 
monocytes, fibroblasts, T and B lymphocytes and FLS cells (Chiozzi et al., 1997, Collo et al., 
1997, Kim et al., 2001, Mancino et al., 2001, North, 2002, Greig et al., 2003, Caporali et al., 
2008, Surprenant and North, 2009), may have been targeted to contribute to the articular 
hyperalgesia induced by bradykinin, PGE2 and dopamine. 
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These findings indicate that bradykinin induces the endogenous release of ATP, which in 
turn, activates P2X3, P2X2/3 and P2X7 receptors located in the knee joint, as previously shown 
in the subcutaneous tissue and in cell culture (Chopra et al., 2005, Zhao et al., 2007, de Oliveira 
Fusaro et al., 2010, Pinheiro et al., 2013). 
After tissue injury, bradykinin is rapidly generated and modulates the increase of vascular 
permeability and vasodilatation, producing local heating and oedema, leukocyte recruitment, 
excitation and sensitization of sensory nerves, evoking pain and hyperalgesia (Marceau et al., 
1998, Calixto et al., 2000, Couture et al., 2001, Pawlak et al., 2008). In the arthritic joints, 
bradykinin has been involved in endothelial cell proliferation, cartilage matrix homeostasis and 
bone resorption, thus potentially affecting the synovial angiogenesis and cartilage destruction 
(Colman, 2006, Brechter and Lerner, 2007, Meini and Maggi, 2008). Considering that bradykinin 
is an inflammatory mediator released at the early phase of inflammatory hyperalgesia (Ferreira et 
al., 1993a, Ferreira et al., 1993b), our results suggest that the activation of P2X3, P2X2/3 and 
P2X7 receptors by endogenous ATP may play a role in the beginning of the development of the 
inflammatory hyperalgesia in the knee joint, reinforcing our previous results that the activation of 
peripheral P2X3, P2X2/3 and P2X7 receptors by endogenous ATP, is essential to the 
development, but not to the maintenance of the carrageenan-induced articular hyperalgesia 
(Teixeira et al., 2014a in press, Teixeira et al., 2014b in press). 
Bradykinin induces hyperalgesia by two distinct pathways that result in the local 
production of prostaglandins and release of sympathomimetic amines (Ferreira et al., 1993a, 
Ferreira et al., 1993b), which directly sensitize the primary afferent nociceptor (Gold et al., 1996, 
Khasar et al., 1999, Rush and Waxman, 2004). The activation of peripheral P2X3, P2X2/3 and 
P2X7 receptors by endogenous ATP in the knee joint, plays an important role not only in the 
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early, but also in the late phase of the inflammatory hyperalgesia. This is because the blockade of 
P2X3, P2X2/3 and P2X7 receptors prevented the articular hyperalgesia induced by final 
inflammatory mediators such as PGE2 and dopamine. Specifically, blockade of P2X3, P2X2/3 
and P2X7 receptors prevented dopamine-induced hyperalgesia, and blockade of P2X3 and 
P2X2/3, but not P2X7 receptor, prevented PGE2-induced hyperalgesia. These findings suggest 
that like bradykinin, PGE2 and dopamine also induce the release of ATP in the articular tissue, 
which in turn, activates P2X3, P2X2/3 and P2X7 receptors of the knee joint.  
We have previously demonstrated that the blockade of P2X3 and P2X2/3 receptors in the 
subcutaneous tissue of the rat’s paw prevents the mechanical hyperalgesia induced only by 
bradykinin (de Oliveira Fusaro et al., 2010). Others unpublished data from our group show that 
blockade of P2X7 receptor prevents the mechanical hyperalgesia induced by TNF-α, IL-6, CINC-
1 and dopamine, but not that induced by bradykinin, PGE2 and IL-1β in the subcutaneous tissue 
of the rat’s paw. Taken together, these findings suggest a significant difference in the purinergic 
mechanisms involved in the inflammatory hyperalgesia in the articular and in the subcutaneous 
tissues. 
In summary, this study shows that in the knee joint, the activation of P2X3, P2X2/3 and 
P2X7 receptors contributes to bradykinin- and dopamine-induced hyperalgesia and that the 
activation of P2X3 and P2X2/3, but not P2X7 receptors, contributes to PGE2-induced 
hyperalgesia. Furthermore, these purinergic receptors contribute to the hyperalgesia induced by 
bradykinin, dopamine and PGE2, through a previous release of endogenous ATP induced by these 
inflammatory mediators. These findings suggest that the P2X3, P2X2/3 and P2X7 receptors are 
important targets to control inflammatory pain in the arthropathies. 
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VII. CONCLUSÕES  
 
Os resultados apresentados nesse estudo em ratos sugerem que:  
- A ativação dos receptores purinérgicos P2X3, P2X2/3 e P2X7 pelo ATP endógeno é 
essencial para o desenvolvimento da hiperalgesia e inflamação articular induzida pela carragenina 
na articulação do joelho de ratos machos e fêmeas em estro (níveis baixos de hormônios 
ovarianos), sendo essas fêmeas mais sensíveis do que os machos aos efeitos anti-hiperalgésicos e 
anti-inflamatórios induzidos pelo bloqueio do receptor P2X7 na articulação do joelho. 
- Durante o processo de inflamação articular ocorre o aumento da expressão dos receptores 
P2X3 nos condrócitos da cartilagem articular, podendo sugerir que o aumento da sua expressão e 
sua ativação pelo ATP extracelular pode contribuir com a liberação de mediadores inflamatórios 
e consequente ativação dos nociceptores aferente primários. 
- O papel essencial dos receptores P2X3, P2X2/3 e P2X7 no desenvolvimento da 
hiperalgesia articular é mediado pela sensibilização indireta nos nociceptores aferentes primários, 
dependente da liberação de citocinas pró-inflamatórias e migração de neutrófilos. 
- A ativação dos receptores P2X3, P2X2/3 e P2X7 induz hiperalgesia articular no joelho de 
ratos dependente da liberação de bradicinina, aminas simpatomiméticas, prostaglandinas e 
citocinas pró-inflamatórias. 
- A hiperalgesia articular induzida pelos mediadores inflamatórios como a bradicinina, a 
PGE2 e dopamina é mediada pela ativação de receptores P2X3 e P2X2/3, enquanto que a ativação 
de receptor P2X7 contribui para a hiperalgesia articular induzida pela bradicinina e dopamina.  
Concluindo, nossos resultados podem sugerir que tanto os receptores purinérgicos P2X3 e 
P2X2/3 quanto os P2X7 são alvos farmacológicos interessantes para o controle da dor e 
inflamação das doenças inflamatórias articulares como a osteoartrite. Particularmente em relação 
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ao receptor P2X7, antagonistas seletivos podem ser usados para reduzir a dor nas artropatias 
especialmente em mulheres, que são mais afetadas por essa doença do que os homens. 
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IX. ANEXOS 
 
A- Certificado aprovação pelo Comitê de Ética em Pesquisa Animal da Universidade 
Estadual de Campinas: 
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B - Deferimento da Comissão de Ética no uso de Animais (CEUA/UNICAMP):  
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C- Equipamento utilizado no Teste de Incapacitação Articular (IA): 
 
 
 
Aparelho utilizado no Teste de Incapacitação Articular (IA): A foto apresenta o aparelho utilizado no 
teste de incapacitação articular (IA) (Modelo EFF 413 - Teste de Incapacitação Articular, Ribeirão Preto, 
São Paulo, Brasil), que consiste em um tambor rotativo de aço (30 cm de largura x 50 cm de diâmetro), 
coberto com uma malha de arame inoxidável, que gira a uma velocidade de 3 rpm.  
 
 
 
 
 
 
